explained	O	O
diagnosis	O	O
and	O	O
treatment	O	O
plan	O	O
;	O	O
patient	O	O
appears	O	O
to	O	O
understand	O	O
the	O	O
content	O	O
of	O	O
our	O	O
discussion	O	O
.	O	O
all	O	O
submitted	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
2	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
)	O	O
sentinel	O	O
lymph	O	O
node	O	O
with	O	O
blue	O	O
dye	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
syn	O	O
report	O	O
:	O	O
laterality	B-laterality	B-laterality
:	O	O
left	B-laterality-value	B-laterality-value
.	O	O
immunostains	O	O
on	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
for	O	O
estrogen	B-receptor	B-receptor
and	O	O
progesterone	B-receptor	B-receptor
receptors	I-receptor	I-receptor
are	O	O
positive	B-receptor-status	B-receptor-status
.	O	O
03	O	O
thomas	O	O
j	O	O
.	O	O
march	O	O
29	O	O
,	O	O
2017	O	O
,	O	O
ultrasound	O	O
biopsy	O	O
showed	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
grade	B-grade	B-grade
1	B-grade-value	B-grade-value
-	I-grade-value	I-grade-value
2	I-grade-value	I-grade-value
.	O	O
br	O	O
j	O	O
cancer	O	O
2007	O	O
may	O	O
21	O	O
;	O	O
96	O	O
(	O	O
10	O	O
)	O	O
:	O	O
150	O	O
-	O	O
151	O	O
ep	O	O
2007	O	O
apr	O	O
24	O	O
method	O	O
:	O	O
immunohistochemical	O	O
staining	O	O
of	O	O
the	O	O
ki	O	O
-	O	O
67	O	O
antigen	O	O
in	O	O
formalin	O	O
paraffin	O	O
tissue	O	O
sections	O	O
has	O	O
been	O	O
valid	O	O
by	O	O
our	O	O
laboratory	O	O
,	O	O
using	O	O
the	O	O
mi	O	O
-	O	O
1	O	O
clone	O	O
and	O	O
a	O	O
proprietary	O	O
detection	O	O
system	O	O
.	O	O
the	O	O
breast	O	O
par	O	O
is	O	O
fibrous	O	O
(	O	O
60	O	O
percent	O	O
)	O	O
and	O	O
fatty	O	O
(	O	O
40	O	O
percent	O	O
)	O	O
,	O	O
gross	O	O
.	O	O
abdomen	O	O
:	O	O
obe	O	O
with	O	O
a	O	O
well	O	O
right	O	O
upper	O	O
quadrant	O	O
inc	O	O
from	O	O
her	O	O
prior	O	O
cho	O	O
.	O	O
she	O	O
is	O	O
happy	O	O
with	O	O
the	O	O
cosmetic	O	O
result	O	O
,	O	O
and	O	O
she	O	O
is	O	O
planning	O	O
to	O	O
follow	O	O
up	O	O
with	O	O
plastic	O	O
surgery	O	O
.	O	O
a	O	O
techno	O	O
views	O	O
the	O	O
digit	O	O
image	O	O
on	O	O
a	O	O
computer	O	O
monitor	O	O
and	O	O
using	O	O
a	O	O
tracing	O	O
tool	O	O
available	O	O
in	O	O
images	O	O
(	O	O
ape	O	O
technologies	O	O
inc	O	O
)	O	O
,	O	O
traces	O	O
around	O	O
areas	O	O
of	O	O
invasive	O	O
or	O	O
metastatic	O	O
cancer	O	O
capturing	O	O
no	O	O
less	O	O
than	O	O
75	O	O
of	O	O
the	O	O
total	O	O
cancer	O	O
within	O	O
the	O	O
image	O	O
.	O	O
she	O	O
was	O	O
placed	O	O
on	O	O
medication	O	O
therapy	O	O
for	O	O
this	O	O
.	O	O
we	O	O
discussed	O	O
the	O	O
treatment	O	O
recommendations	O	O
provided	O	O
her	O	O
by	O	O
medical	O	O
and	O	O
radiation	O	O
oncology	O	O
.	O	O
block	O	O
summary	O	O
:	O	O
part	O	O
a	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
sentinel	O	O
lymph	O	O
node	O	O
#	O	O
1	O	O
rt	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
-	O	O
1	O	O
2	O	O
rt	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
-	O	O
2	O	O
part	O	O
b	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
sentinel	O	O
lymph	O	O
node	O	O
#	O	O
1	O	O
right	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
part	O	O
c	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
sentinel	O	O
lymph	O	O
node	O	O
#	O	O
1	O	O
right	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
2	O	O
right	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
part	O	O
d	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
sentinel	O	O
lymph	O	O
node	O	O
#	O	O
1	O	O
right	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
part	O	O
e	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
sentinel	O	O
lymph	O	O
node	O	O
#	O	O
1	O	O
right	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
part	O	O
f	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
wide	O	O
local	O	O
excision	O	O
1	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
margin	O	O
2	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
mass	O	O
b	O	O
.	O	O
at	O	O
this	O	O
time	O	O
she	O	O
appears	O	O
to	O	O
be	O	O
a	O	O
good	O	O
candidate	O	O
for	O	O
either	O	O
procedure	O	O
.	O	O
mental	O	O
status	O	O
and	O	O
language	O	O
exam	O	O
were	O	O
normal	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
identified	O	O
in	O	O
the	O	O
lymph	O	O
node	O	O
.	O	O
b	O	O
.	O	O
she	O	O
has	O	O
no	O	O
history	O	O
of	O	O
an	O	O
complications	O	O
.	O	O
the	O	O
surgical	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
(	O	O
closest	O	O
margin	O	O
is	O	O
1	O	O
cm	O	O
)	O	O
.	O	O
11	O	O
john	O	O
c	O	O
.	O	O
core	O	O
needle	O	O
biopsy	O	O
revealed	O	O
invasive	B-htype-value	B-htype-value
lobular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
grade	B-grade	B-grade
1	B-grade-value	B-grade-value
with	O	O
associated	O	O
lcis	B-htype-value	B-htype-value
.	O	O
i	O	O
will	O	O
see	O	O
her	O	O
back	O	O
following	O	O
the	O	O
consultation	O	O
.	O	O
2011	O	O
:	O	O
general	O	O
:	O	O
obe	O	O
white	O	O
female	O	O
in	O	O
no	O	O
acute	O	O
distress	O	O
.	O	O
they	O	O
are	O	O
negative	O	O
for	O	O
other	O	O
markers	O	O
tested	O	O
.	O	O
keen	O	O
.	O	O
"	O	O
nas	O	O
,	O	O
m	O	O
.	O	O
lewis	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
64	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
and	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
,	O	O
excision	O	O
:	O	O
multiple	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
negative	O	O
,	O	O
hold	O	O
to	O	O
confirm	O	O
.	O	O
this	O	O
was	O	O
er	B-receptor	B-receptor
/	O	O
pr	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
and	O	O
her	B-receptor	B-receptor
-	I-receptor	I-receptor
2	I-receptor	I-receptor
negative	B-receptor-status	B-receptor-status
.	O	O
case	O	O
seen	O	O
in	O	O
consultation	O	O
with	O	O
dr	O	O
.	O	O
due	O	O
to	O	O
these	O	O
findings	O	O
,	O	O
she	O	O
was	O	O
called	O	O
back	O	O
for	O	O
additional	O	O
views	O	O
on	O	O
april	O	O
11	O	O
,	O	O
which	O	O
showed	O	O
persistence	O	O
of	O	O
the	O	O
mass	O	O
which	O	O
covered	O	O
an	O	O
area	O	O
of	O	O
2	B-size-value	B-size-value
cm	I-size-value	I-size-value
and	O	O
was	O	O
associated	O	O
with	O	O
calcifications	O	O
.	O	O
d	O	O
.	O	O
cytologic	O	O
evidence	O	O
of	O	O
therapeutic	O	O
effect	O	O
:	O	O
present	O	O
:	O	O
fibrosis	O	O
.	O	O
she	O	O
has	O	O
no	O	O
gen	O	O
,	O	O
cardiovascular	O	O
,	O	O
or	O	O
respiratory	O	O
symptoms	O	O
.	O	O
patient	O	O
education	O	O
ready	O	O
to	O	O
learn	O	O
,	O	O
no	O	O
apparent	O	O
learning	O	O
barriers	O	O
were	O	O
identified	O	O
;	O	O
learning	O	O
preferences	O	O
include	O	O
listening	O	O
.	O	O
be	O	O
'	O	O
new	O	O
baseline	O	O
electro	O	O
(	O	O
performed	O	O
following	O	O
an	O	O
episode	O	O
of	O	O
chest	O	O
discomfort	O	O
in	O	O
hospital	O	O
following	O	O
cole	O	O
did	O	O
demonstrate	O	O
changes	O	O
consistent	O	O
with	O	O
an	O	O
inferior	O	O
in	O	O
and	O	O
significant	O	O
changes	O	O
since	O	O
06	O	O
/	O	O
17	O	O
/	O	O
06	O	O
.	O	O
pal	O	O
reveals	O	O
no	O	O
nod	O	O
or	O	O
masses	O	O
along	O	O
the	O	O
chest	O	O
wall	O	O
or	O	O
the	O	O
inc	O	O
.	O	O
see	O	O
syn	O	O
report	O	O
.	O	O
this	O	O
document	O	O
includes	O	O
the	O	O
initial	O	O
and	O	O
any	O	O
subsequent	O	O
pathology	O	O
reports	O	O
,	O	O
a	O	O
summary	O	O
of	O	O
treatments	O	O
received	O	O
(	O	O
type	O	O
and	O	O
dates	O	O
)	O	O
,	O	O
and	O	O
a	O	O
list	O	O
of	O	O
care	O	O
providers	O	O
involved	O	O
in	O	O
the	O	O
treatments	O	O
.	O	O
margin	O	O
submitted	O	O
en	O	O
face	O	O
.	O	O
macro	O	O
and	O	O
microscopic	O	O
extent	O	O
of	O	O
tumor	O	O
:	O	O
nipple	O	O
:	O	O
large	O	O
lac	O	O
ducts	O	O
involved	O	O
by	O	O
lcis	B-htype-value	B-htype-value
.	O	O
j	O	O
cl	O	O
on	O	O
.	O	O
2013	O	O
nov	O	O
1	O	O
;	O	O
31	O	O
(	O	O
31	O	O
)	O	O
:	O	O
39	O	O
-	O	O
401	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
non	O	O
fibrocystic	O	O
changes	O	O
.	O	O
all	O	O
submitted	O	O
.	O	O
kellogg	O	O
is	O	O
a	O	O
very	O	O
pleasant	O	O
83	O	O
-	O	O
year	O	O
female	O	O
with	O	O
a	O	O
history	O	O
of	O	O
stage	B-stage	B-stage
ia	B-stage-value	B-stage-value
breast	O	O
cancer	O	O
,	O	O
er	B-receptor	B-receptor
/	O	O
pr	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
,	O	O
her	B-receptor	B-receptor
-	I-receptor	I-receptor
2	I-receptor	I-receptor
negative	B-receptor-status	B-receptor-status
and	O	O
a	O	O
stage	B-stage	B-stage
ia	B-stage-value	B-stage-value
lung	O	O
cancer	O	O
.	O	O
the	O	O
syn	O	O
report	O	O
incorporates	O	O
information	O	O
from	O	O
all	O	O
relevant	O	O
surgical	O	O
material	O	O
and	O	O
includes	O	O
all	O	O
required	O	O
data	O	O
elements	O	O
of	O	O
the	O	O
current	O	O
cap	O	O
cancer	O	O
protocol	O	O
.	O	O
grade	O	O
1	O	O
art	O	O
unrelated	O	O
to	O	O
radiation	O	O
therapy	O	O
and	O	O
probably	O	O
related	O	O
to	O	O
chemotherapy	O	O
.	O	O
lewis	O	O
who	O	O
is	O	O
reviewing	O	O
the	O	O
pathology	O	O
,	O	O
and	O	O
she	O	O
confirms	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
1	B-size-value	B-size-value
-	I-size-value	I-size-value
cm	I-size-value	I-size-value
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
grade	B-grade	B-grade
2	B-grade-value	B-grade-value
carcinoma	B-htype-value	O
removed	O	O
from	O	O
the	O	O
breast	O	O
and	O	O
3	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
removed	O	O
which	O	O
have	O	O
not	O	O
been	O	O
completely	O	O
evaluated	O	O
at	O	O
this	O	O
time	O	O
.	O	O
breasts	O	O
:	O	O
i	O	O
think	O	O
i	O	O
can	O	O
feel	O	O
a	O	O
very	O	O
subtle	O	O
lesion	O	O
,	O	O
perhaps	O	O
0	B-size-value	B-size-value
to	I-size-value	I-size-value
1	I-size-value	I-size-value
cm	I-size-value	I-size-value
in	I-size-value	I-size-value
diameter	I-size-value	I-size-value
,	O	O
in	O	O
the	O	O
extreme	O	B-site-value
upper	B-site-value	I-site-value
inner	I-site-value	I-site-value
right	B-laterality-value	B-laterality-value
breast	O	O
.	O	O
she	O	O
has	O	O
a	O	O
resolving	O	O
area	O	O
of	O	O
excision	O	O
biopsy	O	O
in	O	O
the	O	O
lower	B-site-value	B-site-value
right	B-laterality-value	B-laterality-value
breast	O	O
at	O	O
6	B-site-value	B-site-value
o	I-site-value	I-site-value
,	I-site-value	I-site-value
6	I-site-value	I-site-value
cm	I-site-value	I-site-value
from	I-site-value	I-site-value
the	I-site-value	I-site-value
nipple	I-site-value	I-site-value
.	O	O
calcifications	O	O
:	O	O
present	O	O
in	O	O
:	O	O
st	O	O
,	O	O
dcis	B-htype-value	B-htype-value
.	O	O
a	O	O
second	O	O
ultrasound	O	O
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
is	O	O
planned	O	O
for	O	O
a	O	O
small	O	O
finding	O	O
in	O	O
that	O	O
breast	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
a	O	O
49	O	O
-	O	O
year	O	O
female	O	O
with	O	O
new	O	O
biopsy	O	O
of	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
of	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
she	O	O
does	O	O
wish	O	O
to	O	O
have	O	O
breast	O	O
treatment	O	O
if	O	O
possible	O	O
;	O	O
however	O	O
if	O	O
mastectomy	O	O
were	O	O
necessary	O	O
,	O	O
she	O	O
does	O	O
consent	O	O
to	O	O
proceed	O	O
.	O	O
however	O	O
,	O	O
i	O	O
do	O	O
not	O	O
have	O	O
all	O	O
the	O	O
records	O	O
as	O	O
to	O	O
the	O	O
adjustments	O	O
that	O	O
have	O	O
been	O	O
made	O	O
,	O	O
so	O	O
i	O	O
would	O	O
prefer	O	O
to	O	O
leave	O	O
it	O	O
to	O	O
her	O	O
primary	O	O
.	O	O
i	O	O
think	O	O
this	O	O
is	O	O
quite	O	O
reasonable	O	O
,	O	O
and	O	O
we	O	O
will	O	O
continue	O	O
to	O	O
monitor	O	O
her	O	O
for	O	O
recurrent	O	O
symptoms	O	O
.	O	O
calcifications	O	O
:	O	O
present	O	O
in	O	O
:	O	O
st	O	O
,	O	O
dcis	B-htype-value	B-htype-value
.	O	O
cytologic	O	O
evidence	O	O
of	O	O
therapeutic	O	O
effect	O	O
present	O	O
:	O	O
his	O	O
and	O	O
apocrine	O	O
change	O	O
.	O	O
distant	O	O
metastasis	O	O
:	O	O
not	O	O
applicable	O	O
.	O	O
she	O	O
has	O	O
also	O	O
had	O	O
low	O	B-grade-value
p	O	O
but	O	O
her	O	O
temperature	O	O
has	O	O
not	O	O
gone	O	O
over	O	O
100	O	O
degrees	O	O
fa	O	O
.	O	O
ex	O	O
:	O	O
no	O	O
peripheral	O	O
edema	O	O
.	O	O
nursing	O	O
clinical	O	O
judgment	O	O
utilized	O	O
.	O	O
no	O	O
cervical	O	O
nodes	O	O
,	O	O
su	O	O
nodes	O	O
.	O	O
the	O	O
tumor	O	O
was	O	O
er	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
and	O	O
pr	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
.	O	O
lewis	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
64	O	O
addendum	O	O
:	O	O
her2	B-receptor	B-receptor
/	O	O
neu	O	O
protein	O	O
overexpress	O	O
is	O	O
weakly	O	O
positive	B-receptor-status	B-receptor-status
,	O	O
score	O	O
of	O	O
2	B-receptor-value	B-receptor-value
+	I-receptor-value	I-receptor-value
,	O	O
according	O	O
to	O	O
the	O	O
interpretation	O	O
guidelines	O	O
in	O	O
the	O	O
fda	O	O
her	O	O
.	O	O
inward	O	O
,	O	O
m	O	O
.	O	O
12	O	O
/	O	O
18	O	O
/	O	O
2015	O	O
15	O	O
:	O	O
29	O	O
:	O	O
47	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
a	O	O
.	O	O
de	O	O
anne	O	O
smith	O	O
.	O	O
we	O	O
discussed	O	O
then	O	O
that	O	O
the	O	O
absolute	O	O
benefit	O	O
of	O	O
having	O	O
received	O	O
chemo	O	O
would	O	O
put	O	O
her	O	O
at	O	O
about	O	O
12	O	O
to	O	O
15	O	O
.	O	O
she	O	O
is	O	O
quite	O	O
adamant	O	O
that	O	O
she	O	O
would	O	O
prefer	O	O
to	O	O
have	O	O
chemotherapy	O	O
,	O	O
even	O	O
though	O	O
her	O	O
risk	O	O
may	O	O
be	O	O
slight	O	O
because	O	O
of	O	O
her	O	O
family	O	O
history	O	O
and	O	O
concern	O	O
about	O	O
rec	O	O
in	O	O
this	O	O
setting	O	O
.	O	O
these	O	O
findings	O	O
support	O	O
the	O	O
diagnosis	O	O
.	O	O
she	O	O
says	O	O
the	O	O
symptoms	O	O
are	O	O
worse	O	O
in	O	O
the	O	O
morning	O	O
and	O	O
started	O	O
last	O	O
week	O	O
.	O	O
grossed	O	O
by	O	O
t	O	O
.	O	O
all	O	O
controls	O	O
show	O	O
appropriate	O	O
react	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
new	O	O
anterior	O	O
margin	O	O
no	O	O
.	O	O
2	O	O
,	O	O
re	O	O
:	O	O
negative	O	O
for	O	O
carcinoma	O	O
and	O	O
ace	O	O
mu	O	O
.	O	O
c	O	O
.	O	O
gross	O	O
description	O	O
226	O	O
:	O	O
a	O	O
.	O	O
the	O	O
patient	O	O
,	O	O
at	O	O
that	O	O
time	O	O
,	O	O
was	O	O
not	O	O
recommended	O	O
to	O	O
undergo	O	O
a	O	O
bilateral	B-laterality-value	B-laterality-value
breast	O	O
mri	O	O
.	O	O
4	O	O
.	O	O
2010	O	O
:	O	O
mrs	O	O
.	O	O
well	O	O
surgical	O	O
scar	O	O
at	O	O
the	O	O
site	O	O
of	O	O
axillary	O	O
node	O	O
evaluation	O	O
.	O	O
known	O	O
invasive	B-htype-value	B-htype-value
mammary	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
a	O	O
site	O	O
of	O	O
lcis	B-htype-value	B-htype-value
that	O	O
was	O	O
ex	O	O
,	O	O
a	O	O
site	O	O
of	O	O
ad	O	O
that	O	O
was	O	O
ex	O	O
,	O	O
and	O	O
another	O	O
site	O	O
of	O	O
al	O	O
that	O	O
was	O	O
ex	O	O
.	O	O
multiple	O	O
(	O	O
11	O	O
of	O	O
27	O	O
)	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
lymph	O	O
nodes	O	O
are	O	O
positive	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
lobular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
gary	O	O
l	O	O
.	O	O
chemistry	O	O
group	O	O
,	O	O
calcium	O	O
,	O	O
and	O	O
ld	O	O
within	O	O
normal	O	O
limits	O	O
.	O	O
a	O	O
brother	O	O
had	O	O
a	O	O
localized	O	O
melanoma	O	O
at	O	O
age	O	O
60	O	O
and	O	O
is	O	O
doing	O	O
well	O	O
at	O	O
67	O	O
.	O	O
mu	O	O
membranes	O	O
moist	O	O
.	O	O
skeletal	O	O
muscle	O	O
:	O	O
not	O	O
present	O	O
.	O	O
block	O	O
summary	O	O
:	O	O
part	O	O
a	O	O
:	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
wide	O	O
local	O	O
excision	O	O
1	O	O
lt	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
site	O	O
1	O	O
2	O	O
lt	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
site	O	O
2	O	O
3	O	O
lt	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
site	O	O
3	O	O
part	O	O
b	O	O
:	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
#	O	O
1	O	O
lt	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
1	O	O
2	O	O
lt	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
2	O	O
part	O	O
c	O	O
:	O	O
new	O	O
anterior	O	O
margin	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
1	O	O
lt	B-laterality-value	O
new	O	O
anterior	O	O
margin	O	O
1	O	O
2	O	O
lt	B-laterality-value	O
new	O	O
anterior	O	O
margin	O	O
2	O	O
3	O	O
lt	B-laterality-value	O
new	O	O
anterior	O	O
margin	O	O
3	O	O
"	O	O
surgical	O	O
scars	O	O
noted	O	O
through	O	O
mid	O	O
breast	O	O
horizontally	O	O
and	O	O
in	O	O
the	O	O
in	O	O
folds	O	O
,	O	O
fresh	O	O
and	O	O
healing	O	O
nicely	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
sentinel	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
excision	O	O
:	O	O
a	O	O
single	O	O
sentinel	O	O
lymph	O	O
node	O	O
is	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
mrs	O	O
.	O	O
transcribed	O	O
by	O	O
:	O	O
sk	O	O
2	O	O
/	O	O
14	O	O
/	O	O
2012	O	O
14	O	O
:	O	O
36	O	O
:	O	O
23	O	O
"	O	O
specimen	O	O
description	O	O
226	O	O
:	O	O
a	O	O
:	O	O
clinic	O	O
consult	O	O
material	O	O
b	O	O
:	O	O
clinic	O	O
consult	O	O
material	O	O
tissue	O	O
description	O	O
:	O	O
material	O	O
received	O	O
:	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
-	O	O
2	O	O
slides	O	O
(	O	O
sp	O	O
-	O	O
231	O	O
)	O	O
left	B-laterality-value	B-laterality-value
sentinel	O	O
lymph	O	O
node	O	O
,	O	O
right	B-laterality-value	B-laterality-value
and	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
-	O	O
9	O	O
slides	O	O
(	O	O
sp	O	O
-	O	O
351	O	O
)	O	O
slide	O	O
disposition	O	O
:	O	O
"	O	O
recognized	O	O
and	O	O
valid	O	O
the	O	O
potential	O	O
emotional	O	O
difficulties	O	O
in	O	O
transition	O	O
from	O	O
active	O	O
treatment	O	O
to	O	O
surveillance	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
nottingham	O	O
grade	B-grade	B-grade
ii	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
.	O	O
fixation	O	O
:	O	O
her2	B-receptor	B-receptor
protein	O	O
immunohistochemical	O	O
(	O	O
i	O	O
)	O	O
test	O	O
results	O	O
are	O	O
only	O	O
valid	O	O
for	O	O
non	O	O
paraffin	O	O
embedded	O	O
specimens	O	O
fixed	O	O
in	O	O
10	O	O
neutral	O	O
buffer	O	O
formalin	O	O
within	O	O
1	O	O
hour	O	O
of	O	O
acquisition	O	O
and	O	O
fixed	O	O
between	O	O
6	O	O
and	O	O
48	O	O
hours	O	O
.	O	O
,	O	O
phd	O	O
.	O	O
"	O	O
d	O	O
.	O	O
this	O	O
document	O	O
includes	O	O
the	O	O
initial	O	O
and	O	O
any	O	O
subsequent	O	O
pathology	O	O
reports	O	O
,	O	O
a	O	O
summary	O	O
of	O	O
treatments	O	O
received	O	O
(	O	O
type	O	O
and	O	O
dates	O	O
)	O	O
,	O	O
and	O	O
a	O	O
list	O	O
of	O	O
care	O	O
providers	O	O
involved	O	O
in	O	O
the	O	O
treatments	O	O
.	O	O
immunohistochemistry	O	O
performed	O	O
on	O	O
paraffin	O	O
blocks	O	O
from	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
show	O	O
negative	O	B-receptor-status
staining	O	O
for	O	O
estrogen	B-receptor	B-receptor
receptor	I-receptor	I-receptor
and	O	O
positive	O	B-receptor-status
staining	O	O
for	O	O
progesterone	B-receptor	B-receptor
receptor	I-receptor	I-receptor
in	O	O
intraductal	B-htype-value	O
and	O	O
infiltrating	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
04	O	O
jorge	O	O
a	O	O
.	O	O
all	O	O
surgical	O	O
resection	O	O
margins	O	O
,	O	O
including	O	O
the	O	O
deep	O	O
margin	O	O
,	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
(	O	O
minimum	O	O
tumor	O	O
free	O	O
margin	O	O
,	O	O
1	O	O
cm	O	O
,	O	O
deep	O	O
margin	O	O
)	O	O
.	O	[CLS]
seen	O	O
with	O	O
dr	O	O
.	O	O
in	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
she	O	O
had	O	O
a	O	O
t1c	B-stage-value	B-stage-value
tumor	O	O
in	O	O
the	O	O
upper	B-site-value	B-site-value
quadrant	I-site-value	I-site-value
and	O	O
a	O	O
t1b	B-stage-value	B-stage-value
tumor	O	O
in	O	O
the	O	O
upper	B-site-value	B-site-value
quadrant	I-site-value	I-site-value
.	O	O
the	O	O
closest	O	O
margins	O	O
(	O	O
deep	O	O
,	O	O
inferior	O	O
,	O	O
and	O	O
anterior	O	O
)	O	O
are	O	O
submitted	O	O
perpendicular	O	O
with	O	O
the	O	O
sections	O	O
of	O	O
the	O	O
nodule	O	O
.	O	O
grossed	O	O
by	O	O
kc	O	O
/	O	O
eh	O	O
.	O	O
may	O	O
3	O	O
,	O	O
2017	O	O
,	O	O
ana	O	O
started	O	O
.	O	O
7	O	O
.	O	O
se	O	O
,	O	O
m	O	O
.	O	O
,	O	O
phd	O	O
.	O	O
4	O	O
-	O	O
75	O	O
report	O	O
electronically	O	O
signed	O	O
by	O	O
thomas	O	O
j	O	O
.	O	O
she	O	O
does	O	O
note	O	O
some	O	O
der	O	O
within	O	O
the	O	O
radiation	O	O
treatment	O	O
fields	O	O
.	O	O
c	O	O
.	O	O
margin	O	O
submitted	O	O
shaved	O	O
.	O	O
there	O	O
is	O	O
some	O	O
nod	O	O
of	O	O
the	O	O
upper	B-site-value	B-site-value
outer	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
without	O	O
the	O	O
a	O	O
distinct	O	O
mass	O	O
.	O	O
e	O	O
.	O	O
surgical	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
she	O	O
is	O	O
applying	O	O
vitamin	O	O
e	O	O
oil	O	O
to	O	O
the	O	O
skin	O	O
around	O	O
the	O	O
scar	O	O
.	O	O
her2	B-receptor	B-receptor
protein	O	O
overexpress	O	O
is	O	O
positive	B-receptor-status	B-receptor-status
,	O	O
score	O	O
of	O	O
3	B-receptor-value	B-receptor-value
+	I-receptor-value	I-receptor-value
.	O	O
(	O	O
hr	O	O
-	O	O
354	O	O
)	O	O
st	O	O
.	O	O
no	O	O
evidence	O	O
of	O	O
distant	O	O
metastases	O	O
.	O	O
-	O	O
-	O	O
pt	O	O
underwent	O	O
surgical	O	O
resection	O	O
of	O	O
her	O	O
known	O	O
ang	B-htype-value	B-htype-value
.	O	O
-	O	O
-	O	O
plan	O	O
is	O	O
to	O	O
complete	O	O
3	O	O
-	O	O
4	O	O
cycles	O	O
of	O	O
chemotherapy	O	O
then	O	O
adjuvant	O	O
radiation	O	O
#	O	O
vt	O	O
prop	O	O
-	O	O
-	O	O
en	O	O
#	O	O
f	O	O
/	O	O
e	O	O
/	O	O
n	O	O
-	O	O
-	O	O
fluids	O	O
:	O	O
iv	O	O
fluids	O	O
according	O	O
to	O	O
the	O	O
cd	O	O
;	O	O
-	O	O
-	O	O
electro	O	O
:	O	O
admission	O	O
labs	O	O
within	O	O
normal	O	O
limits	O	O
.	O	O
all	O	O
submitted	O	O
.	O	O
bei	O	O
chen	O	O
,	O	O
m	O	O
.	O	O
"	O	O
she	O	O
has	O	O
already	O	O
met	O	O
with	O	O
dar	O	O
le	O	O
,	O	O
and	O	O
she	O	O
is	O	O
thinking	O	O
that	O	O
she	O	O
would	O	O
lean	O	O
more	O	O
towards	O	O
the	O	O
implant	O	O
expand	O	O
route	O	O
.	O	O
reviewed	O	O
dr	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
identified	O	O
in	O	O
the	O	O
lymph	O	O
node	O	O
.	O	O
there	O	O
are	O	O
multiple	O	O
(	O	O
4	O	O
)	O	O
skin	O	O
lesions	O	O
(	O	O
ranging	O	O
in	O	O
size	O	B-size
from	O	O
0	O	B-size-value
cm	O	I-size-value
to	O	I-size-value
1	O	B-size-value
cm	O	I-size-value
in	O	O
greatest	O	O
dimension	O	O
)	O	O
.	O	O
lymph	O	O
nodes	O	O
:	O	O
examined	O	O
and	O	O
normal	O	O
.	O	O
tumor	O	O
size	B-size	B-size
(	O	O
largest	O	O
invasive	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
)	O	O
:	O	O
0	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
.	O	O
she	O	O
states	O	O
that	O	O
this	O	O
is	O	O
healing	O	O
well	O	O
.	O	O
r	O	O
.	O	O
number	O	O
of	O	O
negative	O	O
l	O	O
:	O	O
3	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
14	O	O
surgical	O	O
pathology	O	O
requested	O	O
by	O	O
:	O	O
michael	O	O
g	O	O
.	O	O
pathology	O	O
report	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
core	O	O
biopsy	O	O
:	O	O
invasive	O	O
grade	B-grade	B-grade
4	B-grade-value	B-grade-value
(	O	O
of	O	O
4	O	O
)	O	O
,	O	O
nuclear	O	O
grade	B-grade	B-grade
2	B-grade-value	B-grade-value
(	O	O
of	O	O
3	O	O
)	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
the	O	O
largest	O	O
deposit	O	O
is	O	O
0	O	B-size-value
cm	O	I-size-value
.	O	O
she	O	O
is	O	O
thinking	O	O
about	O	O
having	O	O
radiation	O	O
done	O	O
locally	O	O
.	O	O
grossed	O	O
by	O	O
t	O	O
.	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
exam	O	O
reveals	O	O
recent	O	O
inc	O	O
both	O	O
from	O	O
sentinel	O	O
node	O	O
and	O	O
breast	O	O
which	O	O
are	O	O
healing	O	O
well	O	O
without	O	O
evidence	O	O
of	O	O
infection	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
identified	O	O
.	O	O
grossed	O	O
by	O	O
t	O	O
.	O	O
the	O	O
pain	O	O
problem	O	O
she	O	O
has	O	O
is	O	O
bilateral	B-laterality-value	B-laterality-value
chest	O	O
wall	O	O
pain	O	O
which	O	O
she	O	O
feels	O	O
is	O	O
caused	O	O
by	O	O
friction	O	O
against	O	O
her	O	O
arm	O	O
and	O	O
the	O	O
fatty	O	O
tissue	O	O
remaining	O	O
in	O	O
both	O	O
outer	O	O
upper	O	O
chest	O	O
wall	O	O
areas	O	O
.	O	O
delay	O	O
to	O	O
fixation	O	O
,	O	O
under	O	O
fixation	O	O
or	O	O
over	O	O
fixation	O	O
fall	O	O
outside	O	O
of	O	O
cap	O	O
/	O	O
as	O	O
guidelines	O	O
and	O	O
may	O	O
affect	O	O
these	O	O
results	O	O
.	O	O
representative	O	O
sections	O	O
are	O	O
submitted	O	O
.	O	O
after	O	O
consultation	O	O
with	O	O
dr	O	O
.	O	O
she	O	O
did	O	O
not	O	O
breast	O	O
her	O	O
children	O	O
.	O	O
no	O	O
angiolymphatic	O	O
invasion	O	O
is	O	O
seen	O	O
.	O	O
macro	O	O
and	O	O
microscopic	O	O
extent	O	O
of	O	O
tumor	O	O
:	O	O
nipple	O	O
:	O	O
not	O	O
involved	O	O
.	O	O
this	O	O
confirmed	O	O
a	O	O
sp	O	O
lesion	O	O
in	O	O
the	O	O
upper	B-site-value	B-site-value
outer	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
and	O	O
an	O	O
enlarged	O	O
lymph	O	O
node	O	O
in	O	O
the	O	O
axillary	O	O
area	O	O
.	O	O
ha	O	O
,	O	O
m	O	O
.	O	[CLS]
127	O	O
-	O	O
134	O	O
syn	O	O
report	O	O
laterality	B-laterality	B-laterality
:	O	O
right	B-laterality-value	B-laterality-value
procedure	O	O
:	O	O
lumpectomy	O	O
lymph	O	O
node	O	O
sampling	O	O
:	O	O
no	O	O
lymph	O	O
nodes	O	O
submitted	O	O
size	B-size	B-size
(	O	O
extent	O	O
)	O	O
of	O	O
dcis	B-htype-value	B-htype-value
:	O	O
at	O	O
least	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
and	O	O
0	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
(	O	O
tumor	O	O
extended	O	O
to	O	O
initial	O	O
superior	O	O
margin	O	O
and	O	O
was	O	O
present	O	O
in	O	O
first	O	O
margin	O	O
re	O	O
,	O	O
so	O	O
actual	O	O
size	O	O
is	O	O
larger	O	O
)	O	O
type	O	O
:	O	O
apocrine	O	B-grade-value
type	O	O
nuclear	O	O
grade	B-grade	B-grade
:	O	O
intermediate	B-grade-value	B-grade-value
nuclear	O	O
grade	O	B-grade
necrosis	O	O
:	O	O
not	O	O
present	O	O
calcifications	O	O
:	O	O
absent	O	O
biopsy	O	O
site	O	O
:	O	O
biopsy	O	O
site	O	O
changes	O	O
present	O	O
microscopic	O	O
extent	O	O
of	O	O
dcis	B-htype-value	B-htype-value
:	O	O
nipple	O	O
:	O	O
not	O	O
present	O	O
skin	O	O
:	O	O
not	O	O
present	O	O
surgical	O	O
margins	O	O
:	O	O
the	O	O
patient	O	O
is	O	O
an	O	O
occupational	O	O
therapist	O	O
and	O	O
wondered	O	O
whether	O	O
she	O	O
had	O	O
lymph	O	O
of	O	O
the	O	O
arm	O	O
.	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
exam	O	O
-	O	O
-	O	O
specifically	O	O
noted	O	O
was	O	O
the	O	O
nipple	O	O
was	O	O
ever	O	O
whereas	O	O
it	O	O
was	O	O
previously	O	O
inverted	O	O
.	O	O
(	O	O
cr	O	O
-	O	O
202	O	O
)	O	O
tissue	O	O
description	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
(	O	O
4	O	O
x	O	O
3	O	O
x	O	O
3	O	O
cm	O	O
)	O	O
,	O	O
and	O	O
right	B-laterality-value	B-laterality-value
high	O	O
and	O	O
mid	O	O
/	O	O
low	O	O
axillary	O	O
lymph	O	O
tissue	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
deep	O	O
posterior	O	O
tissue	O	O
,	O	O
biopsy	O	O
:	O	O
fi	O	O
tissue	O	O
with	O	O
biopsy	O	O
site	O	O
changes	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
02	O	O
/	O	O
09	O	O
/	O	O
2012	O	O
surgical	O	O
pathology	O	O
(	O	O
cr	O	O
-	O	O
110	O	O
)	O	O
requested	O	O
by	O	O
:	O	O
clive	O	O
s	O	O
.	O	O
in	O	O
general	O	O
she	O	O
has	O	O
been	O	O
feeling	O	O
well	O	O
.	O	O
all	O	O
lymph	O	O
nodes	O	O
submitted	O	O
.	O	O
accompanied	O	O
by	O	O
her	O	O
husband	O	O
who	O	O
appears	O	O
very	O	O
supportive	O	O
.	O	O
because	O	O
these	O	O
were	O	O
new	O	O
and	O	O
suspicious	O	O
,	O	O
the	O	O
patient	O	O
underwent	O	O
an	O	O
excision	O	O
biopsies	O	O
of	O	O
the	O	O
calcification	O	O
area	O	O
11	O	O
-	O	O
1	O	O
-	O	O
99	O	O
.	O	O
no	O	O
organ	O	O
or	O	O
masses	O	O
are	O	O
noted	O	O
.	O	O
page	O	O
:	O	O
127	O	O
-	O	O
119	O	O
.	O	O
lewis	O	O
,	O	O
m	O	O
.	O	O
pathologic	O	O
staging	B-stage	B-stage
des	O	O
:	O	O
s	O	O
pathologic	O	O
staging	B-stage	B-stage
(	O	O
aj	O	O
,	O	O
7th	O	O
edition	O	O
)	O	O
:	O	O
primary	O	O
tumor	O	O
:	O	O
pt1c	B-stage-value	B-stage-value
regional	O	O
lymph	O	O
nodes	O	O
:	O	O
pn0	B-stage-value	B-stage-value
sentinel	O	O
nodes	O	O
,	O	O
total	O	O
number	O	O
examined	O	O
:	O	O
3	O	O
non	O	O
axillary	O	O
nodes	O	O
,	O	O
total	O	O
number	O	O
examined	O	O
:	O	O
0	O	O
all	O	O
(	O	O
sentinel	O	O
plus	O	O
non	O	O
)	O	O
nodes	O	O
,	O	O
total	O	O
number	O	O
:	O	O
3	O	O
number	O	O
of	O	O
negative	O	O
l	O	O
:	O	O
3	O	O
number	O	O
of	O	O
l	O	O
with	O	O
isolated	O	O
tumor	O	O
cells	O	O
:	O	O
0	O	O
number	O	O
of	O	O
l	O	O
with	O	O
micro	O	O
:	O	O
0	O	O
number	O	O
of	O	O
l	O	O
with	O	O
macrometastases	O	O
:	O	O
0	O	O
distant	O	O
metastasis	O	O
:	O	O
not	O	O
applicable	O	O
.	O	O
margin	O	O
submitted	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
new	O	O
deep	O	O
margin	O	O
,	O	O
re	O	O
:	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
16	O	O
pathology	O	O
-	O	O
review	O	O
of	O	O
outside	O	O
specimen	O	O
referring	O	O
physician	O	O
:	O	O
stephen	O	O
m	O	O
.	O	O
2010	O	O
:	O	O
this	O	O
66	O	O
-	O	O
year	O	O
female	O	O
has	O	O
the	O	O
following	O	O
significant	O	O
history	O	O
:	O	O
1	O	O
.	O	O
breasts	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
-	O	O
-	O	O
recent	O	O
surgical	O	O
changes	O	O
with	O	O
blue	O	O
dye	O	O
present	O	O
.	O	O
a	O	O
copy	O	O
of	O	O
this	O	O
document	O	O
was	O	O
provided	O	O
to	O	O
the	O	O
patient	O	O
for	O	O
the	O	O
purposes	O	O
of	O	O
information	O	O
,	O	O
education	O	O
,	O	O
and	O	O
to	O	O
share	O	O
with	O	O
local	O	O
medical	O	O
providers	O	O
.	O	O
she	O	O
is	O	O
a	O	O
never	O	O
smoke	O	O
.	O	O
this	O	O
document	O	O
includes	O	O
the	O	O
initial	O	O
and	O	O
any	O	O
subsequent	O	O
surgical	O	O
pathology	O	O
reports	O	O
,	O	O
a	O	O
summary	O	O
of	O	O
treatments	O	O
received	O	O
(	O	O
type	O	O
and	O	O
dates	O	O
)	O	O
,	O	O
and	O	O
a	O	O
list	O	O
of	O	O
care	O	O
providers	O	O
involved	O	O
in	O	O
the	O	O
treatments	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
no	O	O
.	O	O
2	O	O
\	O	O
"	O	O
is	O	O
a	O	O
single	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
lymph	O	O
node	O	O
.	O	O
i	O	O
encouraged	O	O
her	O	O
to	O	O
take	O	O
a	O	O
the	O	O
along	O	O
,	O	O
and	O	O
if	O	O
she	O	O
develops	O	O
a	O	O
fever	O	O
over	O	O
101	O	O
degrees	O	O
fa	O	O
she	O	O
should	O	O
be	O	O
seen	O	O
in	O	O
an	O	O
emergency	O	O
department	O	O
wherever	O	O
they	O	O
are	O	O
.	O	O
she	O	O
started	O	O
ab	O	O
therapy	O	O
on	O	O
this	O	O
date	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
locally	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
cancer	O	O
with	O	O
positive	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
node	O	O
and	O	O
pea	O	O
d	O	O
with	O	O
some	O	O
inflammatory	O	O
changes	O	O
to	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
#	O	O
ind	O	O
pulmonary	O	O
nodule	O	O
#	O	O
hypertension	O	O
2011	O	O
:	O	O
#	O	O
locally	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
cancer	O	O
with	O	O
positive	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
node	O	O
and	O	O
pea	O	O
d	O	O
with	O	O
some	O	O
inflammatory	O	O
changes	O	O
to	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
mrs	O	O
.	O	O
lymph	O	O
nodes	O	O
submitted	O	O
for	O	O
permanent	O	O
sections	O	O
only	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
new	O	O
superior	O	O
skin	O	O
margin	O	O
no	O	O
.	O	O
2	O	O
\	O	O
"	O	O
is	O	O
a	O	O
9	O	O
x	O	O
1	O	O
cm	O	O
portion	O	O
of	O	O
tan	O	O
skin	O	O
ex	O	O
to	O	O
1	O	O
cm	O	O
with	O	O
orientation	O	O
.	O	[CLS]
the	O	O
ac	O	O
(	O	O
r	O	O
)	O	O
iii	O	O
render	O	O
the	O	O
percentage	O	O
of	O	O
positive	O	O
staining	O	O
tumor	O	O
nuclei	O	O
(	O	O
tumor	O	O
selected	O	O
by	O	O
ac	O	O
operator	O	O
)	O	O
.	O	O
ten	O	O
nodes	O	O
were	O	O
removed	O	O
and	O	O
six	O	O
were	O	O
positive	O	O
for	O	O
a	O	O
total	O	O
of	O	O
seven	O	O
positive	O	O
nodes	O	O
out	O	O
of	O	O
15	O	O
removed	O	O
.	O	O
2010	O	O
:	O	O
history	O	O
reviewed	O	O
.	O	O
she	O	O
also	O	O
felt	O	O
that	O	O
the	O	O
right	O	B-laterality-value
face	O	O
was	O	O
weaker	O	O
.	O	O
se	O	O
,	O	O
m	O	O
.	O	O
,	O	O
phd	O	O
.	O	O
4	O	O
-	O	O
75	O	O
electronically	O	O
signed	O	O
by	O	O
t	O	O
2	O	O
/	O	O
15	O	O
/	O	O
2008	O	O
17	O	O
:	O	O
08	O	O
:	O	O
07	O	O
addendum	O	O
:	O	O
estrogen	B-receptor	B-receptor
:	O	O
positive	B-receptor-status	B-receptor-status
,	O	O
51	O	O
-	O	O
75	O	O
tumor	O	O
nuclei	O	O
staining	O	O
.	O	O
.	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
and	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
,	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
and	O	O
a	O	O
single	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	[CLS]
she	O	O
presents	O	O
today	O	O
for	O	O
discussion	O	O
in	O	O
this	O	O
setting	O	O
.	O	O
fa	O	O
examination	O	O
done	O	O
.	O	O
07	O	O
john	O	O
c	O	O
.	O	O
the	O	O
slides	O	O
and	O	O
test	O	O
results	O	O
are	O	O
then	O	O
reviewed	O	O
by	O	O
a	O	O
path	O	O
who	O	O
provides	O	O
a	O	O
final	O	O
interpretation	O	O
.	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
and	O	O
axillary	O	O
lymph	O	O
nodes	O	O
:	O	O
residual	O	B-htype-value
ductal	B-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
is	O	O
identified	O	O
(	O	O
2	B-size-value	B-size-value
cm	I-size-value	I-size-value
in	O	O
maximum	O	O
size	B-size	B-size
)	O	O
and	O	O
several	O	O
foci	O	O
of	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
(	O	O
less	B-size-value	O
than	I-size-value	O
2	I-size-value	B-size-value
mm	I-size-value	I-size-value
maximum	O	O
dimension	O	O
)	O	O
.	O	O
mitotic	O	O
rate	O	O
:	O	O
1	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
10	O	O
/	O	O
09	O	O
/	O	O
2014	O	O
surgical	O	O
pathology	O	O
(	O	O
cr	O	O
-	O	O
70	O	O
)	O	O
revised	O	O
report	O	O
(	O	O
revised	O	O
information	O	O
under	O	O
)	O	O
addendum	O	O
/	O	O
procedure	O	O
included	O	O
requested	O	O
by	O	O
:	O	O
judy	O	O
c	O	O
.	O	O
lo	O	O
,	O	O
for	O	O
specific	O	O
recommendations	O	O
.	O	O
2011	O	O
:	O	O
general	O	O
:	O	O
well	O	O
woman	O	O
in	O	O
no	O	O
apparent	O	O
distress	O	O
.	O	O
the	O	O
non	O	O
breast	O	O
par	O	O
shows	O	O
pro	O	O
fibrocystic	O	O
changes	O	O
.	O	O
patient	O	O
had	O	O
a	O	O
pet	O	O
scan	O	O
in	O	O
2007	O	O
which	O	O
was	O	O
negative	O	O
.	O	O
all	O	O
submitted	O	O
.	O	O
therefore	O	O
,	O	O
we	O	O
will	O	O
tentatively	O	O
schedule	O	O
her	O	O
for	O	O
an	O	O
ac	O	O
the	O	O
week	O	O
of	O	O
9	O	O
/	O	O
20	O	O
/	O	O
99	O	O
.	O	O
#	O	O
nod	O	O
in	O	O
the	O	O
reconstructed	O	O
breast	O	O
and	O	O
in	O	O
the	O	O
sub	O	O
upper	O	I-site-value
abdomen	O	O
.	O	O
reviewed	O	O
signs	O	O
and	O	O
symptoms	O	O
that	O	O
might	O	O
suggest	O	O
cancer	O	O
rec	O	O
as	O	O
listed	O	O
in	O	O
the	O	O
survivors	O	O
plan	O	O
of	O	O
care	O	O
.	O	O
there	O	O
was	O	O
mild	O	O
tenderness	O	O
in	O	O
the	O	O
superior	O	O
aspect	O	O
of	O	O
the	O	O
tunnel	O	O
on	O	O
pal	O	O
.	O	O
it	O	O
should	O	O
be	O	O
noted	O	O
that	O	O
the	O	O
tumor	O	O
measured	B-size	B-size
over	O	O
6	B-size-value	B-size-value
by	O	O
mr	O	O
and	O	O
there	O	O
was	O	O
involvement	O	O
of	O	O
overly	O	O
skin	O	O
in	O	O
the	O	O
region	O	O
of	O	O
the	O	O
nipple	O	O
are	O	O
complex	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
new	O	O
inferior	O	O
skin	O	O
margin	O	O
,	O	O
no	O	O
.	O	O
6	O	O
,	O	O
excision	O	O
:	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
multiple	O	O
(	O	O
1	O	O
high	O	O
,	O	O
3	O	O
axillary	O	O
)	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
within	B-site-value	O
the	I-site-value	O
firm	I-site-value	O
area	I-site-value	O
is	O	O
a	O	O
0	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
nodule	O	O
which	O	O
is	O	O
present	O	O
at	B-site-value	O
the	I-site-value	O
superior	I-site-value	O
margin	I-site-value	O
(	I-site-value	O
submitted	I-site-value	O
perpendicular	I-site-value	O
)	I-site-value	O
and	I-site-value	O
at	I-site-value	O
the	I-site-value	O
medial	I-site-value	O
margin	I-site-value	O
.	O	O
she	O	O
received	O	O
some	O	O
literature	O	O
about	O	O
divert	O	O
.	O	O
#	O	O
status	O	O
post	O	O
lu	O	O
disk	O	O
surgery	O	O
x	O	O
3	O	O
,	O	O
with	O	O
some	O	O
residual	O	O
low	O	O
back	O	O
pain	O	O
and	O	O
left	O	B-laterality-value
lower	O	O
ex	O	O
pain	O	O
she	O	O
can	O	O
continue	O	O
with	O	O
neu	O	O
.	O	O
a	O	O
needle	O	O
local	O	O
wire	O	O
is	O	O
identified	O	O
.	O	O
the	O	O
nipple	O	O
and	O	O
are	O	O
areas	O	O
are	O	O
preserved	O	O
,	O	O
although	O	O
the	O	O
left	B-laterality-value	B-laterality-value
nipple	O	O
had	O	O
nec	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
identified	O	O
in	O	O
the	O	O
lymph	O	O
node	O	O
.	O	O
likely	O	O
as	O	O
pneumonia	O	O
.	O	O
4	O	O
.	O	O
i	O	O
offered	O	O
encouragement	O	O
and	O	O
my	O	O
continued	O	O
support	O	O
during	O	O
this	O	O
difficult	O	O
time	O	O
.	O	O
she	O	O
then	O	O
inquired	O	O
about	O	O
receiving	O	O
radiation	O	O
in	O	O
winnipeg	O	O
,	O	O
canada	O	O
,	O	O
and	O	O
was	O	O
told	O	O
that	O	O
she	O	O
would	O	O
have	O	O
to	O	O
wait	O	O
15	O	O
weeks	O	O
to	O	O
be	O	O
treated	O	O
.	O	O
april	O	O
29	O	O
,	O	O
2016	O	O
:	O	O
patient	O	O
attended	O	O
routine	O	O
der	O	O
examination	O	O
for	O	O
long	O	O
history	O	O
of	O	O
several	O	O
melanoma	O	O
removal	O	O
.	O	O
provided	O	O
assurance	O	O
that	O	O
,	O	O
as	O	O
a	O	O
team	O	O
of	O	O
care	O	O
providers	O	O
,	O	O
we	O	O
will	O	O
continue	O	O
to	O	O
be	O	O
available	O	O
for	O	O
questions	O	O
and	O	O
will	O	O
evaluate	O	O
new	O	O
concerns	O	O
.	O	O
it	O	O
has	O	O
not	O	O
been	O	O
cleared	O	O
or	O	O
approved	O	O
by	O	O
the	O	O
u	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
additional	O	O
tissue	O	O
#	O	O
\	O	O
"	O	O
is	O	O
a	O	O
4	O	O
x	O	O
3	O	O
x	O	O
2	O	O
cm	O	O
aggregate	O	O
of	O	O
adi	O	O
and	O	O
lymph	O	O
tissue	O	O
.	O	O
the	O	O
skin	O	O
and	O	O
nipple	O	O
were	O	O
un	O	O
,	O	O
and	O	O
the	O	O
surgical	O	O
margins	O	O
were	O	O
free	O	O
of	O	O
tumor	O	O
.	O	O
block	O	O
summary	O	O
:	O	O
part	O	O
a	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
,	O	O
lumpectomy	O	O
-	O	O
deep	O	O
margin	O	O
1	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
deep	O	O
margin	O	O
part	O	O
b	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
,	O	O
lumpectomy	O	O
1	O	O
*	O	O
la	O	O
aspect	O	O
biopsy	O	O
cavity	O	O
1	O	O
2	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
cavity	O	O
1	O	O
3	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
cavity	O	O
2	O	O
4	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
cavity	O	O
3	O	O
5	O	O
*	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
cavity	O	O
4	O	O
6	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
cavity	O	O
5	O	O
7	O	O
rt	O	B-laterality-value
med	O	O
aspect	O	O
biopsy	O	O
cavity	O	O
8	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
la	O	O
margin	O	O
1	O	O
9	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
la	O	O
margin	O	O
2	O	O
part	O	O
c	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
new	O	O
superior	O	O
margin	O	O
at	O	O
deep	O	O
/	O	O
lateral	O	O
1	O	O
new	O	O
su	O	O
/	O	O
deep	O	O
/	O	O
la	O	O
margin	O	O
1	O	O
2	O	O
new	O	O
su	O	O
/	O	O
deep	O	O
/	O	O
la	O	O
margin	O	O
2	O	O
3	O	O
*	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
from	O	O
su	O	O
/	O	O
deep	O	O
the	O	O
edges	O	O
are	O	O
very	O	O
soft	O	O
and	O	O
difficult	O	O
to	O	O
pal	O	O
.	O	O
uterus	O	O
and	O	O
o	O	O
in	O	O
situ	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
24	O	O
surgical	O	O
pathology	O	O
requested	O	O
by	O	O
:	O	O
john	O	O
h	O	O
.	O	O
gross	O	O
description	O	O
226	O	O
:	O	O
a	O	O
.	O	O
frozen	O	O
section	O	O
histologic	O	O
interpretation	O	O
performed	O	O
by	O	O
:	O	O
rafael	O	O
e	O	O
.	O	O
she	O	O
was	O	O
unavailable	O	O
at	O	O
both	O	O
her	O	O
home	O	O
phone	O	O
number	O	O
and	O	O
cell	O	O
phone	O	O
number	O	O
.	O	O
she	O	O
has	O	O
been	O	O
using	O	O
some	O	O
van	O	O
to	O	O
the	O	O
area	O	O
.	O	O
fa	O	O
done	O	O
.	O	O
8	O	O
/	O	O
10	O	O
/	O	O
2006	O	O
andrew	O	O
l	O	O
.	O	O
she	O	O
will	O	O
visit	O	O
with	O	O
the	O	O
radiation	O	O
on	O	O
,	O	O
our	O	O
clinical	O	O
nurse	O	O
practitioner	O	O
,	O	O
and	O	O
the	O	O
surgeon	O	O
.	O	O
[	O	O
aj	O	B-stage-value
]	O	O
angiolymphatic	O	O
invasion	O	O
is	O	O
absent	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
wide	O	O
local	O	O
excision	O	O
\	O	O
"	O	O
is	O	O
a	O	O
5	O	O
x	O	O
4	O	O
x	O	O
2	O	O
cm	O	O
oriented	O	O
wide	O	O
local	O	O
excision	O	O
breast	O	O
specimen	O	O
with	O	O
a	O	O
3	O	O
x	O	O
0	O	O
cm	O	O
skin	O	O
el	O	O
.	O	O
the	O	O
patient	O	O
says	O	O
that	O	O
she	O	O
is	O	O
comfortable	O	O
with	O	O
not	O	O
undergoing	O	O
radiation	O	O
therapy	O	O
and	O	O
she	O	O
understands	O	O
that	O	O
she	O	O
is	O	O
at	O	O
a	O	O
somewhat	O	O
increased	O	O
risk	O	O
of	O	O
rec	O	O
of	O	O
either	O	O
dcis	B-htype-value	B-htype-value
or	O	O
invasive	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
.	O	O
discussion	O	O
about	O	O
clinical	O	O
trial	O	O
on	O	O
the	O	O
i	O	O
versus	O	O
standard	O	O
chemotherapy	O	O
was	O	O
discussed	O	O
.	O	O
4	O	O
.	O	O
d	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
wide	O	O
local	O	O
excision	O	O
:	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
new	O	O
superior	O	O
skin	O	O
margin	O	O
,	O	O
no	O	O
.	O	O
4	O	O
,	O	O
excision	O	O
:	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
cl	O	O
is	O	O
a	O	O
very	O	O
pleasant	O	O
52	O	O
-	O	O
year	O	O
woman	O	O
who	O	O
is	O	O
seen	O	O
in	O	O
the	O	O
company	O	O
of	O	O
her	O	O
spouse	O	O
,	O	O
gary	O	O
,	O	O
and	O	O
her	O	O
daughter	O	O
,	O	O
allison	O	O
.	O	O
she	O	O
is	O	O
a	O	O
school	O	O
bus	O	O
driver	O	O
and	O	O
cannot	O	O
afford	O	O
to	O	O
have	O	O
these	O	O
vertigo	O	O
episodes	O	O
.	O	O
she	O	O
continues	O	O
on	O	O
calcium	O	O
and	O	O
vitamin	O	O
d	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
status	O	O
post	O	O
ultrasound	O	O
core	O	O
biopsy	O	O
consistent	O	O
with	O	O
invasive	B-htype-value	B-htype-value
lobular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
and	O	O
hormone	B-receptor	B-receptor
receptor	I-receptor	I-receptor
positive	B-receptor-status	B-receptor-status
,	O	O
on	O	O
neoadjuvant	O	O
treatment	O	O
with	O	O
let	O	O
#	O	O
os	O	O
2011	O	O
:	O	O
#	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
status	O	O
post	O	O
ultrasound	O	O
core	O	O
biopsy	O	O
consistent	O	O
with	O	O
invasive	B-htype-value	B-htype-value
lobular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
and	O	O
hormone	B-receptor	B-receptor
receptor	I-receptor	I-receptor
positive	B-receptor-status	B-receptor-status
,	O	O
on	O	O
neoadjuvant	O	O
treatment	O	O
with	O	O
let	O	O
recommendations	O	O
reassured	O	O
ms	O	O
.	O	O
run	O	O
tomorrow	O	O
.	O	O
2011	O	O
:	O	O
hee	O	O
:	O	O
per	O	O
,	O	O
e	O	O
.	O	O
all	O	O
submitted	O	O
.	O	O
subsequent	O	O
additional	O	O
12	O	O
axillary	O	O
lymph	O	O
nodes	O	O
at	O	O
resection	O	O
showed	O	O
4	O	O
nodes	O	O
positive	O	O
for	O	O
a	O	O
total	O	O
of	O	O
5	O	O
of	O	O
16	O	O
nodes	O	O
positive	O	O
.	O	O
(	O	O
cr	O	O
-	O	O
207	O	O
)	O	O
tissue	O	O
description	O	O
:	O	O
tissue	O	O
from	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
(	O	O
4	O	O
x	O	O
4	O	O
x	O	O
2	O	O
cm	O	O
;	O	O
separate	O	O
anterior	O	O
margin	O	O
,	O	O
4	O	O
x	O	O
3	O	O
x	O	O
2	O	O
cm	O	O
)	O	O
and	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
lymph	O	O
nodes	O	O
.	O	O
pee	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
78	O	O
"	O	O
diagnosis	O	O
226	O	O
:	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
core	O	O
biopsy	O	O
(	O	O
sp	O	O
-	O	O
231	O	O
,	O	O
a1	O	O
(	O	O
2	O	O
)	O	O
,	O	O
2	O	O
slides	O	O
;	O	O
1	O	O
/	O	O
20	O	O
/	O	O
12	O	O
)	O	O
:	O	O
invasive	B-htype-value	B-htype-value
mammary	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
with	O	O
mu	O	O
features	O	O
,	O	O
nottingham	O	O
grade	B-grade	B-grade
i	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
.	O	O
aside	O	O
from	O	O
the	O	O
lump	O	O
,	O	O
she	O	O
has	O	O
had	O	O
no	O	O
other	O	O
breast	O	O
symptoms	O	O
.	O	O
page	O	O
:	O	O
127	O	O
-	O	O
146	O	O
.	O	O
breast	O	O
cancer	O	O
risk	O	O
profile	O	O
gr	O	O
3	O	O
,	O	O
para	O	O
3	O	O
.	O	O
she	O	O
attempted	O	O
adjuvant	O	O
chemo	O	O
,	O	O
received	O	O
one	O	O
cycle	O	O
,	O	O
had	O	O
severe	O	O
electro	O	O
im	O	O
and	O	O
had	O	O
a	O	O
seizure	O	O
,	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
room	O	O
.	O	O
the	O	O
syn	O	O
report	O	O
incorporates	O	O
information	O	O
from	O	O
all	O	O
relevant	O	O
surgical	O	O
material	O	O
and	O	O
includes	O	O
all	O	O
required	O	O
data	O	O
elements	O	O
of	O	O
the	O	O
current	O	O
cap	O	O
cancer	O	O
protocol	O	O
.	O	O
1	O	O
/	O	O
29	O	O
/	O	O
2014	O	O
14	O	O
:	O	O
03	O	O
interpreted	O	O
by	O	O
:	O	O
jean	O	O
e	O	O
.	O	O
che	O	O
,	O	O
m	O	O
.	O	O
bo	O	O
,	O	O
m	O	O
.	O	[CLS]
4	O	O
-	O	O
75	O	O
additional	O	O
physician	O	O
:	O	O
nh	O	O
v	O	O
.	O	O
tumor	O	O
size	B-size	B-size
(	O	O
largest	O	O
invasive	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
)	O	O
:	O	O
2	B-size-value	B-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
cm	I-size-value	I-size-value
.	O	O
distance	O	O
to	O	O
closest	O	O
margin	O	O
:	O	O
0	O	O
cm	O	O
,	O	O
deep	O	O
margin	O	O
lymph	O	O
invasion	O	O
:	O	O
not	O	O
identified	O	O
.	O	O
heart	O	O
:	O	O
regular	O	O
rate	O	O
and	O	O
rhythm	O	O
.	O	O
(	O	O
07	O	O
/	O	O
20	O	O
/	O	O
2006	O	O
)	O	O
al	O	O
carol	O	O
a	O	O
.	O	O
additionally	O	O
there	O	O
is	O	O
an	O	O
invasive	B-htype-value	B-htype-value
,	O	O
nottingham	O	O
grade	B-grade	B-grade
i	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
ductal	B-htype-value	B-htype-value
adenocarcinoma	I-htype-value	I-htype-value
,	O	O
forming	O	O
a	O	O
separate	O	O
mass	O	O
measuring	B-size	B-size
1	B-size-value	B-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
cm	I-size-value	I-size-value
.	O	O
there	O	O
is	O	O
no	O	O
evidence	O	O
of	O	O
extra	O	O
extension	O	O
.	O	O
she	O	O
has	O	O
never	O	O
had	O	O
radiation	O	O
treatments	O	O
for	O	O
a	O	O
medical	O	O
condition	O	O
.	O	O
a	O	O
wing	O	O
biopsy	O	O
clip	O	O
is	O	O
identified	O	O
within	O	O
the	O	O
mass	O	O
.	O	O
c	O	O
.	O	O
patrick	O	O
bu	O	O
comment	O	O
in	O	O
that	O	O
regard	O	O
in	O	O
his	O	O
admitting	O	O
note	O	O
when	O	O
he	O	O
sent	O	O
her	O	O
to	O	O
the	O	O
er	O	O
.	O	O
this	O	O
time	O	O
the	O	O
symptoms	O	O
seem	O	O
to	O	O
have	O	O
lasted	O	O
a	O	O
little	O	O
bit	O	O
longer	O	O
and	O	O
are	O	O
currently	O	O
still	O	O
present	O	O
.	O	O
my	O	O
recommendation	O	O
would	O	O
be	O	O
to	O	O
observe	O	O
her	O	O
closely	O	O
and	O	O
treat	O	O
her	O	O
only	O	O
if	O	O
there	O	O
is	O	O
cancer	O	O
rec	O	O
.	O	O
lungs	O	O
:	O	O
clear	O	O
to	O	O
aus	O	O
.	O	O
she	O	O
also	O	O
had	O	O
a	O	O
5	B-size-value	B-size-value
x	I-size-value	I-size-value
3	I-size-value	I-size-value
cm	I-size-value	I-size-value
mass	O	O
in	O	O
the	O	O
upper	B-site-value	B-site-value
outer	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
of	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
.	O	O
she	O	O
has	O	O
obviously	O	O
had	O	O
to	O	O
make	O	O
a	O	O
number	O	O
of	O	O
decisions	O	O
fairly	O	O
quickly	O	O
and	O	O
would	O	O
like	O	O
to	O	O
take	O	O
some	O	O
time	O	O
to	O	O
carefully	O	O
consider	O	O
this	O	O
newest	O	O
concern	O	O
.	O	O
i	O	O
advised	O	O
her	O	O
that	O	O
generally	O	O
a	O	O
cbc	O	O
with	O	O
differential	O	O
and	O	O
plate	O	O
count	O	O
is	O	O
done	O	O
as	O	O
well	O	O
as	O	O
blood	O	O
cultures	O	O
,	O	O
chest	O	O
x	O	O
,	O	O
and	O	O
ur	O	O
.	O	O
diagnosis	O	O
comment	O	O
226	O	O
:	O	O
immunohistochemical	O	O
studies	O	O
for	O	O
estrogen	B-receptor	B-receptor
and	O	O
progesterone	B-receptor	B-receptor
receptors	I-receptor	I-receptor
were	O	O
performed	O	O
previously	O	O
by	O	O
dr	O	O
.	O	O
may	O	O
9	O	O
,	O	O
2016	O	O
:	O	O
the	O	O
patient	O	O
underwent	O	O
core	O	O
biopsy	O	O
with	O	O
pathology	O	O
consistent	O	O
for	O	O
invasive	B-htype-value	B-htype-value
lobular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
with	O	O
associated	O	O
lcis	B-htype-value	B-htype-value
.	O	O
the	O	O
area	O	O
of	O	O
calcifications	O	O
is	O	O
am	O	O
to	O	O
lumpectomy	O	O
as	O	O
long	O	O
as	O	O
significant	O	O
additional	O	O
tissue	O	O
does	O	O
not	O	O
need	O	O
to	O	O
be	O	O
removed	O	O
.	O	O
all	O	O
submitted	O	O
.	O	O
a	O	O
radioactive	O	O
seed	O	O
is	O	O
identified	O	O
within	O	O
the	O	O
specimen	O	O
.	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
,	O	O
131	O	O
grams	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
_	O	O
"	O	O
diagnosis	O	O
226	O	O
:	O	O
a	O	O
.	O	O
transcribed	O	O
by	O	O
:	O	O
mao	O	O
7	O	O
/	O	O
26	O	O
/	O	O
2017	O	O
14	O	O
:	O	O
16	O	O
:	O	O
20	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
a	O	O
.	O	O
after	O	O
re	O	O
of	O	O
the	O	O
anterior	O	O
margin	O	O
(	O	O
see	O	O
part	O	O
b	O	O
)	O	O
,	O	O
all	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
(	O	O
closest	O	O
margin	O	O
is	O	O
the	O	O
inferior	O	O
at	O	O
0	O	O
cm	O	O
)	O	O
.	O	O
eyes	O	O
:	O	O
sc	O	O
an	O	O
.	O	O
all	O	O
submitted	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
,	O	O
excision	O	O
:	O	O
multiple	O	O
(	O	O
2	O	O
)	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	[CLS]
there	O	O
is	O	O
a	O	O
1	O	O
x	O	O
1	O	O
x	O	O
0	O	O
cm	O	O
firm	O	O
area	O	O
in	O	O
the	O	O
lateral	O	O
/	O	O
deep	O	O
portion	O	O
of	O	O
the	O	O
specimen	O	O
located	O	O
immediately	O	O
adjacent	O	O
/	O	O
lateral	O	O
to	O	O
the	O	O
biopsy	O	O
cavity	O	O
,	O	O
extending	O	O
to	O	O
the	O	O
superior	O	O
margin	O	O
(	O	O
submitted	O	O
perpendicular	O	O
)	O	O
and	O	O
the	O	O
lateral	O	O
/	O	O
deep	O	O
margin	O	O
(	O	O
submitted	O	O
shaved	O	O
)	O	O
,	O	[CLS]
and	O	O
located	O	O
0	O	O
cm	O	O
from	O	O
the	O	O
inferior	O	O
margin	O	O
(	O	O
submitted	O	O
perpendicular	O	O
)	O	O
.	O	O
macro	O	O
and	O	O
microscopic	O	O
extent	O	O
of	O	O
tumor	O	O
:	O	O
nipple	O	O
:	O	O
not	O	O
present	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
08	O	O
/	O	O
04	O	O
/	O	O
2011	O	O
surgical	O	O
pathology	O	O
(	O	O
cr	O	O
-	O	O
58	O	O
)	O	O
requested	O	O
by	O	O
:	O	O
james	O	O
w	O	O
.	O	O
she	O	O
has	O	O
had	O	O
some	O	O
ma	O	O
abnormalities	O	O
that	O	O
have	O	O
been	O	O
observed	O	O
every	O	O
six	O	O
to	O	O
twelve	O	O
months	O	O
for	O	O
the	O	O
past	O	O
several	O	O
years	O	O
.	O	O
biopsy	O	O
site	O	O
:	O	O
biopsy	O	O
site	O	O
changes	O	O
present	O	O
.	O	O
alternatively	O	O
,	O	O
she	O	O
could	O	O
begin	O	O
using	O	O
an	O	O
oral	O	O
contra	O	O
.	O	O
a	O	O
biopsy	O	O
site	O	O
and	O	O
firm	O	O
ill	O	O
area	O	O
(	O	O
1	O	B-size-value
x	O	I-size-value
1	O	I-size-value
x	O	I-size-value
1	O	I-size-value
cm	O	I-size-value
)	O	O
is	O	O
present	O	O
in	O	B-site-value
the	O	I-site-value
upper	O	I-site-value
outer	O	I-site-value
quadrant	O	I-site-value
and	O	I-site-value
2	O	I-site-value
cm	O	I-site-value
from	O	I-site-value
the	O	I-site-value
deep	O	I-site-value
margin	O	I-site-value
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
11	O	O
/	O	O
10	O	O
/	O	O
2011	O	O
path	O	O
review	O	O
of	O	O
outside	O	O
specimen	O	O
(	O	O
hr	O	O
-	O	O
62	O	O
)	O	O
referring	O	O
physician	O	O
:	O	O
fair	O	O
south	O	O
hospital	O	O
640	O	O
france	O	O
avenue	O	O
south	O	O
ed	O	O
,	O	O
mn	O	O
55	O	O
-	O	O
219	O	O
95	O	O
-	O	O
92	O	O
-	O	O
51	O	O
fa	O	O
phone	O	O
:	O	O
95	O	O
-	O	O
92	O	O
-	O	O
525	O	O
requested	O	O
by	O	O
:	O	O
jessica	O	O
n	O	O
.	O	O
she	O	O
was	O	O
also	O	O
noted	O	O
to	O	O
have	O	O
dcis	B-htype-value	B-htype-value
of	O	O
the	O	O
posterior	O	O
margin	O	O
.	O	O
the	O	O
one	O	O
at	O	O
9	B-site-value	B-site-value
o	I-site-value	I-site-value
showed	O	O
a	O	O
radial	O	O
scar	O	O
on	O	O
biopsy	O	O
and	O	O
the	O	O
second	O	O
that	O	O
measured	B-size	B-size
9	B-size-value	B-size-value
mm	I-size-value	I-size-value
in	I-size-value	I-size-value
diameter	I-size-value	I-size-value
at	O	O
11	B-site-value	B-site-value
o	I-site-value	I-site-value
showed	O	O
an	O	O
infiltrating	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
that	O	O
was	O	O
er	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
,	O	O
weakly	O	O
pr	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
,	O	O
and	O	O
her2	B-receptor	B-receptor
/	O	O
neu	O	O
negative	B-receptor-status	B-receptor-status
.	O	[CLS]
blue	O	O
dye	O	O
is	O	O
identified	O	O
in	O	O
the	O	O
lymph	O	O
node	O	O
.	O	O
mrs	O	O
.	O	O
she	O	O
has	O	O
good	O	O
functional	O	O
status	O	O
and	O	O
a	O	O
negative	O	O
recent	O	O
cardiovascular	O	O
evaluation	O	O
.	O	O
histologic	O	O
grade	B-grade	B-grade
:	O	O
nottingham	O	O
histologic	O	O
score	O	O
:	O	O
nottingham	O	O
score	O	O
:	O	O
glandular	O	O
/	O	O
tubular	O	O
differentiation	O	O
:	O	O
3	O	O
.	O	O
there	O	O
is	O	O
an	O	O
associated	O	O
(	O	O
approx	O	O
.	O	O
10	O	O
)	O	O
intraductal	O	O
component	O	O
,	O	O
come	O	O
type	O	O
.	O	O
margin	O	O
submitted	O	O
shaved	O	O
.	O	O
june	O	O
25	O	O
,	O	O
2013	O	O
:	O	O
the	O	O
patient	O	O
had	O	O
an	O	O
mb	O	O
which	O	O
showed	O	O
diffuse	O	O
,	O	O
marked	O	O
non	O	O
up	O	O
involving	O	O
a	O	O
majority	O	O
of	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
with	O	O
associated	O	O
diffuse	O	O
skin	O	O
up	O	O
.	O	O
all	O	O
submitted	O	O
.	O	O
histologic	O	O
grade	B-grade	B-grade
:	O	O
nottingham	O	O
histologic	O	O
score	O	O
:	O	O
nottingham	O	O
score	O	O
:	O	O
glandular	O	O
/	O	O
tubular	O	O
differentiation	O	O
:	O	O
no	O	O
residual	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
a	O	O
1	O	O
cm	O	O
biopsy	O	O
site	O	O
is	O	O
present	O	O
,	O	O
located	O	O
at	O	O
the	O	O
anterior	O	O
margin	O	O
,	O	O
and	O	O
4	O	O
mm	O	O
from	O	O
the	O	O
superior	O	O
margin	O	O
.	O	O
she	O	O
had	O	O
questions	O	O
about	O	O
her	O	O
lipid	O	O
status	O	O
and	O	O
management	O	O
of	O	O
the	O	O
l	O	O
.	O	O
no	O	O
residual	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
seen	O	O
.	O	O
d	O	O
.	O	O
explained	O	O
diagnosis	O	O
and	O	O
treatment	O	O
plan	O	O
;	O	O
patient	O	O
appears	O	O
to	O	O
understand	O	O
the	O	O
content	O	O
of	O	O
our	O	O
discussion	O	O
.	O	O
2011	O	O
:	O	O
on	O	O
physical	O	O
exam	O	O
she	O	O
is	O	O
a	O	O
pleasant	O	O
middle	O	O
woman	O	O
who	O	O
is	O	O
very	O	O
petite	O	O
.	O	O
el	O	O
is	O	O
ok	O	O
for	O	O
surgery	O	O
with	O	O
minimal	O	O
risk	O	O
for	O	O
cardiac	O	O
complications	O	O
related	O	O
to	O	O
this	O	O
procedure	O	O
.	O	O
in	O	O
case	O	O
she	O	O
does	O	O
need	O	O
mastectomy	O	O
,	O	O
the	O	O
patient	O	O
might	O	O
be	O	O
interested	O	O
in	O	O
rec	O	O
surgery	O	O
,	O	O
and	O	O
dr	O	O
.	O	O
estrogen	B-receptor	B-receptor
and	O	O
progesterone	B-receptor	B-receptor
receptors	I-receptor	I-receptor
were	O	O
positive	B-receptor-status	B-receptor-status
.	O	O
don	O	O
,	O	O
m	O	O
.	O	O
cloud	O	O
,	O	O
mn	O	O
56	O	O
(	O	O
320	O	O
)	O	O
251	O	O
-	O	O
270	O	O
ex	O	O
5	O	O
-	O	O
730	O	O
requested	O	O
by	O	O
:	O	O
sand	O	O
pr	O	O
,	O	O
m	O	O
.	O	O
"	O	O
she	O	O
has	O	O
not	O	O
noticed	O	O
any	O	O
abnormalities	O	O
in	O	O
her	O	O
breast	O	O
but	O	O
does	O	O
believe	O	O
that	O	O
some	O	O
fluid	O	O
has	O	O
accumulated	O	O
there	O	O
.	O	O
aziz	O	O
nas	O	O
.	O	O
4	O	O
/	O	O
20	O	O
/	O	O
2012	O	O
16	O	O
:	O	O
46	O	O
interpreted	O	O
by	O	O
:	O	O
tao	O	O
mo	O	O
,	O	O
m	O	O
.	O	O
3	O	O
-	O	O
52	O	O
report	O	O
electronically	O	O
signed	O	O
by	O	O
tao	O	O
mo	O	O
,	O	O
m	O	O
.	O	O
progesterone	B-receptor	B-receptor
:	O	O
positive	B-receptor-status	B-receptor-status
,	O	O
26	O	O
-	O	O
50	O	O
tumor	O	O
nuclei	O	O
staining	O	O
.	O	O
lymphovascular	O	O
invasion	O	O
was	O	O
ind	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
left	B-laterality-value	B-laterality-value
deep	O	O
posterior	O	O
breast	O	O
tissue	O	O
\	O	O
"	O	O
is	O	O
a	O	O
3	O	O
x	O	O
2	O	O
x	O	O
0	O	O
cm	O	O
portion	O	O
of	O	O
tan	O	O
fi	O	O
tissue	O	O
.	O	O
k	O	O
.	O	O
lymph	O	O
node	O	O
sampling	O	O
:	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
submitted	O	O
.	O	O
ultrasound	O	O
of	O	O
the	O	O
axilla	O	O
showed	O	O
multiple	O	O
axillary	O	O
masses	O	O
.	O	O
she	O	O
has	O	O
a	O	O
good	O	O
level	O	O
of	O	O
energy	O	O
and	O	O
appetite	O	O
.	O	O
lester	O	O
wo	O	O
as	O	O
mm	O	O
consultation	O	O
case	O	O
pr	O	O
-	O	O
61	O	O
;	O	O
slides	O	O
not	O	O
re	O	O
.	O	O
2	O	O
/	O	O
16	O	O
/	O	O
05	O	O
lester	O	O
e	O	O
.	O	O
ko	O	O
in	O	O
albert	O	O
lea	O	O
.	O	O
dr	O	O
.	O	O
a	O	O
techno	O	O
views	O	O
the	O	O
captured	O	O
digital	O	O
image	O	O
and	O	O
traces	O	O
around	O	O
areas	O	O
of	O	O
cancer	O	O
to	O	O
include	O	O
at	O	O
least	O	O
75	O	O
of	O	O
the	O	O
total	O	O
invasive	O	O
cancer	O	O
within	O	O
the	O	O
image	O	O
.	O	O
she	O	O
drinks	O	O
less	O	O
than	O	O
one	O	O
to	O	O
two	O	O
alcoholic	O	O
beverages	O	O
per	O	O
week	O	O
.	O	O
ultrasound	O	O
of	O	O
the	O	O
left	B-laterality-value	B-laterality-value
axilla	O	O
did	O	O
not	O	O
reveal	O	O
any	O	O
wo	O	O
findings	O	O
.	O	O
2010	O	O
:	O	O
ms	O	O
.	O	O
a	O	O
needle	O	O
local	O	O
wire	O	O
is	O	O
identified	O	O
.	O	O
heart	O	O
:	O	O
pal	O	O
,	O	O
aus	O	O
,	O	O
jug	O	O
veins	O	O
examined	O	O
and	O	O
normal	O	O
.	O	O
d	O	O
.	O	O
ste	O	O
several	O	O
years	O	O
previously	O	O
.	O	O
hold	O	O
over	O	O
for	O	O
further	O	O
evaluation	O	O
on	O	O
permanent	O	O
sections	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
new	O	O
superior	O	O
medial	O	O
margin	O	O
,	O	O
excision	O	O
:	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
transcribed	O	O
by	O	O
:	O	O
er	O	O
1	O	O
/	O	O
15	O	O
/	O	O
2009	O	O
09	O	O
:	O	O
11	O	O
:	O	O
35	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
benign	O	O
breast	O	O
par	O	O
with	O	O
a	O	O
single	O	O
fibroadenoma	B-htype-value	B-htype-value
(	O	O
1	B-size-value	B-size-value
cm	I-size-value	I-size-value
in	O	O
greatest	O	O
dimension	O	O
)	O	O
and	O	O
focal	O	O
sc	O	O
aden	O	O
.	O	[CLS]
ruth	O	O
johnson	O	O
who	O	O
had	O	O
seen	O	O
the	O	O
patient	O	O
in	O	O
the	O	O
past	O	O
for	O	O
fibrocystic	O	O
breast	O	O
tissue	O	O
.	O	O
we	O	O
also	O	O
have	O	O
dr	O	O
.	O	O
heart	O	O
:	O	O
regular	O	O
rate	O	O
and	O	O
rhythm	O	O
.	O	O
keen	O	O
,	O	O
m	O	O
.	O	O
see	O	O
syn	O	O
report	O	O
.	O	O
she	O	O
has	O	O
had	O	O
prior	O	O
breast	O	O
radiation	O	O
but	O	O
no	O	O
cr	O	O
radiation	O	O
in	O	O
the	O	O
past	O	O
.	O	O
nodule	O	O
#	O	O
6	O	O
lt	O	B-laterality-value
upper	O	B-site-value
inner	O	I-site-value
quadrant	O	I-site-value
7	O	O
lt	O	B-laterality-value
lower	O	B-site-value
outer	O	I-site-value
quadrant	O	I-site-value
8	O	O
lt	B-laterality-value	B-laterality-value
li	O	O
tumor	O	O
-	O	O
3	O	O
part	O	O
d	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
1	O	O
right	B-laterality-value	B-laterality-value
nipple	O	O
2	O	O
rt	B-laterality-value	B-laterality-value
u	O	O
biopsy	O	O
site	O	O
-	O	O
1	O	O
3	O	O
rt	B-laterality-value	B-laterality-value
u	O	O
biopsy	O	O
site	O	O
-	O	O
2	O	O
4	O	O
rt	B-laterality-value	B-laterality-value
intra	O	O
l	O	O
1	O	O
(	O	O
d	O	O
)	O	O
5	O	O
rt	O	B-laterality-value
skin	O	O
lesion	O	O
#	O	O
6	O	O
rt	O	B-laterality-value
skin	O	O
lesion	O	O
#	O	O
7	O	O
rt	B-laterality-value	B-laterality-value
u	O	O
nodule	O	O
?	O	O
patient	O	O
education	O	O
ready	O	O
to	O	O
learn	O	O
,	O	O
no	O	O
apparent	O	O
learning	O	O
barriers	O	O
were	O	O
identified	O	O
;	O	O
learning	O	O
preferences	O	O
include	O	O
listening	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
tissue	O	O
set	O	O
#	O	O
,	O	O
biopsy	O	O
:	O	O
multiple	O	O
(	O	O
3	O	O
)	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
she	O	O
has	O	O
also	O	O
started	O	O
radiation	O	O
therapy	O	O
.	O	O
has	O	O
had	O	O
bilateral	B-laterality-value	B-laterality-value
mast	O	O
for	O	O
two	O	O
separate	O	O
breast	O	O
cancer	O	O
dia	O	O
.	O	O
tumor	O	O
location	O	B-site
(	O	O
mastectomy	O	O
)	O	O
:	O	O
#	O	O
size	B-size	B-size
(	O	O
extent	O	O
)	O	O
of	O	O
dcis	B-htype-value	B-htype-value
:	O	O
3	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
.	O	O
2010	O	O
:	O	O
since	O	O
her	O	O
last	O	O
visit	O	O
,	O	O
mrs	O	O
.	O	O
there	O	O
was	O	O
no	O	O
angiolymphatic	O	O
invasion	O	O
.	O	O
lymph	O	O
node	O	O
sampling	O	O
:	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
submitted	O	O
.	O	O
the	O	O
nipple	O	O
is	O	O
un	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
01	O	O
/	O	O
27	O	O
/	O	O
2014	O	O
surgical	O	O
pathology	O	O
(	O	O
cr	O	O
-	O	O
64	O	O
)	O	O
revised	O	O
report	O	O
(	O	O
addendum	O	O
/	O	O
procedure	O	O
included	O	O
)	O	O
requested	O	O
by	O	O
:	O	O
tina	O	O
j	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
left	B-laterality-value	B-laterality-value
intra	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
)	O	O
sentinel	O	O
lymph	O	O
node	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
d	O	O
.	O	O
she	O	O
had	O	O
an	O	O
excision	O	O
biopsy	O	O
of	O	O
two	O	O
lymph	O	O
nodes	O	O
from	O	O
the	O	O
left	B-laterality-value	B-laterality-value
axilla	O	O
which	O	O
were	O	O
reported	O	O
to	O	O
be	O	O
benign	O	O
.	O	O
at	O	O
this	O	O
time	O	O
she	O	O
is	O	O
leaning	O	O
towards	O	O
the	O	O
lumpectomy	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
2	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
)	O	O
sentinel	O	O
lymph	O	O
node	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	[CLS]
left	B-laterality-value	B-laterality-value
breast	O	O
firm	O	O
tissue	O	O
-	O	O
fi	O	O
tissue	O	O
with	O	O
focal	O	O
dense	O	O
fibrosis	O	O
.	O	O
pet	O	O
scan	O	O
on	O	O
july	O	O
24	O	O
,	O	O
2008	O	O
,	O	O
showed	O	O
no	O	O
evidence	O	O
of	O	O
disease	O	O
spread	O	O
outside	O	O
the	O	O
chest	O	O
wall	O	O
and	O	O
axilla	O	O
.	O	[CLS]
7	O	O
.	O	O
all	O	O
submitted	O	O
.	O	O
teaching	O	O
methods	O	O
included	O	O
:	O	O
discussion	O	O
,	O	O
explanation	O	O
,	O	O
printed	O	O
material	O	O
.	O	O
following	O	O
discussions	O	O
,	O	O
the	O	O
patient	O	O
has	O	O
decided	O	O
not	O	O
to	O	O
take	O	O
tamoxifen	O	O
.	O	O
the	O	O
closest	O	O
margin	O	O
is	O	O
the	O	O
anterior	O	O
by	O	O
<	O	O
0	O	O
cm	O	O
.	O	O
additional	O	O
dimensions	O	O
:	O	O
4	B-size-value	B-size-value
x	I-size-value	O
4	I-size-value	I-size-value
cm	I-size-value	O
.	O	O
preliminary	O	O
report	O	O
indicates	O	O
enhancement	O	O
at	O	O
the	O	O
6	B-site-value	B-site-value
o	I-site-value	I-site-value
position	I-site-value	I-site-value
of	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
which	O	O
covers	O	O
an	O	O
area	O	O
up	O	O
to	O	O
4	B-size-value	B-size-value
cm	I-size-value	I-size-value
in	O	O
size	B-size	B-size
,	O	O
although	O	O
some	O	O
of	O	O
this	O	O
enhancement	O	O
was	O	O
felt	O	O
possibly	O	O
to	O	O
be	O	O
a	O	O
result	O	O
of	O	O
blood	O	O
from	O	O
the	O	O
recent	O	O
biopsy	O	O
.	O	O
progesterone	B-receptor	B-receptor
:	O	O
positive	B-receptor-status	B-receptor-status
,	O	O
>	O	O
75	O	O
tumor	O	O
nuclei	O	O
staining	O	O
.	O	O
informed	O	O
the	O	O
patient	O	O
that	O	O
further	O	O
discussion	O	O
regarding	O	O
the	O	O
role	O	O
of	O	O
chemotherapy	O	O
and	O	O
hormone	O	O
therapy	O	O
would	O	O
take	O	O
place	O	O
with	O	O
medical	O	O
oncology	O	O
after	O	O
surgery	O	O
.	O	O
as	O	O
28	O	O
.	O	O
the	O	O
patient	O	O
is	O	O
going	O	O
to	O	O
return	O	O
in	O	O
november	O	O
to	O	O
see	O	O
dr	O	O
.	O	O
2010	O	O
:	O	O
mrs	O	O
.	O	O
the	O	O
nipple	O	O
,	O	O
and	O	O
surgical	O	O
margins	O	O
are	O	O
free	O	O
of	O	O
tumor	O	O
.	O	[CLS]
sk	O	O
today	O	O
approximately	O	O
three	O	O
months	O	O
after	O	O
our	O	O
last	O	O
visit	O	O
and	O	O
approximately	O	O
six	O	O
months	O	O
after	O	O
the	O	O
conclusion	O	O
of	O	O
her	O	O
radiation	O	O
therapy	O	O
.	O	O
el	O	O
met	O	O
with	O	O
a	O	O
local	O	O
surgeon	O	O
as	O	O
well	O	O
as	O	O
a	O	O
medical	O	O
on	O	O
.	O	O
she	O	O
was	O	O
previously	O	O
on	O	O
ho	O	O
birth	O	O
control	O	O
for	O	O
over	O	O
11	O	O
years	O	O
,	O	O
but	O	O
not	O	O
currently	O	O
.	O	O
hee	O	O
eun	O	O
lee	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
01	O	O
/	O	O
16	O	O
/	O	O
2007	O	O
surgical	O	O
pathology	O	O
(	O	O
cr	O	O
-	O	O
46	O	O
)	O	O
requested	O	O
by	O	O
:	O	O
judy	O	O
c	O	O
.	O	O
i	O	O
reviewed	O	O
with	O	O
ms	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
05	O	O
/	O	O
03	O	O
/	O	O
2013	O	O
path	O	O
review	O	O
of	O	O
outside	O	O
specimen	O	O
(	O	O
hr	O	O
-	O	O
2010	O	O
)	O	O
referring	O	O
physician	O	O
:	O	O
jeremy	O	O
b	O	O
.	O	O
laboratory	O	O
developed	O	O
test	O	O
transcribed	O	O
by	O	O
:	O	O
j	O	O
6	O	O
/	O	O
10	O	O
/	O	O
2016	O	O
09	O	O
:	O	O
08	O	O
:	O	O
08	O	O
signed	O	O
by	O	O
rafael	O	O
e	O	O
.	O	O
er	B-receptor	B-receptor
(	O	O
estrogen	B-receptor	B-receptor
receptor	I-receptor	I-receptor
)	O	O
test	O	O
was	O	O
developed	O	O
and	O	O
its	O	O
performance	O	O
characteristics	O	O
determined	O	O
by	O	O
laboratory	O	O
medicine	O	O
and	O	O
pathology	O	O
,	O	O
mayo	O	O
clinic	O	O
rochester	O	O
.	O	O
advance	O	O
directive	O	O
advance	O	O
directive	O	O
or	O	O
living	O	O
will	O	O
:	O	O
no	O	O
,	O	O
not	O	O
interested	O	O
in	O	O
additional	O	O
information	O	O
.	O	O
abdomen	O	O
:	O	O
well	O	O
mid	O	O
surgical	O	O
scar	O	O
.	O	O
hu	O	O
is	O	O
a	O	O
34	O	O
y	O	O
/	O	O
o	O	O
woman	O	O
with	O	O
a	O	O
history	O	O
of	O	O
ang	B-htype-value	B-htype-value
of	O	[CLS]
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
s	O	O
/	O	O
p	O	O
surgical	O	O
resection	O	O
which	O	O
revealed	O	O
an	O	O
ind	B-grade-value	O
to	I-grade-value	I-grade-value
high	I-grade-value	I-grade-value
grade	B-grade	B-grade
sar	B-htype-value	O
.	O	O
grossed	O	O
by	O	O
t	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
contents	O	O
,	O	O
dissection	O	O
:	O	O
multiple	O	O
(	O	O
16	O	O
)	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
all	O	O
of	O	O
her	O	O
questions	O	O
were	O	O
answered	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
1	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
)	O	O
sentinel	O	O
lymph	O	O
node	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	[CLS]
rodriguez	O	O
,	O	O
m	O	O
.	O	O
8	O	O
-	O	O
97	O	O
report	O	O
electronically	O	O
signed	O	O
by	O	O
faust	O	O
j	O	O
.	O	O
the	O	O
non	O	O
breast	O	O
par	O	O
shows	O	O
atypical	O	O
ductal	O	O
hyperplasia	O	O
and	O	O
pro	O	O
fibrocystic	O	O
changes	O	O
.	O	O
thank	O	O
you	O	O
for	O	O
involving	O	O
me	O	O
in	O	O
the	O	O
care	O	O
of	O	O
this	O	O
patient	O	O
.	O	O
review	O	O
of	O	O
her	O	O
staging	O	O
studies	O	O
indicates	O	O
that	O	O
she	O	O
does	O	O
not	O	O
have	O	O
any	O	O
evidence	O	O
of	O	O
metastasis	O	O
.	O	O
grossed	O	O
by	O	O
jr	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
1	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
)	O	O
sentinel	O	O
lymph	O	O
node	O	O
with	O	O
blue	O	O
dye	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
.	O	O
patient	O	O
had	O	O
evaluation	O	O
by	O	O
radiation	O	O
oncology	O	O
.	O	O
since	O	O
her	O	O
therapy	O	O
in	O	O
2007	O	O
,	O	O
she	O	O
has	O	O
not	O	O
had	O	O
any	O	O
recurrent	O	O
episodes	O	O
since	O	O
.	O	O
breasts	O	O
:	O	O
bilateral	B-laterality-value	B-laterality-value
mast	O	O
.	O	O
mental	O	O
:	O	O
the	O	O
patient	O	O
is	O	O
alert	O	O
and	O	O
pleasant	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
new	O	O
inferior	O	O
skin	O	O
margin	O	O
,	O	O
excision	O	O
:	O	O
lateral	O	O
portion	O	O
(	O	O
no	O	O
.	O	O
4	O	O
)	O	O
is	O	O
positive	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
she	O	O
has	O	O
been	O	O
known	O	O
to	O	O
have	O	O
diffuse	O	O
ve	O	O
metastases	O	O
without	O	O
any	O	O
apparent	O	O
du	O	O
invasion	O	O
.	O	O
heart	O	O
:	O	O
regular	O	O
rate	O	O
and	O	O
rhythm	O	O
.	O	O
skin	O	O
and	O	O
nipple	O	O
without	O	O
diagnostic	O	O
abnormalities	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
lumpectomy	O	O
:	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
nottingham	O	O
grade	B-grade	B-grade
ii	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
.	O	O
her	O	O
dex	O	O
scan	O	O
performed	O	O
at	O	O
the	O	O
start	O	O
of	O	O
ai	O	O
therapy	O	O
was	O	O
not	O	O
completely	O	O
diagnostic	O	O
but	O	O
essentially	O	O
un	O	O
.	O	O
c	O	O
.	O	O
fixation	O	O
:	O	O
estrogen	B-receptor	B-receptor
receptor	I-receptor	I-receptor
(	O	O
er	B-receptor	B-receptor
)	O	O
and	O	O
progesterone	B-receptor	B-receptor
receptor	I-receptor	I-receptor
(	O	O
pr	B-receptor	B-receptor
)	O	O
immunohistochemical	O	O
(	O	O
i	O	O
)	O	O
test	O	O
results	O	O
are	O	O
only	O	O
valid	O	O
for	O	O
non	O	O
paraffin	O	O
embedded	O	O
specimens	O	O
section	O	O
at	O	O
5	O	O
intervals	O	O
and	O	O
fixed	O	O
in	O	O
10	O	O
neutral	O	O
buffer	O	O
formalin	O	O
within	O	O
1	O	O
hour	O	O
of	O	O
acquisition	O	O
and	O	O
fixed	O	O
between	O	O
6	O	O
and	O	O
72	O	O
hours	O	O
.	O	O
transcribed	O	O
by	O	O
:	O	O
k	O	O
6	O	O
/	O	O
29	O	O
/	O	O
2016	O	O
16	O	O
:	O	O
50	O	O
:	O	O
31	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
a	O	O
.	O	O
skeletal	O	O
muscle	O	O
:	O	O
not	O	O
present	O	O
.	O	O
tumor	O	O
extends	O	O
to	O	O
the	O	O
initial	O	O
superior	O	O
and	O	O
inferior	O	O
skin	O	O
margins	O	O
.	O	O
she	O	O
also	O	O
was	O	O
explained	O	O
that	O	O
she	O	O
will	O	O
need	O	O
a	O	O
repeat	O	O
dex	O	O
scan	O	O
in	O	O
1	O	O
year	O	O
.	O	O
(	O	O
cd	O	O
46	O	O
)	O	O
4	O	O
/	O	O
9	O	O
/	O	O
04	O	O
eric	O	O
a	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
lumpectomy	O	O
:	O	O
biopsy	O	O
site	O	O
changes	O	O
.	O	O
lloyd	O	O
,	O	O
m	O	O
.	O	[CLS]
4	O	O
-	O	O
67	O	O
"	O	O
procedure	O	O
:	O	O
lumpectomy	O	O
:	O	O
wire	O	O
localized	O	O
.	O	O
hold	O	O
over	O	O
to	O	O
evaluate	O	O
.	O	O
"	O	O
she	O	O
is	O	O
currently	O	O
on	O	O
tamoxifen	O	O
therapy	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
1	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
)	O	O
sentinel	O	O
lymph	O	O
node	O	O
without	O	O
blue	O	O
dye	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
her	O	O
only	O	O
sy	O	O
change	O	O
is	O	O
since	O	O
going	O	O
back	O	O
to	O	O
work	O	O
,	O	O
she	O	O
has	O	O
noted	O	O
an	O	O
increase	O	O
in	O	O
lower	O	O
back	O	O
discomfort	O	O
.	O	O
:	O	O
k	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
:	O	O
no	O	O
residual	O	O
tumor	O	O
identified	O	O
.	O	O
a	O	O
.	O	O
deborah	O	O
j	O	O
.	O	O
b	O	O
.	O	O
ga	O	O
,	O	O
m	O	O
.	O	O
discussed	O	O
follow	O	O
with	O	O
medical	O	O
oncology	O	O
and	O	O
possible	O	O
radiation	O	O
oncology	O	O
at	O	O
mayo	O	O
or	O	O
locally	O	O
.	O	O
all	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
carcinoma	O	O
.	O	O
biopsy	O	O
site	O	O
changes	O	O
are	O	O
present	O	O
.	O	O
o	O	O
communicated	O	O
these	O	O
results	O	O
to	O	O
patient	O	O
over	O	O
the	O	O
phone	O	O
.	O	O
7	O	O
.	O	O
the	O	O
par	O	O
showed	O	O
pro	O	O
fibrocystic	O	O
change	O	O
including	O	O
sc	O	O
aden	O	O
,	O	O
radial	O	O
scar	O	O
,	O	O
apocrine	O	O
metaplasia	O	O
,	O	O
and	O	O
duct	O	O
ec	O	O
.	O	O
h	O	O
.	O	O
skin	O	O
:	O	O
no	O	O
rash	O	O
or	O	O
lesions	O	O
of	O	O
concern	O	O
to	O	O
upper	O	O
ex	O	O
or	O	O
tr	O	O
region	O	O
.	O	O
ultrasound	O	O
confirmed	O	O
a	O	O
7	B-size-value	B-size-value
mill	I-size-value	I-size-value
h	O	O
mass	O	O
at	O	O
the	O	O
2	B-site-value	B-site-value
o	I-site-value	I-site-value
position	I-site-value	I-site-value
ms	O	O
.	O	O
,	O	O
and	O	O
a	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
lymph	O	O
node	O	O
with	O	O
mild	O	O
co	O	O
thick	O	O
.	O	[CLS]
2	O	O
.	O	O
she	O	O
is	O	O
in	O	O
no	O	O
acute	O	O
distress	O	O
.	O	O
tap	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
on	O	O
july	O	O
12	O	O
,	O	O
2000	O	O
,	O	O
at	O	O
which	O	O
time	O	O
she	O	O
underwent	O	O
lymph	O	O
by	O	O
the	O	O
nuclear	O	O
medicine	O	O
staff	O	O
.	O	[CLS]
michael	O	O
pa	O	O
.	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
mastectomy	O	O
was	O	O
performed	O	O
prop	O	O
and	O	O
demonstrated	O	O
non	O	O
fibrocystic	O	O
changes	O	O
and	O	O
no	O	O
evidence	O	O
of	O	O
any	O	O
mali	O	O
.	O	O
charles	O	O
lo	O	O
and	O	O
was	O	O
initiated	O	O
on	O	O
neoadjuvant	O	O
chemotherapy	O	O
and	O	O
participating	O	O
in	O	O
the	O	O
mc	O	O
beauty	O	O
clinical	O	O
trial	O	O
.	O	O
gross	O	O
description	O	O
226	O	O
:	O	O
a	O	O
.	O	O
chest	O	O
x	O	O
(	O	O
9	O	O
/	O	O
10	O	O
/	O	O
99	O	O
)	O	O
-	O	O
post	O	O
changes	O	O
in	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
,	O	O
surgical	O	O
clips	O	O
upper	O	O
abdomen	O	O
,	O	O
otherwise	O	O
negative	O	O
.	O	O
j	O	O
cl	O	O
on	O	O
2005	O	O
oct	O	O
1	O	O
;	O	O
23	O	O
(	O	O
28	O	O
)	O	O
:	O	O
72	O	O
-	O	O
72	O	O
2	O	O
.	O	O
de	O	O
az	O	O
e	O	O
,	O	O
card	O	O
f	O	O
,	O	O
de	O	O
castro	O	O
g	O	O
jr	O	O
,	O	O
et	O	O
al	O	O
.	O	O
hold	O	O
over	O	O
for	O	O
permanent	O	O
sections	O	O
.	O	O
she	O	O
did	O	O
use	O	O
oral	O	O
contra	O	O
for	O	O
11	O	O
years	O	O
or	O	O
more	O	O
,	O	O
never	O	O
before	O	O
1975	O	O
,	O	O
and	O	O
none	O	O
currently	O	O
.	O	O
she	O	O
has	O	O
had	O	O
the	O	O
breast	O	O
biopsy	O	O
as	O	O
well	O	O
as	O	O
bladder	O	O
sling	O	O
,	O	O
hysterectomy	O	O
,	O	O
and	O	O
cho	O	O
with	O	O
no	O	O
an	O	O
complications	O	O
.	O	O
also	O	O
present	O	O
in	O	O
the	O	O
room	O	O
was	O	O
her	O	O
daughter	O	O
.	O	O
#	O	O
os	O	O
recommendations	O	O
will	O	O
plan	O	O
to	O	O
repeat	O	O
rec	O	O
in	O	O
in	O	O
may	O	O
2011	O	O
.	O	O
grossed	O	O
by	O	O
jr	O	O
.	O	O
f	O	O
.	O	O
i	O	O
agree	O	O
that	O	O
it	O	O
appears	O	O
normal	O	O
including	O	O
the	O	O
internal	O	O
acoustic	O	O
meat	O	O
bilaterally	O	O
.	O	O
grossed	O	O
by	O	O
t	O	O
.	O	O
pathologic	O	O
staging	B-stage	B-stage
des	O	O
:	O	O
y	O	O
(	O	O
post	O	O
)	O	O
.	O	O
cr	O	O
-	O	O
58	O	O
a1	O	O
,	O	O
a2	O	O
,	O	O
b1	O	O
,	O	O
b	O	O
,	O	O
b	O	O
,	O	O
c1	O	O
,	O	O
c2	O	O
,	O	O
c	O	O
,	O	O
c	O	O
,	O	O
c	O	O
,	O	O
c	O	O
"	O	O
diagnosis	O	O
226	O	O
:	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
grade	B-grade	B-grade
4	B-grade-value	B-grade-value
(	O	O
of	O	O
4	O	O
)	O	O
,	O	O
nuclear	O	O
grade	B-grade	B-grade
2	B-grade-value	B-grade-value
(	O	O
of	O	O
3	O	O
)	O	O
,	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
forming	O	O
a	O	O
ci	O	O
mass	O	O
(	O	O
2	B-size-value	B-size-value
x	I-size-value	I-size-value
2	I-size-value	I-size-value
x	I-size-value	I-size-value
2	I-size-value	I-size-value
cm	I-size-value	I-size-value
)	O	O
(	O	O
aj	O	O
pt1c	B-stage-value	B-stage-value
)	O	O
located	B-site	B-site
in	B-site-value	B-site-value
the	I-site-value	I-site-value
lower	I-site-value	I-site-value
outer	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
of	O	I-site-value
the	O	I-site-value
breast	O	I-site-value
.	O	O
on	O	O
clinical	O	O
breast	O	O
exam	O	O
,	O	O
she	O	O
did	O	O
have	O	O
a	O	O
2	B-size-value	B-size-value
-	I-size-value	I-size-value
cm	I-size-value	I-size-value
nodule	O	O
at	O	O
the	O	O
5	B-site-value	B-site-value
o	I-site-value	I-site-value
position	I-site-value	I-site-value
within	I-site-value	I-site-value
the	I-site-value	I-site-value
are	I-site-value	I-site-value
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
that	O	O
was	O	O
extremely	O	O
firm	O	O
and	O	O
mobile	O	O
.	O	O
don	O	O
had	O	O
suggested	O	O
that	O	O
she	O	O
undergo	O	O
the	O	O
radiation	O	O
since	O	O
this	O	O
is	O	O
the	O	O
standard	O	O
treatment	O	O
,	O	O
though	O	O
he	O	O
was	O	O
not	O	O
opposed	O	O
to	O	O
her	O	O
entering	O	O
the	O	O
eco	O	O
study	O	O
.	O	O
i	O	O
handed	O	O
her	O	O
printed	O	O
material	O	O
with	O	O
information	O	O
on	O	O
these	O	O
drugs	O	O
.	O	O
be	O	O
has	O	O
had	O	O
to	O	O
her	O	O
neoadjuvant	O	O
chemotherapy	O	O
.	O	O
the	O	O
tumor	O	O
is	O	O
present	O	O
in	O	O
two	O	O
separate	O	O
areas	O	O
,	O	O
measuring	B-size	B-size
0	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
and	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
.	O	[CLS]
grossed	O	O
by	O	O
t	O	O
.	O	O
the	O	O
above	O	O
history	O	O
and	O	O
physical	O	O
exam	O	O
was	O	O
performed	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
dr	O	O
.	O	O
she	O	O
had	O	O
a	O	O
bone	O	O
density	O	O
test	O	O
which	O	O
was	O	O
normal	O	O
five	O	O
or	O	O
six	O	O
years	O	O
ago	O	O
.	O	O
procedure	O	O
:	O	O
lumpectomy	O	O
:	O	O
wire	O	O
localized	O	O
.	O	O
we	O	O
have	O	O
also	O	O
suggested	O	O
that	O	O
it	O	O
would	O	O
also	O	O
be	O	O
reasonable	O	O
,	O	O
if	O	O
the	O	O
echocardiogram	O	O
is	O	O
satisfactory	O	O
,	O	O
to	O	O
proceed	O	O
with	O	O
four	O	O
to	O	O
six	O	O
cycles	O	O
of	O	O
chemotherapy	O	O
.	O	O
i	O	O
will	O	O
discuss	O	O
follow	O	O
up	O	O
plans	O	O
with	O	O
dr	O	O
.	O	O
miller	O	O
appears	O	O
to	O	O
be	O	O
coping	O	O
adequately	O	O
at	O	O
this	O	O
time	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
additional	O	O
tissue	O	O
\	O	O
"	O	O
is	O	O
a	O	O
3	O	O
x	O	O
2	O	O
x	O	O
0	O	O
cm	O	O
aggregate	O	O
of	O	O
adi	O	O
and	O	O
lymph	O	O
tissue	O	O
.	O	O
we	O	O
will	O	O
likely	O	O
repeat	O	O
the	O	O
ct	O	O
at	O	O
a	O	O
later	O	O
date	O	O
.	O	O
we	O	O
will	O	O
work	O	O
on	O	O
getting	O	O
this	O	O
done	O	O
.	O	O
transcribed	O	O
by	O	O
:	O	O
la	O	O
8	O	O
/	O	O
28	O	O
/	O	O
2017	O	O
08	O	O
:	O	O
56	O	O
:	O	O
19	O	O
signed	O	O
by	O	O
bei	O	O
chen	O	O
,	O	O
m	O	O
.	O	O
9	O	O
/	O	O
5	O	O
/	O	O
2017	O	O
08	O	O
:	O	O
29	O	O
:	O	O
47	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
a	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
new	O	O
inferior	O	O
skin	O	O
margin	O	O
,	O	O
no	O	O
.	O	O
2	O	O
,	O	O
excision	O	O
:	O	O
all	O	O
positive	O	O
for	O	O
tumor	O	O
.	O	O
however	O	O
,	O	O
given	O	O
the	O	O
questionable	O	O
areas	O	O
in	O	O
the	O	O
liver	O	O
noted	O	O
on	O	O
the	O	O
ct	O	O
ur	O	O
,	O	O
i	O	O
would	O	O
like	O	O
to	O	O
appreciate	O	O
with	O	O
an	O	O
ultrasound	O	O
to	O	O
define	O	O
these	O	O
lesions	O	O
.	O	O
discussed	O	O
transient	O	O
the	O	O
elevated	O	O
cho	O	O
levels	O	O
that	O	O
are	O	O
present	O	O
.	O	O
two	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
.	O	O
a	O	O
single	O	O
intra	O	O
lymph	O	O
node	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
otherwise	O	O
,	O	O
there	O	O
are	O	O
no	O	O
palpable	O	O
nod	O	O
or	O	O
masses	O	O
in	O	O
either	O	O
breast	O	O
.	O	O
all	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
following	O	O
re	O	O
of	O	O
the	O	O
medial	O	O
and	O	O
lateral	O	O
margins	O	O
(	O	O
see	O	O
parts	O	O
b	O	O
and	O	O
c	O	O
)	O	O
.	O	O
d	O	O
.	O	O
far	O	O
,	O	O
m	O	O
.	O	O
f	O	O
.	O	O
tumor	O	O
focality	O	O
:	O	O
single	O	O
focus	O	O
of	O	O
invasive	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
cytologic	O	O
evidence	O	O
of	O	O
therapeutic	O	O
effect	O	O
:	O	O
present	O	O
:	O	O
fibrosis	O	O
.	O	O
there	O	O
is	O	O
a	O	O
second	O	O
nodule	O	O
(	O	O
0	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
)	O	O
,	O	O
1	B-site-value	B-site-value
cm	I-site-value	I-site-value
lateral	I-site-value	I-site-value
/	I-site-value	I-site-value
anterior	I-site-value	I-site-value
from	I-site-value	I-site-value
the	I-site-value	I-site-value
mass	I-site-value	I-site-value
,	I-site-value	I-site-value
1	I-site-value	I-site-value
cm	I-site-value	I-site-value
from	I-site-value	I-site-value
the	I-site-value	I-site-value
nearest	I-site-value	I-site-value
anterior	I-site-value	I-site-value
margin	I-site-value	I-site-value
,	O	O
which	O	O
is	O	O
ink	O	O
and	O	O
taken	O	O
perpendicular	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
contents	O	O
,	O	O
dissection	O	O
:	O	O
one	O	O
gross	O	O
positive	O	O
lymph	O	O
node	O	O
confirmed	O	O
to	O	O
show	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
transcribed	O	O
by	O	O
:	O	O
j	O	O
5	O	O
/	O	O
3	O	O
/	O	O
2013	O	O
11	O	O
:	O	O
46	O	O
:	O	O
11	O	O
"	O	O
specimen	O	O
description	O	O
226	O	O
:	O	O
a	O	O
:	O	O
clinic	O	O
consult	O	O
material	O	O
tissue	O	O
description	O	O
:	O	O
material	O	O
received	O	O
:	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
-	O	O
4	O	O
slides	O	O
(	O	O
sp	O	O
-	O	O
36	O	O
)	O	O
slide	O	O
disposition	O	O
:	O	O
4	O	O
slides	O	O
returned	O	O
5	O	O
/	O	O
10	O	O
/	O	O
2013	O	O
-	O	O
j	O	O
"	O	O
the	O	O
patient	O	O
comes	O	O
today	O	O
for	O	O
discussion	O	O
in	O	O
this	O	O
setting	O	O
.	O	O
hem	O	O
was	O	O
seen	O	O
by	O	O
dr	O	O
.	O	O
gross	O	O
,	O	O
there	O	O
is	O	O
a	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
mass	O	O
located	B-site	B-site
in	B-site-value	B-site-value
retroareolar	I-site-value	I-site-value
area	I-site-value	I-site-value
,	I-site-value	I-site-value
1	I-site-value	I-site-value
cm	I-site-value	I-site-value
to	I-site-value	I-site-value
the	I-site-value	I-site-value
nearest	I-site-value	I-site-value
inferior	I-site-value	I-site-value
margin	I-site-value	I-site-value
,	O	O
which	O	O
is	O	O
ink	O	O
and	O	O
taken	O	O
perpendicular	O	O
.	O	O
histologic	O	O
grade	B-grade	B-grade
:	O	O
nottingham	O	O
grade	B-grade	B-grade
ii	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
.	O	O
this	O	O
is	O	O
similar	O	O
to	O	O
the	O	O
risk	O	O
expected	O	O
with	O	O
the	O	O
use	O	O
of	O	O
hormone	O	O
therapy	O	O
during	O	O
men	O	O
.	O	O
surgical	O	O
margins	O	O
:	O	O
negative	O	O
for	O	O
invasive	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
:	O	O
nearest	O	O
anterior	O	O
margin	O	O
,	O	O
0	O	O
cm	O	O
.	O	O
psycho	O	O
ms	O	O
.	O	O
histologic	B-htype	B-htype
type	I-htype	I-htype
of	O	O
invasive	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
:	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
lymph	O	O
node	O	O
sampling	O	O
:	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
submitted	O	O
.	O	O
one	O	O
of	O	O
three	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
was	O	O
positive	O	O
on	O	O
frozen	O	O
section	O	O
,	O	O
and	O	O
thus	O	O
a	O	O
total	O	O
of	O	O
nine	O	O
right	O	B-laterality-value
axillary	O	O
nodes	O	O
were	O	O
removed	O	O
.	O	O
we	O	O
reviewed	O	O
that	O	O
tamoxifen	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
yearly	O	O
risk	O	O
of	O	O
approximately	O	O
3	O	O
/	O	O
1000	O	O
ut	O	O
cancers	O	O
in	O	O
post	O	O
women	O	O
(	O	O
compared	O	O
to	O	O
an	O	O
expected	O	O
1	O	O
/	O	O
1000	O	O
yearly	O	O
risk	O	O
)	O	O
and	O	O
that	O	O
this	O	O
risk	O	O
is	O	O
lower	O	O
for	O	O
prem	O	O
women	O	O
.	O	O
g	O	O
.	O	O
ki	O	O
-	O	O
67	O	O
as	O	O
pro	O	O
marker	O	O
in	O	O
early	O	O
breast	O	O
cancer	O	O
:	O	O
a	O	O
meta	O	O
of	O	O
published	O	O
studies	O	O
involving	O	O
12	O	O
patients	O	O
.	O	O
discussed	O	O
the	O	O
role	O	O
of	O	O
the	O	O
sentinel	O	O
lymph	O	O
node	O	O
biopsy	O	O
and	O	O
technique	O	O
to	O	O
assess	O	O
lymph	O	O
node	O	O
involvement	O	O
in	O	O
invasive	O	O
breast	O	O
cancer	O	O
.	O	O
diagnosis	O	O
226	O	O
:	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
,	O	O
solid	O	O
type	O	O
,	O	O
intermediate	B-grade-value	B-grade-value
nuclear	O	O
grade	B-grade	B-grade
,	O	O
with	O	O
intra	O	O
necrosis	O	O
and	O	O
micro	O	O
involving	O	O
an	O	O
area	O	O
over	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
.	O	O
in	O	O
brief	O	O
,	O	O
she	O	O
had	O	O
a	O	O
screening	O	O
mammogram	O	O
in	O	O
august	O	O
,	O	O
2004	O	O
,	O	O
which	O	O
revealed	O	O
a	O	O
suspicious	O	O
lesion	O	O
in	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
,	O	O
excision	O	O
:	O	O
a	O	O
single	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
is	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
per	O	O
report	O	O
,	O	O
fluorescence	O	O
in	O	O
situ	O	O
hybrid	O	O
(	O	O
fish	O	O
)	O	O
for	O	O
her2	B-receptor	B-receptor
is	O	O
not	B-receptor-status	O
amplified	B-receptor-status	B-receptor-status
(	O	O
ratio	O	O
1	B-receptor-value	O
)	O	O
.	O	O
12	O	O
/	O	O
10	O	O
/	O	O
2010	O	O
14	O	O
:	O	O
45	O	O
interpreted	O	O
by	O	O
:	O	O
jason	O	O
t	O	O
.	O	O
a	O	O
path	O	O
reviews	O	O
the	O	O
ac	O	O
data	O	O
and	O	O
corresponding	O	O
slide	O	O
to	O	O
verify	O	O
accuracy	O	O
of	O	O
regions	O	O
scored	O	O
.	O	O
i	O	O
shared	O	O
all	O	O
of	O	O
this	O	O
information	O	O
with	O	O
mrs	O	O
.	O	O
dr	O	O
.	O	O
immunohistochemical	O	O
show	O	O
that	O	O
the	O	O
neoplastic	O	O
cells	O	O
are	O	O
positive	B-receptor-status	B-receptor-status
for	O	O
estrogen	B-receptor	B-receptor
receptor	I-receptor	I-receptor
(	O	O
>	O	O
75	O	O
tumor	O	O
nuclei	O	O
staining	O	O
)	O	O
and	O	O
focally	O	O
positive	B-receptor-status	B-receptor-status
for	O	O
progesterone	B-receptor	B-receptor
receptor	I-receptor	I-receptor
(	O	O
1	O	O
-	O	O
10	O	O
tumor	O	O
nuclei	O	O
staining	O	O
)	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
10	O	O
/	O	O
07	O	O
/	O	O
2009	O	O
surgical	O	O
pathology	O	O
(	O	O
mr	O	O
-	O	O
85	O	O
)	O	O
requested	O	O
by	O	O
:	O	O
david	O	O
r	O	O
.	O	O
lymph	O	O
node	O	O
sampling	O	O
:	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
submitted	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
1	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
of	O	O
2	O	O
)	O	O
sentinel	O	O
lymph	O	O
node	O	O
is	O	O
positive	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
the	O	O
lobular	O	O
changes	O	O
were	O	O
not	O	O
felt	O	O
sufficient	O	O
to	O	O
dia	O	O
carcinoma	B-htype-value	B-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
sentinel	O	O
lymph	O	O
node	O	O
#	O	O
\	O	O
"	O	O
is	O	O
a	O	O
single	O	O
0	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
lymph	O	O
node	O	O
.	O	O
two	O	O
masses	O	O
were	O	O
bio	O	O
with	O	O
sizes	B-size	O
of	O	O
3	B-size-value	B-size-value
x	I-size-value	I-size-value
2	I-size-value	I-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
cm	I-size-value	I-size-value
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
and	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
contents	O	O
\	O	O
"	O	O
is	O	O
a	O	O
95	O	O
gram	O	O
,	O	O
28	O	O
x	O	O
19	O	O
x	O	O
9	O	O
cm	O	O
oriented	O	O
modified	O	O
radical	O	O
mastectomy	O	O
with	O	O
an	O	O
11	O	O
x	O	O
4	O	O
cm	O	O
skin	O	O
el	O	O
and	O	O
axillary	O	O
tail	O	O
dissection	O	O
.	O	O
surgical	O	O
margins	O	O
:	O	O
negative	O	O
for	O	O
dcis	B-htype-value	B-htype-value
:	O	O
nearest	O	O
anterior	O	O
margin	O	O
,	O	O
0	O	O
cm	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
identified	O	O
in	O	O
the	O	O
lymph	O	O
nodes	O	O
.	O	O
family	O	O
history	O	O
family	O	O
history	O	O
is	O	O
negative	O	O
for	O	O
any	O	O
known	O	O
breast	O	O
,	O	O
o	O	O
,	O	O
or	O	O
colon	O	O
cancers	O	O
.	O	O
b	O	O
.	O	O
she	O	O
will	O	O
be	O	O
following	O	O
up	O	O
with	O	O
dr	O	O
.	O	O
the	O	O
superior	O	O
margin	O	O
is	O	O
ink	O	O
black	O	O
.	O	O
keen	O	O
.	O	O
"	O	O
biopsy	O	O
clip	O	O
not	O	O
identified	O	O
.	O	O
the	O	O
tumor	O	O
is	O	O
approaching	O	O
within	O	O
0	B-site-value	O
cm	I-site-value	O
to	I-site-value	O
the	I-site-value	O
superior	I-site-value	O
margin	I-site-value	O
.	O	O
hi	O	O
reports	O	O
a	O	O
two	O	O
to	O	O
three	O	O
month	O	O
history	O	O
of	O	O
intermittent	O	O
low	O	O
thor	O	O
back	O	O
pain	O	O
.	O	O
all	O	O
surgical	O	O
resection	O	O
margins	O	O
,	O	O
after	O	O
re	O	O
of	O	O
the	O	O
anterior	O	O
/	O	O
superior	O	O
margin	O	O
,	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
(	O	O
minimum	O	O
tumor	O	O
free	O	O
margin	O	O
,	O	O
0	O	O
cm	O	O
)	O	O
.	O	[CLS]
she	O	O
will	O	O
call	O	O
for	O	O
an	O	O
appointment	O	O
here	O	O
after	O	O
she	O	O
has	O	O
contacted	O	O
a	O	O
local	O	O
on	O	O
and	O	O
begun	O	O
treatment	O	O
.	O	O
the	O	O
assumption	O	O
at	O	O
this	O	O
point	O	O
is	O	O
that	O	O
it	O	O
is	O	O
a	O	O
breast	O	O
cancer	O	O
,	O	O
metastatic	O	O
to	O	O
an	O	O
in	O	O
lymph	O	O
node	O	O
.	O	O
margin	O	O
submitted	O	O
shaved	O	O
.	O	O
the	O	O
non	O	O
breast	O	O
par	O	O
shows	O	O
pro	O	O
fibrocystic	O	O
changes	O	O
with	O	O
sc	O	O
aden	O	O
,	O	O
radial	O	O
sc	O	O
lesion	O	O
,	O	O
and	O	O
a	O	O
fibroadenoma	B-htype-value	B-htype-value
.	O	O
the	O	O
overly	O	O
skin	O	O
shows	O	O
se	O	O
ke	O	O
.	O	O
she	O	O
first	O	O
underwent	O	O
a	O	O
core	O	O
needle	O	O
biopsy	O	O
in	O	O
april	O	O
which	O	O
showed	O	O
atypical	O	O
hyperplasia	O	O
.	O	O
she	O	O
does	O	O
do	O	O
breast	O	O
self	O	O
regularly	O	O
,	O	O
but	O	O
this	O	O
was	O	O
found	O	O
between	O	O
exams	O	O
.	O	O
infiltrative	O	O
small	O	O
lymphocytes	O	O
.	O	O
the	O	O
surrounding	O	O
breast	O	O
par	O	O
shows	O	O
pro	O	O
fibrocystic	O	O
changes	O	O
.	O	O
transcribed	O	O
by	O	O
:	O	O
em	O	O
10	O	O
/	O	O
7	O	O
/	O	O
2009	O	O
20	O	O
:	O	O
20	O	O
:	O	O
35	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
a	O	O
.	O	O
on	O	O
a	O	O
screening	O	O
chest	O	O
x	O	O
as	O	O
part	O	O
of	O	O
an	O	O
annual	O	O
physical	O	O
,	O	O
ms	O	O
.	O	O
by	O	O
outside	O	O
report	O	O
,	O	O
the	O	O
focus	O	O
of	O	O
in	O	O
situ	O	O
cancer	O	O
extends	O	O
within	O	O
0	O	O
cm	O	O
in	O	O
the	O	O
nearest	O	O
ink	O	O
margin	O	O
.	O	O
herr	O	O
is	O	O
a	O	O
woman	O	O
from	O	O
eden	O	O
prairie	O	O
minnesota	O	O
with	O	O
the	O	O
following	O	O
breast	O	O
cancer	O	O
history	O	O
:	O	O
1	O	O
.	O	O
this	O	O
has	O	O
been	O	O
complicated	O	O
by	O	O
rare	O	O
hot	O	O
flashes	O	O
,	O	O
which	O	O
number	O	O
in	O	O
the	O	O
two	O	O
to	O	O
four	O	O
per	O	O
day	O	O
range	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
superficial	O	O
biopsy	O	O
\	O	O
"	O	O
is	O	O
a	O	O
2	O	O
x	O	O
2	O	O
x	O	O
1	O	O
cm	O	O
oriented	O	O
wide	O	O
local	O	O
excision	O	O
breast	O	O
specimen	O	O
.	O	O
immunohistochemical	O	O
cyto	O	O
stains	O	O
were	O	O
performed	O	O
on	O	O
the	O	O
paraffin	O	O
embedded	O	O
sentinel	O	O
lymph	O	O
node	O	O
tissues	O	O
and	O	O
confirm	O	O
the	O	O
h	O	O
&	O	O
e	O	O
impression	O	O
.	O	O
may	O	O
12	O	O
,	O	O
2017	O	O
,	O	O
completed	O	O
partial	O	O
breast	O	O
radiotherapy	O	O
to	O	O
the	O	O
left	B-laterality-value	B-laterality-value
side	O	O
receiving	O	O
385	O	O
c	O	O
in	O	O
10	O	O
fraction	O	O
.	O	O
c	O	O
.	O	O
lungs	O	O
:	O	O
clear	O	O
to	O	O
percussion	O	O
and	O	O
aus	O	O
.	O	O
there	O	O
was	O	O
no	O	O
suspicious	O	O
mass	O	O
or	O	O
ind	O	O
in	O	O
the	O	O
right	B-laterality-value	B-laterality-value
axilla	O	O
.	O	O
oz	O	O
in	O	O
medical	O	O
oncology	O	O
,	O	O
and	O	O
they	O	O
discussed	O	O
options	O	O
as	O	O
well	O	O
.	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
ultrasound	O	O
december	O	O
2	O	O
,	O	O
2015	O	O
,	O	O
shows	O	O
a	O	O
4	B-size-value	B-size-value
-	I-size-value	I-size-value
5	I-size-value	I-size-value
mm	I-size-value	I-size-value
h	O	O
lesion	O	O
at	O	O
the	O	O
1	B-site-value	B-site-value
o	I-site-value	I-site-value
position	I-site-value	I-site-value
8	I-site-value	I-site-value
cm	I-site-value	I-site-value
from	I-site-value	I-site-value
the	I-site-value	I-site-value
nipple	I-site-value	I-site-value
corresponding	O	O
to	O	O
the	O	O
abnormality	O	O
seen	O	O
on	O	O
mammogram	O	O
.	O	[CLS]
4	O	O
.	O	O
she	O	O
was	O	O
treated	O	O
with	O	O
three	O	O
cycles	O	O
of	O	O
ad	O	O
/	O	O
cyto	O	O
.	O	O
we	O	O
do	O	O
note	O	O
on	O	O
review	O	O
of	O	O
outside	O	O
imaging	O	O
here	O	O
that	O	O
there	O	O
is	O	O
a	O	O
distant	O	O
8	B-size-value	B-size-value
-	I-size-value	I-size-value
to	I-size-value	I-size-value
9	I-size-value	I-size-value
-	I-size-value	I-size-value
mm	I-size-value	I-size-value
mass	O	O
in	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
in	O	B-site-value
the	O	I-site-value
lower	B-site-value	I-site-value
inner	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
,	O	O
which	O	O
has	O	O
not	O	O
been	O	O
assessed	O	O
,	O	O
and	O	O
i	O	O
have	O	O
discussed	O	O
this	O	O
with	O	O
mrs	O	O
.	O	O
frozen	O	O
section	O	O
histologic	O	O
interpretation	O	O
performed	O	O
by	O	O
:	O	O
faust	O	O
j	O	O
.	O	O
ur	O	O
is	O	O
normal	O	O
.	O	O
24	O	O
-	O	O
hour	O	O
ur	O	O
acid	O	O
ex	O	O
is	O	O
160	O	O
,	O	O
normal	O	O
less	O	O
than	O	O
750	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
not	O	O
identified	O	O
in	O	O
either	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
.	O	O
representative	O	O
sections	O	O
are	O	O
submitted	O	O
.	O	O
she	O	O
will	O	O
continue	O	O
to	O	O
use	O	O
van	O	O
b	O	O
.	O	O
to	O	O
the	O	O
radiation	O	O
fields	O	O
.	O	O
en	O	O
:	O	O
oral	O	O
mu	O	O
membranes	O	O
are	O	O
moist	O	O
,	O	O
pink	O	O
,	O	O
and	O	O
without	O	O
ex	O	O
.	O	O
i	O	O
also	O	O
reviewed	O	O
the	O	O
pre	O	O
mammogram	O	O
and	O	O
met	O	O
with	O	O
the	O	O
patient	O	O
to	O	O
discuss	O	O
all	O	O
these	O	O
issues	O	O
.	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
lumpectomy	O	O
and	O	O
sentinel	O	O
node	O	O
biopsy	O	O
on	O	O
january	O	O
12	O	O
,	O	O
2016	O	O
,	O	O
by	O	O
dr	O	O
.	O	O
grossed	O	O
by	O	O
st	O	O
.	O	O
patterson	O	O
,	O	O
m	O	O
.	O	O
127	O	O
-	O	O
134	O	O
syn	O	O
report	O	O
:	O	O
laterality	B-laterality	B-laterality
:	O	O
right	B-laterality-value	B-laterality-value
.	O	O
immunohistochemical	O	O
studies	O	O
performed	O	O
on	O	O
paraffin	O	O
embedded	O	O
tissue	O	O
reveal	O	O
the	O	O
tumor	O	O
cells	O	O
are	O	O
im	O	O
for	O	O
both	O	O
estrogen	B-receptor	B-receptor
and	O	O
progesterone	B-receptor	B-receptor
receptors	I-receptor	I-receptor
.	O	O
denies	O	O
second	O	O
smoke	O	O
exposure	O	O
.	O	O
lungs	O	O
:	O	O
chest	O	O
clear	O	O
to	O	O
aus	O	O
.	O	O
ve	O	O
,	O	O
m	O	O
.	O	O
of	O	O
note	O	O
,	O	O
however	O	O
,	O	O
is	O	O
that	O	O
same	O	O
aunt	O	O
had	O	O
history	O	O
of	O	O
ho	O	O
disease	O	O
in	O	O
her	O	O
late	O	O
20s	O	O
and	O	O
did	O	O
receive	O	O
man	O	O
radiation	O	O
.	O	O
ex	O	O
:	O	O
no	O	O
edema	O	O
.	O	O
margin	O	O
submitted	O	O
.	O	O
june	O	O
27	O	O
,	O	O
2013	O	O
:	O	O
consultation	O	O
with	O	O
dr	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
15	O	O
cytology	O	O
-	O	O
fine	O	O
needle	O	O
as	O	O
requested	O	O
by	O	O
:	O	O
jeffrey	O	O
qu	O	O
,	O	O
m	O	O
.	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
(	O	O
mastectomy	O	O
)	O	O
and	O	O
lymph	O	O
nodes	O	O
-	O	O
infiltrating	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
adenocarcinoma	I-htype-value	I-htype-value
,	O	O
grade	B-grade	B-grade
3	B-grade-value	B-grade-value
of	O	O
3	O	O
grades	O	O
by	O	O
nottingham	O	O
classification	O	O
.	O	O
her	O	O
last	O	O
men	O	O
cycle	O	O
was	O	O
november	O	O
2007	O	O
.	O	O
i	O	O
discussed	O	O
with	O	O
her	O	O
that	O	O
we	O	O
would	O	O
support	O	O
the	O	O
pre	O	O
recommendation	O	O
for	O	O
radiation	O	O
and	O	O
that	O	O
her	O	O
systemic	O	O
therapy	O	O
would	O	O
be	O	O
determined	O	O
by	O	O
the	O	O
remainder	O	O
of	O	O
her	O	O
pathology	O	O
information	O	O
.	O	O
she	O	O
was	O	O
treated	O	O
with	O	O
cl	O	O
.	O	O
hem	O	O
underwent	O	O
a	O	O
lumpectomy	O	O
and	O	O
sentinel	O	O
node	O	O
biopsy	O	O
for	O	O
carcinoma	B-htype-value	B-htype-value
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
with	O	O
focal	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
no	O	O
.	O	O
2	O	O
\	O	O
"	O	O
is	O	O
a	O	O
single	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
lymph	O	O
node	O	O
.	O	O
testing	O	O
is	O	O
performed	O	O
using	O	O
monoclonal	O	O
er	B-receptor	B-receptor
clone	O	O
6	O	O
and	O	O
pr	B-receptor	B-receptor
clone	O	O
pgr	O	O
63	O	O
and	O	O
a	O	O
polymer	O	O
detection	O	O
system	O	O
.	O	O
ribbon	O	O
biopsy	O	O
clip	O	O
is	O	O
identified	O	O
within	O	O
the	O	O
biopsy	O	O
site	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
contents	O	O
\	O	O
"	O	O
is	O	O
a	O	O
6	O	O
x	O	O
4	O	O
x	O	O
2	O	O
cm	O	O
aggregate	O	O
of	O	O
adi	O	O
and	O	O
lymph	O	O
tissue	O	O
(	O	O
dissection	O	O
)	O	O
.	O	O
blood	O	O
cultures	O	O
remain	O	O
negative	O	O
to	O	O
date	O	O
,	O	O
respiratory	O	O
pathogen	O	O
panel	O	O
was	O	O
negative	O	O
.	O	O
advised	O	O
report	O	O
of	O	O
worse	O	O
or	O	O
persistent	O	O
symptoms	O	O
.	O	O
reviewed	O	O
grading	O	O
and	O	O
staging	O	O
of	O	O
breast	O	O
cancer	O	O
.	O	O
research	O	O
tissue	O	O
collected	O	O
,	O	O
ir	O	O
08	O	O
-	O	O
00	O	O
.	O	O
john	O	O
don	O	O
,	O	O
in	O	O
this	O	O
setting	O	O
.	O	O
discussed	O	O
follow	O	O
with	O	O
medical	O	O
oncology	O	O
and	O	O
possible	O	O
radiation	O	O
oncology	O	O
at	O	O
mayo	O	O
or	O	O
locally	O	O
.	O	O
c	O	O
.	O	O
comment	O	O
226	O	O
:	O	O
combining	O	O
all	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
lymph	O	O
nodes	O	O
removed	O	O
,	O	O
including	O	O
the	O	O
additional	O	O
lymph	O	O
nodes	O	O
(	O	O
part	O	O
c	O	O
)	O	O
and	O	O
the	O	O
sentinel	O	O
lymph	O	O
node	O	O
,	O	O
a	O	O
total	O	O
of	O	O
5	O	O
of	O	O
16	O	O
lymph	O	O
nodes	O	O
are	O	O
positive	O	O
for	O	O
metastatic	O	O
patient	O	O
name	O	O
:	O	O
schumann	O	O
,	O	O
lori	O	O
ann	O	O
medical	O	O
record	O	O
no	O	O
.	O	O
:	O	O
xl	O	O
do	O	O
:	O	O
01	O	O
/	O	O
08	O	O
/	O	O
60	O	O
adenocarcinoma	B-htype-value	B-htype-value
.	O	O
blue	O	O
dye	O	O
identified	O	O
.	O	O
fran	O	O
is	O	O
interested	O	O
in	O	O
both	O	O
adjuvant	O	O
chemotherapy	O	O
and	O	O
end	O	O
therapy	O	O
(	O	O
tamoxifen	O	O
or	O	O
aroma	O	O
inhibitor	O	O
)	O	O
.	O	O
i	O	O
reassured	O	O
her	O	O
again	O	O
that	O	O
dcis	B-htype-value	B-htype-value
almost	O	O
never	O	O
meta	O	O
,	O	O
and	O	O
it	O	O
should	O	O
not	O	O
affect	O	O
her	O	O
survival	O	O
.	O	O
rest	O	O
of	O	O
tissue	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
not	O	O
identified	O	O
in	O	O
any	O	O
of	O	O
the	O	O
lymph	O	O
nodes	O	O
.	O	O
no	O	O
extra	O	O
extension	O	O
.	O	O
ki	O	O
-	O	O
67	O	O
has	O	O
been	O	O
ordered	O	O
and	O	O
will	O	O
be	O	O
reported	O	O
in	O	O
an	O	O
addendum	O	O
.	O	O
gross	O	O
,	O	O
there	O	O
is	O	O
a	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
mass	O	O
located	B-site	B-site
at	B-site-value	O
the	I-site-value	I-site-value
lateral	I-site-value	I-site-value
and	I-site-value	I-site-value
anterior	I-site-value	I-site-value
margins	I-site-value	I-site-value
.	O	O
there	O	O
,	O	O
her	O	O
pain	O	O
was	O	O
initially	O	O
controlled	O	O
with	O	O
iv	O	O
anal	O	O
.	O	O
results	O	O
:	O	O
diagnostic	O	O
mammogram	O	O
reveals	O	O
no	O	O
significant	O	O
mass	O	O
or	O	O
evidence	O	O
of	O	O
mali	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
,	O	O
simple	O	O
mastectomy	O	O
\	O	O
"	O	O
is	O	O
a	O	O
1	O	O
gram	O	O
,	O	O
28	O	O
(	O	O
m	O	O
)	O	O
x	O	O
11	O	O
(	O	O
a	O	O
)	O	O
x	O	O
14	O	O
(	O	O
s	O	O
)	O	O
cm	O	O
oriented	O	O
simple	O	O
mastectomy	O	O
with	O	O
a	O	O
27	O	O
x	O	O
13	O	O
cm	O	O
skin	O	O
el	O	O
and	O	O
10	O	O
(	O	O
m	O	O
)	O	O
x	O	O
3	O	O
(	O	O
a	O	O
)	O	O
x	O	O
9	O	O
(	O	O
s	O	O
)	O	O
cm	O	O
axillary	O	O
tail	O	O
dissection	O	O
.	O	O
ex	O	O
:	O	O
no	O	O
club	O	O
,	O	O
cy	O	O
or	O	O
edema	O	O
.	O	O
macro	O	O
extent	O	O
of	O	O
tumor	O	O
:	O	O
deep	O	O
.	O	O
hold	O	O
over	O	O
for	O	O
further	O	O
evaluation	O	O
on	O	O
permanent	O	O
sections	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
no	O	O
.	O	O
2	O	O
,	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
,	O	O
without	O	O
blue	O	O
dye	O	O
,	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
ec	O	O
a	O	O
discussion	O	O
with	O	O
dr	O	O
.	O	O
frost	O	O
,	O	O
m	O	O
.	O	O
b	O	O
.	O	O
h	O	O
.	O	O
a	O	O
clip	O	O
was	O	O
left	O	O
in	O	O
place	O	O
in	O	O
the	O	O
axilla	O	O
.	O	[CLS]
6	O	O
.	O	O
neck	O	O
:	O	O
no	O	O
palpable	O	O
adenopathy	O	O
.	O	O
discussed	O	O
type	O	O
of	O	O
cancer	O	O
,	O	O
grading	O	O
and	O	O
staging	O	O
of	O	O
breast	O	O
cancer	O	O
.	O	O
c	O	O
.	O	O
lymph	O	O
invasion	O	O
:	O	O
absent	O	O
.	O	O
final	O	O
pathology	O	O
in	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
indicated	O	O
grade	B-grade	B-grade
1	B-grade-value	B-grade-value
(	O	O
of	O	O
3	O	O
)	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
with	O	O
tubular	O	O
features	O	O
forming	O	O
0	B-size-value	B-size-value
-	I-size-value	I-size-value
cm	I-size-value	I-size-value
mass	O	O
at	O	O
greatest	O	O
dimension	O	O
in	O	B-site-value
the	O	I-site-value
upper	B-site-value	I-site-value
quadrant	I-site-value	I-site-value
.	O	O
ma	O	O
,	O	O
there	O	O
was	O	O
nothing	O	O
specific	O	O
for	O	O
mali	O	O
.	O	O
grossed	O	O
by	O	O
t	O	O
.	O	O
[	O	O
aj	O	B-stage-value
]	O	O
extra	O	O
extension	O	O
is	O	O
not	O	O
present	O	O
.	O	O
lloyd	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
67	O	O
"	O	O
specimen	O	O
description	O	O
226	O	O
:	O	O
a	O	O
:	O	O
clinic	O	O
consult	O	O
material	O	O
tissue	O	O
description	O	O
:	O	O
material	O	O
received	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
in	O	O
-	O	O
8	O	O
slides	O	O
(	O	O
ms	O	O
-	O	O
45	O	O
)	O	O
slide	O	O
disposition	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
in	O	O
-	O	O
8	O	O
slides	O	O
(	O	O
ms	O	O
-	O	O
45	O	O
)	O	O
8	O	O
slides	O	O
returned	O	O
3	O	O
/	O	O
26	O	O
/	O	O
07	O	O
-	O	O
j	O	O
"	O	O
reviewed	O	O
benefits	O	O
and	O	O
side	O	O
effects	O	O
of	O	O
radiation	O	O
therapy	O	O
.	O	O
lymph	O	O
:	O	O
no	O	O
cervical	O	O
,	O	O
su	O	O
,	O	O
axillary	O	O
,	O	O
or	O	O
ing	O	O
adenopathy	O	O
noted	O	O
.	O	O
men	O	O
at	O	O
age	O	O
14	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
mali	O	O
found	O	O
in	O	O
lymph	O	O
node	O	O
of	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
#	O	O
hypertension	O	O
#	O	O
h	O	O
on	O	O
t4	O	O
replacement	O	O
#	O	O
estrogen	O	O
replacement	O	O
therapy	O	O
#	O	O
as	O	O
men	O	O
#	O	O
recent	O	O
episode	O	O
of	O	O
go	O	O
#	O	O
mac	O	O
de	O	O
#	O	O
chronic	O	O
sensor	O	O
hearing	O	O
loss	O	O
2011	O	O
:	O	O
i	O	O
have	O	O
carefully	O	O
reviewed	O	O
in	O	O
great	O	O
detail	O	O
the	O	O
significance	O	O
of	O	O
each	O	O
of	O	O
the	O	O
following	O	O
laboratory	O	O
studies	O	O
.	O	O
el	O	O
is	O	O
a	O	O
very	O	O
pleasant	O	O
,	O	O
49	O	O
-	O	O
year	O	O
woman	O	O
seen	O	O
in	O	O
the	O	O
company	O	O
of	O	O
her	O	O
spouse	O	O
,	O	O
jerry	O	O
,	O	O
and	O	O
her	O	O
mother	O	O
,	O	O
lorraine	O	O
.	O	[CLS]
no	O	O
angiolymphatic	O	O
invasion	O	O
identified	O	O
.	O	O
breast	O	O
,	O	O
new	O	O
right	B-laterality-value	B-laterality-value
medial	O	O
margin	O	O
,	O	O
excision	O	O
:	O	O
negative	O	O
for	O	O
carcinoma	O	O
.	O	O
right	O	B-laterality-value
breast	O	O
,	O	O
additional	O	O
tissue	O	O
,	O	O
biopsy	O	O
:	O	O
benign	O	O
breast	O	O
tissue	O	O
.	O	O
no	O	O
regional	O	O
wall	O	O
motion	O	O
abnormalities	O	O
.	O	O
all	O	O
submitted	O	O
.	O	O
i	O	O
did	O	O
provide	O	O
prescription	O	O
today	O	O
for	O	O
bra	O	O
and	O	O
pro	O	O
.	O	O
laboratory	O	O
studies	O	O
:	O	O
chest	O	O
x	O	O
reveals	O	O
no	O	O
active	O	O
disease	O	O
.	O	O
2010	O	O
:	O	O
mrs	O	O
.	O	O
d	O	O
.	O	O
risks	O	O
of	O	O
local	O	O
rec	O	O
discussed	O	O
.	O	O
no	O	O
extra	O	O
extension	O	O
.	O	O
ai	O	O
ravi	O	O
.	O	O
benson	O	O
is	O	O
to	O	O
radiotherapy	O	O
adequately	O	O
.	O	O
immunohistochemical	O	O
stained	O	O
slides	O	O
are	O	O
scanned	O	O
using	O	O
the	O	O
ape	O	O
scans	O	O
instrument	O	O
.	O	O
david	O	O
far	O	O
tomorrow	O	O
.	O	O
the	O	O
family	O	O
decision	O	O
is	O	O
to	O	O
pursue	O	O
rt	O	O
.	O	O
no	O	O
blue	O	O
dye	O	O
identified	O	O
in	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
no	O	O
.	O	O
and	O	O
no	O	O
.	O	O
.	O	O
cytologic	O	O
evidence	O	O
of	O	O
therapeutic	O	O
effect	O	O
is	O	O
present	O	O
:	O	O
lobular	O	O
appearance	O	O
.	O	O
last	O	O
men	O	O
period	O	O
september	O	O
25	O	O
,	O	O
2006	O	O
.	O	O
for	O	O
urine	O	O
inc	O	O
,	O	O
she	O	O
can	O	O
be	O	O
seen	O	O
by	O	O
ur	O	O
at	O	O
a	O	O
later	O	O
time	O	O
.	O	O
#	O	O
nico	O	O
dependence	O	O
she	O	O
agrees	O	O
to	O	O
have	O	O
a	O	O
nico	O	O
dependence	O	O
center	O	O
consultation	O	O
.	O	O
#	O	O
bilateral	O	B-laterality-value
carp	O	O
tunnel	O	O
syndrome	O	O
,	O	O
moderate	O	O
to	O	O
severe	O	O
she	O	O
will	O	O
be	O	O
seen	O	O
in	O	O
hand	O	O
clinic	O	O
.	O	O
#	O	O
colon	O	O
divert	O	O
a	O	O
screening	O	O
colonoscopy	O	O
was	O	O
un	O	O
except	O	O
for	O	O
right	O	B-laterality-value
colon	O	O
divert	O	O
.	O	O
bilateral	O	B-laterality-value
breast	O	O
mri	O	O
was	O	O
also	O	O
performed	O	O
which	O	O
red	O	O
the	O	O
biopsy	O	O
mali	O	O
in	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
as	O	O
well	O	O
as	O	O
multiple	O	O
small	O	O
cysts	O	O
within	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
.	O	[CLS]
2011	O	O
:	O	O
#	O	O
new	O	O
diagnosis	O	O
of	O	O
er	B-receptor	B-receptor
/	O	O
pr	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
,	O	O
her	B-receptor	B-receptor
-	I-receptor	I-receptor
2	I-receptor	I-receptor
negative	B-receptor-status	B-receptor-status
,	O	O
invasive	B-htype-value	B-htype-value
mammary	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
with	O	O
associated	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
of	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
#	O	O
palpable	O	O
lesion	O	O
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
for	O	O
which	O	O
further	O	O
work	O	O
is	O	O
required	O	O
2011	O	O
:	O	O
#	O	O
new	O	O
diagnosis	O	O
of	O	O
er	B-receptor	B-receptor
/	O	O
pr	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
,	O	O
her	B-receptor	B-receptor
-	I-receptor	I-receptor
2	I-receptor	I-receptor
negative	B-receptor-status	B-receptor-status
,	O	O
invasive	B-htype-value	B-htype-value
mammary	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
with	O	O
associated	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
of	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
#	O	O
palpable	O	O
lesion	O	O
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
for	O	O
which	O	O
further	O	O
work	O	O
is	O	O
required	O	O
i	O	O
had	O	O
grossed	O	O
by	O	O
cm	O	O
.	O	O
she	O	O
has	O	O
never	O	O
used	O	O
hormone	O	O
replacement	O	O
therapy	O	O
or	O	O
fertility	O	O
meds	O	O
and	O	O
denies	O	O
exposure	O	O
to	O	O
des	O	O
.	O	O
background	O	O
par	O	O
showed	O	O
pro	O	O
fibrocystic	O	O
change	O	O
including	O	O
mild	O	O
ductal	O	O
hyperplasia	O	O
,	O	O
sc	O	O
aden	O	O
,	O	O
and	O	O
fibroadenoma	O	O
change	O	O
.	O	O
margins	O	O
were	O	O
negative	O	O
after	O	O
re	O	O
.	O	O
f	O	O
.	O	O
angiolymphatic	O	O
invasion	O	O
is	O	O
absent	O	O
.	O	O
margin	O	O
submitted	O	O
.	O	O
frozen	O	O
section	O	O
histologic	O	O
interpretation	O	O
performed	O	O
by	O	O
:	O	O
se	O	O
s	O	O
.	O	O
the	O	O
patient	O	O
has	O	O
never	O	O
used	O	O
fertility	O	O
medications	O	O
nor	O	O
des	O	O
.	O	O
grossed	O	O
by	O	O
t	O	O
.	O	O
slight	O	O
lo	O	O
and	O	O
thick	O	O
in	O	O
the	O	O
lateral	O	O
limb	O	O
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
ad	O	O
gland	O	O
felt	O	O
likely	O	O
to	O	O
be	O	O
an	O	O
adenoma	B-htype-value	O
.	O	O
at	O	O
about	O	O
the	O	O
7	B-site-value	B-site-value
o	I-site-value	I-site-value
position	I-site-value	I-site-value
and	O	O
on	O	O
the	O	O
lower	B-site-value	B-site-value
inner	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
at	I-site-value	O
about	I-site-value	O
the	I-site-value	O
4	I-site-value	B-site-value
o	I-site-value	I-site-value
position	I-site-value	I-site-value
,	O	O
there	O	O
is	O	O
a	O	O
2	B-size-value	B-size-value
cm	I-size-value	I-size-value
,	O	O
hard	O	O
nod	O	O
sub	O	O
lesion	O	O
.	O	O
she	O	O
is	O	O
due	O	O
to	O	O
receive	O	O
her	O	O
fourth	O	O
treatment	O	O
of	O	O
ad	O	O
and	O	O
cyto	O	O
chemotherapy	O	O
today	O	O
for	O	O
neoadjuvant	O	O
chemotherapy	O	O
.	O	O
distant	O	O
metastasis	O	O
:	O	O
not	O	O
applicable	O	O
.	O	O
she	O	O
also	O	O
denies	O	O
any	O	O
pain	O	O
.	O	O
(	O	O
11	O	O
/	O	O
03	O	O
/	O	O
2006	O	O
)	O	O
cd	O	O
gary	O	O
l	O	O
.	O	O
(	O	O
pr	O	O
-	O	O
90	O	O
)	O	O
"	O	O
diagnosis	O	O
226	O	O
:	O	O
a	O	O
.	O	O
located	B-site	B-site
0	B-site-value	B-site-value
cm	I-site-value	I-site-value
superior	I-site-value	I-site-value
to	I-site-value	I-site-value
the	I-site-value	I-site-value
main	I-site-value	I-site-value
mass	I-site-value	I-site-value
is	O	O
a	O	O
0	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
fibroadenoma	B-htype-value	B-htype-value
.	O	O
one	O	O
of	O	O
these	O	O
lymph	O	O
nodes	O	O
did	O	O
have	O	O
extra	O	O
extension	O	O
noted	O	O
.	O	O
she	O	O
also	O	O
has	O	O
intermittent	O	O
sharp	O	O
pains	O	O
over	O	O
the	O	O
anterior	O	O
chest	O	O
,	O	O
but	O	O
these	O	O
are	O	O
of	O	O
less	O	O
concern	O	O
to	O	O
her	O	O
.	O	O
the	O	O
patient	O	O
is	O	O
dismissed	O	O
from	O	O
the	O	O
breast	O	O
clinic	O	O
.	O	O
2011	O	O
:	O	O
general	O	O
:	O	O
she	O	O
appears	O	O
well	O	O
and	O	O
comfortable	O	O
.	O	O
procedure	O	O
:	O	O
mastectomy	O	O
:	O	O
simple	O	O
.	O	O
abdomen	O	O
:	O	O
obe	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
nottingham	O	O
grade	B-grade	B-grade
i	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
,	O	O
forming	O	O
a	O	O
3	B-size-value	B-size-value
x	I-size-value	I-size-value
2	I-size-value	I-size-value
x	I-size-value	I-size-value
2	I-size-value	I-size-value
cm	I-size-value	I-size-value
mass	O	O
associated	O	O
with	O	O
extensive	O	B-htype-value
ductal	B-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
at	O	O
1	B-site-value	B-site-value
o	I-site-value	I-site-value
in	I-site-value	I-site-value
the	I-site-value	I-site-value
upper	I-site-value	I-site-value
outer	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
.	O	[CLS]
procedure	O	O
:	O	O
lumpectomy	O	O
:	O	O
seed	O	O
localized	O	O
.	O	O
mitotic	O	O
rate	O	O
:	O	O
no	O	O
residual	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
left	B-laterality-value	B-laterality-value
axilla	O	O
-	O	O
-	O	O
no	O	O
adenopathy	O	O
.	O	O
there	O	O
is	O	O
mild	O	O
signs	O	O
of	O	O
radiation	O	O
der	O	O
on	O	O
the	O	O
anterior	O	O
chest	O	O
wall	O	O
,	O	O
healing	O	O
well	O	O
thyroid	O	O
:	O	O
neck	O	O
,	O	O
thyroid	O	O
examined	O	O
and	O	O
normal	O	O
.	O	[CLS]
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
wide	O	O
local	O	O
excision	O	O
:	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
both	O	O
nodes	O	O
contain	O	O
identifiable	O	O
blue	O	O
dye	O	O
.	O	O
multiple	O	O
(	O	O
2	O	O
)	O	O
ribbon	O	O
biopsy	O	O
clips	O	O
are	O	O
identified	O	O
within	O	O
the	O	O
mass	O	O
.	O	O
chest	O	O
x	O	O
showed	O	O
fibrotic	O	O
strands	O	O
in	O	O
the	O	O
right	B-laterality-value	B-laterality-value
upper	O	O
lobe	O	O
and	O	O
left	B-laterality-value	B-laterality-value
base	O	O
with	O	O
interval	O	O
resolution	O	O
of	O	O
her	O	O
bilateral	O	O
pl	O	O
ef	O	O
.	O	O
f	O	O
,	O	O
m	O	O
.	O	[CLS]
8	O	O
-	O	O
99	O	O
report	O	O
electronically	O	O
signed	O	O
by	O	O
andrew	O	O
l	O	O
.	O	O
when	O	O
she	O	O
saw	O	O
him	O	O
in	O	O
january	O	O
he	O	O
recommended	O	O
an	O	O
excision	O	O
biopsy	O	O
,	O	O
and	O	O
at	O	O
that	O	O
time	O	O
she	O	O
was	O	O
diagnosed	O	O
with	O	O
high	B-grade-value	B-grade-value
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
with	O	O
extension	O	O
to	O	O
the	O	O
ink	O	O
margin	O	O
.	O	[CLS]
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
lumpectomy	O	O
\	O	O
"	O	O
is	O	O
a	O	O
5	O	O
(	O	O
m	O	O
)	O	O
x	O	O
4	O	O
(	O	O
a	O	O
)	O	O
x	O	O
2	O	O
(	O	O
s	O	O
)	O	O
cm	O	O
oriented	O	O
wide	O	O
local	O	O
excision	O	O
breast	O	O
specimen	O	O
.	O	O
also	O	O
,	O	O
the	O	O
open	O	O
area	O	O
that	O	O
had	O	O
been	O	O
weeping	O	O
prior	O	O
to	O	O
treatment	O	O
closes	O	O
up	O	O
shortly	O	O
before	O	O
her	O	O
treatment	O	O
.	O	O
she	O	O
has	O	O
never	O	O
had	O	O
a	O	O
colon	O	O
examination	O	O
,	O	O
and	O	O
she	O	O
needs	O	O
further	O	O
pulmonary	O	O
evaluation	O	O
regarding	O	O
the	O	O
ongoing	O	O
cough	O	O
and	O	O
sp	O	O
,	O	O
assuming	O	O
that	O	O
her	O	O
chest	O	O
x	O	O
is	O	O
negative	O	O
.	O	O
patient	O	O
education	O	O
education	O	O
provided	O	O
to	O	O
:	O	O
patient	O	O
.	O	O
breasts	O	O
:	O	O
status	O	O
post	O	O
right	B-laterality-value	B-laterality-value
excision	O	O
biopsy	O	O
.	O	O
she	O	O
was	O	O
treated	O	O
with	O	O
ci	O	O
and	O	O
cl	O	O
for	O	O
14	O	O
days	O	O
.	O	O
pal	O	O
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
reveals	O	O
soft	O	O
,	O	O
fatty	O	O
texture	O	O
without	O	O
dominant	O	O
masses	O	O
or	O	O
nipple	O	O
discharge	O	O
.	O	O
will	O	O
not	O	O
proceed	O	O
on	O	O
with	O	O
any	O	O
treatment	O	O
at	O	O
this	O	O
time	O	O
,	O	O
since	O	O
she	O	O
has	O	O
more	O	O
pressing	O	O
concerns	O	O
regarding	O	O
her	O	O
breast	O	O
cancer	O	O
.	O	O
gross	O	O
description	O	O
226	O	O
:	O	O
a	O	O
.	O	O
i	O	O
advised	O	O
her	O	O
as	O	O
to	O	O
how	O	O
the	O	O
appointments	O	O
are	O	O
scheduled	O	O
,	O	O
and	O	O
she	O	O
does	O	O
express	O	O
preference	O	O
for	O	O
wednesday	O	O
mornings	O	O
,	O	O
which	O	O
we	O	O
will	O	O
try	O	O
to	O	O
honor	O	O
.	O	O
additional	O	O
work	O	O
has	O	O
included	O	O
a	O	O
bone	O	O
marrow	O	O
evaluation	O	O
,	O	O
which	O	O
was	O	O
negative	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
left	B-laterality-value	B-laterality-value
sentinel	O	O
,	O	O
biopsy	O	O
(	O	O
sp	O	O
-	O	O
351	O	O
,	O	O
9	O	O
slides	O	O
/	O	O
af	O	O
(	O	O
3	O	O
)	O	O
,	O	O
af	O	O
(	O	O
3	O	O
)	O	O
,	O	O
af	O	O
(	O	O
3	O	O
)	O	O
,	O	O
af	O	O
(	O	O
3	O	O
)	O	O
;	O	O
2	O	O
/	O	O
1	O	O
/	O	O
2012	O	O
)	O	O
:	O	O
lymph	O	O
node	O	O
with	O	O
no	O	O
evidence	O	O
of	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
"	O	O
lymph	O	O
invasion	O	O
:	O	O
absent	O	O
.	O	O
men	O	O
was	O	O
at	O	O
age	O	O
12	O	O
.	O	O
c	O	O
.	O	O
patient	O	O
informed	O	O
that	O	O
clinical	O	O
trials	O	O
and	O	O
research	O	O
studies	O	O
are	O	O
available	O	O
at	O	O
mayo	O	O
clinic	O	O
and	O	O
that	O	O
she	O	O
may	O	O
participate	O	O
in	O	O
studies	O	O
for	O	O
which	O	O
she	O	O
meets	O	O
enrollment	O	O
criteria	O	O
.	O	O
lymph	O	O
node	O	O
sampling	O	O
:	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
submitted	O	O
.	O	O
john	O	O
h	O	O
.	O	O
reynolds	O	O
,	O	O
m	O	O
.	O	O
"	O	O
resources	O	O
breast	O	O
cancer	O	O
handbook	O	O
mc	O	O
,	O	O
computer	O	O
education	O	O
module	O	O
.	O	O
neck	O	O
is	O	O
su	O	O
without	O	O
adenopathy	O	O
.	O	O
all	O	O
surgical	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
carcinoma	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
identified	O	O
in	O	O
the	O	O
lymph	O	O
node	O	O
.	O	O
breasts	O	O
:	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
without	O	O
abnormality	O	O
,	O	O
mass	O	O
,	O	O
or	O	O
nod	O	O
.	O	O
in	O	O
addition	O	O
,	O	O
she	O	O
has	O	O
signed	O	O
a	O	O
release	O	O
,	O	O
and	O	O
we	O	O
will	O	O
make	O	O
sure	O	O
that	O	O
her	O	O
outside	O	O
pathology	O	O
is	O	O
reviewed	O	O
here	O	O
,	O	O
specifically	O	O
the	O	O
margin	O	O
information	O	O
.	O	O
referred	O	O
patient	O	O
to	O	O
our	O	O
cancer	O	O
education	O	O
center	O	O
which	O	O
offers	O	O
a	O	O
wide	O	O
variety	O	O
of	O	O
written	O	O
and	O	O
electronic	O	O
resources	O	O
,	O	O
as	O	O
well	O	O
as	O	O
classes	O	O
which	O	O
may	O	O
be	O	O
helpful	O	O
during	O	O
this	O	O
time	O	O
of	O	O
transition	O	O
.	O	O
reynolds	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
66	O	O
report	O	O
electronically	O	O
signed	O	O
by	O	O
carol	O	O
a	O	O
.	O	O
post	O	O
fever	O	O
and	O	O
chill	O	O
with	O	O
eventual	O	O
inc	O	O
and	O	O
drainage	O	O
and	O	O
take	O	O
of	O	O
tram	O	O
flap	O	O
july	O	O
25	O	O
,	O	O
2008	O	O
.	O	O
6	O	O
.	O	O
hughes	O	O
and	O	O
her	O	O
daughter	O	O
who	O	O
was	O	O
also	O	O
present	O	O
.	O	O
estrogen	O	O
and	O	O
progesterone	O	O
analysis	O	O
has	O	O
been	O	O
ordered	O	O
on	O	O
paraffin	O	O
embedded	O	O
tissue	O	O
,	O	O
bilaterally	B-laterality-value	O
.	O	O
3	O	O
/	O	O
30	O	O
/	O	O
2001	O	O
john	O	O
c	O	O
.	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
;	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
nos	O	O
.	O	O
1	O	O
,	O	O
2	O	O
,	O	O
and	O	O
3	O	O
;	O	O
sentinel	O	O
biopsies	O	O
:	O	O
one	O	O
(	O	O
of	O	O
3	O	O
)	O	O
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
is	O	O
positive	O	O
for	O	O
two	O	O
micro	O	O
measuring	B-size	B-size
0	B-size-value	B-size-value
and	O	O
0	B-size-value	I-size-value
mm	I-size-value	I-size-value
[	O	O
aj	O	O
pn1	B-stage-value	B-stage-value
mi	B-stage-value	O
(	O	O
s	O	O
)	O	O
]	O	O
.	O	O
i	O	O
have	O	O
had	O	O
the	O	O
opportunity	O	O
to	O	O
review	O	O
her	O	O
outside	O	O
materials	O	O
,	O	O
and	O	O
pending	O	O
additional	O	O
lab	O	O
and	O	O
chest	O	O
x	O	O
studies	O	O
she	O	O
is	O	O
ok	O	O
for	O	O
surgery	O	O
with	O	O
minimal	O	O
risk	O	O
for	O	O
cardiac	O	O
complications	O	O
related	O	O
to	O	O
this	O	O
particular	O	O
procedure	O	O
.	O	O
es	O	O
on	O	O
this	O	O
date	O	O
were	O	O
reviewed	O	O
.	O	O
representative	O	O
sections	O	O
are	O	O
submitted	O	O
.	O	O
estrogen	O	O
replacement	O	O
therapy	O	O
,	O	O
was	O	O
on	O	O
prem	O	O
initially	O	O
from	O	O
the	O	O
time	O	O
of	O	O
her	O	O
early	O	O
men	O	O
,	O	O
switched	O	O
to	O	O
prem	O	O
in	O	O
1995	O	O
,	O	O
she	O	O
continued	O	O
this	O	O
until	O	O
november	O	O
1	O	O
,	O	O
1999	O	O
at	O	O
which	O	O
time	O	O
her	O	O
cancer	O	O
was	O	O
noted	O	O
on	O	O
biopsy	O	O
.	O	O
long	O	O
who	O	O
advises	O	O
continuing	O	O
with	O	O
the	O	O
natural	O	O
tears	O	O
or	O	O
vis	O	O
.	O	O
amy	O	O
c	O	O
.	O	O
she	O	O
recently	O	O
had	O	O
implant	O	O
exchange	O	O
,	O	O
and	O	O
she	O	O
is	O	O
very	O	O
happy	O	O
with	O	O
the	O	O
cosmetic	O	O
results	O	O
.	O	O
she	O	O
believes	O	O
one	O	O
or	O	O
two	O	O
had	O	O
cancer	O	O
in	O	O
them	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
no	O	O
.	O	O
1	O	O
\	O	O
"	O	O
is	O	O
a	O	O
single	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
lymph	O	O
node	O	O
.	O	O
advance	O	O
directive	O	O
advance	O	O
directive	O	O
or	O	O
living	O	O
will	O	O
:	O	O
no	O	O
,	O	O
but	O	O
would	O	O
like	O	O
additional	O	O
information	O	O
.	O	O
hormone	O	O
receptors	O	O
were	O	O
also	O	O
still	O	O
pending	O	O
.	O	O
if	O	O
these	O	O
look	O	O
like	O	O
fat	O	O
necrosis	O	O
,	O	O
fine	O	O
,	O	O
if	O	O
they	O	O
do	O	O
not	O	O
or	O	O
if	O	O
there	O	O
is	O	O
any	O	O
question	O	O
,	O	O
they	O	O
should	O	O
be	O	O
needle	O	O
bio	O	O
or	O	O
bio	O	O
.	O	O
2011	O	O
:	O	O
general	O	O
:	O	O
thin	O	O
,	O	O
trim	O	O
woman	O	O
in	O	O
no	O	O
acute	O	O
distress	O	O
.	O	O
she	O	O
did	O	O
have	O	O
bilateral	B-laterality-value	B-laterality-value
redundant	O	O
tissue	O	O
in	O	O
both	O	O
low	O	O
axillary	O	O
regions	O	O
,	O	O
which	O	O
she	O	O
noted	O	O
to	O	O
be	O	O
the	O	O
area	O	O
of	O	O
pain	O	O
.	O	O
an	O	O
additional	O	O
0	B-size-value	B-size-value
cm	I-size-value	I-size-value
tumor	O	O
nodule	O	O
is	O	O
located	B-site	B-site
1	B-site-value	B-site-value
cm	I-site-value	I-site-value
lateral	I-site-value	I-site-value
to	I-site-value	I-site-value
the	I-site-value	I-site-value
main	I-site-value	I-site-value
mass	I-site-value	I-site-value
,	O	O
nottingham	O	O
grade	B-grade	B-grade
ii	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
.	O	O
grossed	O	O
by	O	O
j	O	O
.	O	O
se	O	O
,	O	O
m	O	O
.	O	O
,	O	O
phd	O	O
.	O	O
discussed	O	O
estrogen	B-receptor	B-receptor
and	O	O
progesterone	B-receptor	B-receptor
receptor	I-receptor	I-receptor
status	O	O
and	O	O
impact	O	O
in	O	O
determining	O	O
use	O	O
of	O	O
adjuvant	O	O
ho	O	O
treatment	O	O
.	O	O
skeletal	O	O
muscle	O	O
:	O	O
not	O	O
present	O	O
.	O	O
tick	O	O
is	O	O
encouraged	O	O
to	O	O
call	O	O
with	O	O
any	O	O
questions	O	O
or	O	O
concerns	O	O
regarding	O	O
side	O	O
effects	O	O
of	O	O
radiation	O	O
therapy	O	O
.	O	O
c	O	O
.	O	O
.	O	O
2010	O	O
:	O	O
ms	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
tissue	O	O
set	O	O
#	O	O
,	O	O
biopsy	O	O
:	O	O
multiple	O	O
(	O	O
3	O	O
)	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
:	O	O
j	O	O
addendum	O	O
:	O	O
estrogen	B-receptor	B-receptor
and	O	O
progesterone	B-receptor	B-receptor
receptors	I-receptor	I-receptor
were	O	O
performed	O	O
on	O	O
paraffin	O	O
embedded	O	O
tissue	O	O
(	O	O
block	O	O
a1	O	O
)	O	O
.	O	O
data	O	O
review	O	O
:	O	O
cbc	O	O
within	O	O
normal	O	O
limits	O	O
except	O	O
for	O	O
mildly	O	O
elevated	O	O
leukocytes	O	O
11	O	O
with	O	O
left	B-laterality-value	O
shift	O	O
.	O	O
a	O	O
biopsy	O	O
clip	O	O
is	O	O
identified	O	O
within	O	O
the	O	O
specimen	O	O
.	O	O
the	O	O
right	B-laterality-value	B-laterality-value
axilla	O	O
is	O	O
un	O	O
.	O	O
the	O	O
surgical	O	O
margins	O	O
,	O	O
including	O	O
deep	O	O
margin	O	O
and	O	O
peripheral	O	O
skin	O	O
margins	O	O
,	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
advance	O	O
directive	O	O
advance	O	O
directive	O	O
or	O	O
living	O	O
will	O	O
:	O	O
no	O	O
,	O	O
not	O	O
interested	O	O
in	O	O
additional	O	O
information	O	O
.	O	O
h	O	O
.	O	O
the	O	O
surgical	O	O
margins	O	O
are	O	O
negative	O	O
.	O	O
she	O	O
denies	O	O
any	O	O
bone	O	O
pain	O	O
,	O	O
nausea	O	O
,	O	O
or	O	O
vomiting	O	O
or	O	O
fever	O	O
or	O	O
chill	O	O
.	O	O
surgical	O	O
margins	O	O
:	O	O
negative	O	O
for	O	O
invasive	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
:	O	O
nearest	O	O
inferior	O	O
margin	O	O
,	O	O
1	O	O
cm	O	O
.	O	O
this	O	O
is	O	O
in	O	O
the	O	O
setting	O	O
of	O	O
dcis	B-htype-value	B-htype-value
.	O	O
the	O	O
finding	O	O
is	O	O
consistent	O	O
with	O	O
inflammatory	O	O
breast	O	O
cancer	O	O
.	O	O
angiolymphatic	O	O
invasion	O	O
is	O	O
present	O	O
.	O	O
she	O	O
tolerated	O	O
radiation	O	O
fairly	O	O
well	O	O
with	O	O
only	O	O
some	O	O
mild	O	O
fatigue	O	O
and	O	O
mild	O	O
skin	O	O
burn	O	O
for	O	O
which	O	O
she	O	O
is	O	O
using	O	O
petroleum	O	O
cream	O	O
.	O	O
she	O	O
still	O	O
has	O	O
jp	O	O
drains	O	O
bilaterally	B-laterality-value	B-laterality-value
.	O	O
advance	O	O
directive	O	O
advance	O	O
directive	O	O
or	O	O
living	O	O
will	O	O
:	O	O
no	O	O
,	O	O
not	O	O
interested	O	O
in	O	O
additional	O	O
information	O	O
.	O	O
f	O	O
,	O	O
m	O	O
.	O	[CLS]
8	O	O
-	O	O
99	O	O
report	O	O
electronically	O	O
signed	O	O
by	O	O
andrew	O	O
l	O	O
.	O	O
grossed	O	O
by	O	O
t	O	O
.	O	O
histologic	O	O
grade	B-grade	B-grade
:	O	O
nottingham	O	O
histologic	O	O
score	O	O
:	O	O
nottingham	O	O
score	O	O
:	O	O
glandular	O	O
/	O	O
tubular	O	O
differentiation	O	O
:	O	O
2	O	O
nuclear	O	O
pleomorphism	O	O
:	O	O
2	O	O
mitotic	O	O
rate	O	O
:	O	O
1	O	O
nottingham	O	O
grade	B-grade	B-grade
:	O	O
i	B-grade-value	B-grade-value
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
(	O	O
dcis	B-htype-value	B-htype-value
)	O	O
:	O	O
no	O	O
dcis	B-htype-value	B-htype-value
present	O	O
.	O	O
the	O	O
traced	O	O
areas	O	O
are	O	O
analyzed	O	O
using	O	O
ape	O	O
software	O	O
,	O	O
an	O	O
fda	O	O
510	O	O
(	O	O
k	O	O
)	O	O
cleared	O	O
application	O	O
for	O	O
precise	O	O
measurement	O	O
of	O	O
the	O	O
level	O	O
of	O	O
her2	B-receptor	B-receptor
protein	O	O
on	O	O
cell	O	O
membranes	O	O
of	O	O
breast	O	O
tumor	O	O
cells	O	O
.	O	O
she	O	O
does	O	O
have	O	O
a	O	O
history	O	O
of	O	O
hypertension	O	O
which	O	O
has	O	O
previously	O	O
been	O	O
well	O	O
managed	O	O
with	O	O
anti	O	O
medication	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
dcis	B-htype-value	B-htype-value
with	O	O
1	O	O
foci	O	O
of	O	O
micro	O	O
status	O	O
post	O	O
lumpectomy	O	O
and	O	O
bra	O	O
,	O	O
july	O	O
2017	O	O
#	O	O
dense	O	O
breasts	O	O
#	O	O
breast	O	O
cancer	O	O
survivors	O	O
2011	O	O
:	O	O
#	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
dcis	B-htype-value	B-htype-value
with	O	O
1	O	O
foci	O	O
of	O	O
micro	O	O
status	O	O
post	O	O
lumpectomy	O	O
and	O	O
bra	O	O
,	O	O
july	O	O
2017	O	O
clinical	O	O
exam	O	O
satisfactory	O	O
.	O	O
all	O	O
controls	O	O
show	O	O
appropriate	O	O
react	O	O
.	O	O
she	O	O
said	O	O
that	O	O
,	O	O
compared	O	O
to	O	O
august	O	O
,	O	O
she	O	O
has	O	O
been	O	O
doing	O	O
relatively	O	O
well	O	O
but	O	O
has	O	O
noted	O	O
some	O	O
thick	O	O
yellow	O	O
fluid	O	O
on	O	O
the	O	O
dressing	O	O
.	O	O
ultrasound	O	O
of	O	O
the	O	O
left	B-laterality-value	B-laterality-value
sub	B-site-value	O
region	I-site-value	O
showed	O	O
no	O	O
son	O	O
abnormality	O	O
,	O	O
and	O	O
5	B-size-value	O
-	I-size-value	I-size-value
mm	I-size-value	I-size-value
of	O	O
skin	O	O
thick	O	O
was	O	O
noted	O	O
.	O	[CLS]
5	O	O
.	O	O
breast	O	O
cancer	O	O
risk	O	O
profile	O	O
:	O	O
gr	O	O
4	O	O
,	O	O
para	O	O
4	O	O
;	O	O
first	O	O
par	O	O
at	O	O
age	O	O
21	O	O
.	O	O
frozen	O	O
section	O	O
histologic	O	O
interpretation	O	O
performed	O	O
by	O	O
:	O	O
ya	O	O
huang	O	O
,	O	O
m	O	O
.	O	O
"	O	O
du	O	O
,	O	O
m	O	O
.	O	O
"	O	O
frozen	O	O
section	O	O
histologic	O	O
interpretation	O	O
performed	O	O
by	O	O
:	O	O
carrie	O	O
y	O	O
.	O	O
diagnostic	O	O
mammogram	O	O
and	O	O
ultrasound	O	O
performed	O	O
at	O	O
mayo	O	O
clinic	O	O
.	O	O
electronically	O	O
listed	O	O
for	O	O
tomorrow	O	O
,	O	O
go	O	O
15	O	O
.	O	O
tu	O	O
had	O	O
.	O	O
may	O	O
7	O	O
,	O	O
2013	O	O
:	O	O
clinical	O	O
breast	O	O
exam	O	O
by	O	O
her	O	O
primary	O	O
care	O	O
provider	O	O
at	O	O
ol	O	O
medical	O	O
center	O	O
.	O	O
er	B-receptor	B-receptor
,	O	O
pr	B-receptor	B-receptor
,	O	O
and	O	O
her	O	O
status	O	O
is	O	O
pending	O	O
at	O	O
this	O	O
time	O	O
.	O	O
f	O	O
.	O	O
sentinel	O	O
nodes	O	O
,	O	O
total	O	O
number	O	O
examined	O	O
:	O	O
6	O	O
.	O	O
patient	O	O
informed	O	O
of	O	O
cancer	O	O
surveillance	O	O
schedule	O	O
to	O	O
include	O	O
at	O	O
a	O	O
minimum	O	O
six	O	O
clinical	O	O
breast	O	O
exam	O	O
and	O	O
annual	O	O
mammogram	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
1	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
)	O	O
sentinel	O	O
lymph	O	O
node	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
2010	O	O
:	O	O
mrs	O	O
.	O	O
negative	O	O
for	O	O
residual	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
.	O	O
ex	O	O
:	O	O
examined	O	O
and	O	O
normal	O	O
.	O	O
:	O	O
ter	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
invasive	O	O
grade	B-grade	B-grade
3	B-grade-value	B-grade-value
(	O	O
of	O	O
4	O	O
)	O	O
ductal	B-htype-value	B-htype-value
adenocarcinoma	I-htype-value	I-htype-value
right	B-laterality-value	B-laterality-value
breast	O	O
.	O	O
she	O	O
is	O	O
scheduled	O	O
to	O	O
received	O	O
her	O	O
neu	O	O
injection	O	O
on	O	O
monday	O	O
1	O	O
/	O	O
18	O	O
in	O	O
the	O	O
am	O	O
.	O	O
2011	O	O
:	O	O
general	O	O
:	O	O
she	O	O
is	O	O
alert	O	O
and	O	O
oriented	O	O
,	O	O
in	O	O
note	O	O
acute	O	O
distress	O	O
,	O	O
she	O	O
looks	O	O
rather	O	O
tired	O	O
eyes	O	O
:	O	O
sc	O	O
white	O	O
,	O	O
per	O	O
heart	O	O
:	O	O
rr	O	O
,	O	O
no	O	O
murmur	O	O
lungs	O	O
:	O	O
ct	O	O
b	O	O
/	O	O
l	O	O
abdomen	O	O
:	O	O
soft	O	O
and	O	O
non	O	O
,	O	O
no	O	O
abdominal	O	O
dis	O	O
ex	O	O
:	O	O
no	O	O
le	O	O
edema	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
contents	O	O
\	O	O
"	O	O
is	O	O
a	O	O
12	O	O
x	O	O
7	O	O
x	O	O
2	O	O
cm	O	O
aggregate	O	O
of	O	O
adi	O	O
and	O	O
lymph	O	O
tissue	O	O
(	O	O
dissection	O	O
)	O	O
.	O	O
family	O	O
history	O	O
significant	O	O
for	O	O
breast	O	O
cancer	O	O
in	O	O
her	O	O
mother	O	O
at	O	O
the	O	O
age	O	O
of	O	O
82	O	O
for	O	O
which	O	O
her	O	O
mother	O	O
underwent	O	O
a	O	O
mastectomy	O	O
.	O	O
with	O	O
available	O	O
surgical	O	O
material	O	O
,	O	O
[	O	O
aj	O	O
pt1c	B-stage-value	B-stage-value
]	O	O
(	O	O
7th	O	O
edition	O	O
,	O	O
2010	O	O
)	O	O
.	O	O
she	O	O
had	O	O
an	O	O
additional	O	O
abnormality	O	O
in	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
identified	O	O
by	O	O
mri	O	O
,	O	O
but	O	O
second	O	O
ultrasound	O	O
needle	O	O
biopsy	O	O
demonstrated	O	O
just	O	O
a	O	O
fibroadenoma	B-htype-value	B-htype-value
.	O	O
far	O	O
,	O	O
m	O	O
.	O	O
i	O	O
will	O	O
discuss	O	O
all	O	O
of	O	O
the	O	O
above	O	O
with	O	O
dr	O	O
.	O	O
fixation	O	O
conditions	O	O
for	O	O
this	O	O
specimen	O	O
were	O	O
indicated	O	O
to	O	O
be	O	O
within	O	O
the	O	O
cap	O	O
/	O	O
as	O	O
guidelines	O	O
for	O	O
er	B-receptor	B-receptor
/	O	O
pr	B-receptor	B-receptor
testing	O	O
.	O	O
no	O	O
additional	O	O
masses	O	O
are	O	O
identified	O	O
in	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
.	O	O
all	O	O
surgical	O	O
resection	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
(	O	O
minimum	O	O
tumor	O	O
free	O	O
margin	O	O
,	O	O
0	O	O
cm	O	O
,	O	O
inferior	O	O
margin	O	O
)	O	O
.	O	O
d	O	O
.	O	O
lc	O	O
path	O	O
,	O	O
p	O	O
.	O	O
102	O	O
marsh	O	O
street	O	O
p	O	O
.	O	O
se	O	O
,	O	O
m	O	O
.	O	O
,	O	O
ph	O	O
.	O	O
"	O	O
pr	B-receptor	B-receptor
51	O	O
to	O	O
75	O	O
.	O	O
she	O	O
noted	O	O
on	O	O
the	O	O
tamoxifen	O	O
bottle	O	O
that	O	O
side	O	O
effects	O	O
include	O	O
di	O	O
.	O	O
gross	O	O
description	O	O
226	O	O
:	O	O
a	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
,	O	O
non	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
)	O	O
lymph	O	O
node	O	O
is	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
pathologic	O	O
staging	B-stage	B-stage
(	O	O
aj	O	O
,	O	O
7th	O	O
edition	O	O
)	O	O
:	O	O
primary	O	O
tumor	O	O
:	O	O
pt1c	B-stage-value	B-stage-value
regional	O	O
lymph	O	O
nodes	O	O
:	O	O
pn0	B-stage-value	B-stage-value
sentinel	O	O
nodes	O	O
,	O	O
total	O	O
number	O	O
examined	O	O
:	O	O
4	O	O
non	O	O
axillary	O	O
nodes	O	O
,	O	O
total	O	O
number	O	O
examined	O	O
:	O	O
0	O	O
all	O	O
(	O	O
sentinel	O	O
plus	O	O
non	O	O
)	O	O
nodes	O	O
,	O	O
total	O	O
number	O	O
:	O	O
4	O	O
number	O	O
of	O	O
negative	O	O
l	O	O
:	O	O
4	O	O
number	O	O
of	O	O
l	O	O
with	O	O
isolated	O	O
tumor	O	O
cells	O	O
:	O	O
0	O	O
number	O	O
of	O	O
l	O	O
with	O	O
micro	O	O
:	O	O
0	O	O
number	O	O
of	O	O
l	O	O
with	O	O
macrometastases	O	O
:	O	O
0	O	O
treatment	O	O
effect	O	O
(	O	O
lymph	O	O
nodes	O	O
)	O	O
:	O	O
not	O	O
applicable	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
additional	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
tissue	O	O
\	O	O
"	O	O
is	O	O
a	O	O
4	O	O
x	O	O
3	O	O
x	O	O
1	O	O
cm	O	O
aggregate	O	O
of	O	O
adi	O	O
and	O	O
lymph	O	O
tissue	O	O
.	O	O
a	O	O
single	O	O
intra	O	O
lymph	O	O
node	O	O
is	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
ren	O	O
is	O	O
a	O	O
49	O	O
-	O	O
year	O	O
per	O	O
woman	O	O
who	O	O
presents	O	O
today	O	O
for	O	O
discussion	O	O
following	O	O
newly	O	O
diagnosed	O	O
and	O	O
res	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
cancer	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
left	B-laterality-value	B-laterality-value
simple	O	O
mastectomy	O	O
#	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
reconstruction	O	O
2011	O	O
:	O	O
patient	O	O
is	O	O
a	O	O
69	O	O
-	O	O
year	O	O
female	O	O
.	O	O
timothy	O	O
f	O	O
.	O	O
c	O	O
.	O	O
it	O	O
has	O	O
not	O	O
been	O	O
cleared	O	O
or	O	O
approved	O	O
by	O	O
the	O	O
u	O	O
.	O	O
j	O	O
.	O	O
jimenez	O	O
,	O	O
m	O	O
.	O	O
8	O	O
/	O	O
19	O	O
/	O	O
2011	O	O
16	O	O
:	O	O
26	O	O
:	O	O
28	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
a	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
11	O	O
/	O	O
17	O	O
/	O	O
2004	O	O
surgical	O	O
pathology	O	O
(	O	O
cr	O	O
-	O	O
89	O	O
)	O	O
requested	O	O
by	O	O
:	O	O
amy	O	O
c	O	O
.	O	O
neck	O	O
su	O	O
.	O	O
micro	O	O
is	O	O
identified	O	O
.	O	O
she	O	O
could	O	O
also	O	O
have	O	O
another	O	O
et	O	O
of	O	O
back	O	O
pain	O	O
such	O	O
as	O	O
compression	O	O
fracture	O	O
.	O	O
biopsy	O	O
site	O	O
changes	O	O
are	O	O
present	O	O
.	O	O
she	O	O
also	O	O
understands	O	O
that	O	O
we	O	O
would	O	O
plan	O	O
to	O	O
proceed	O	O
to	O	O
completion	O	O
axillary	O	O
lymph	O	O
node	O	O
dissection	O	O
if	O	O
metastases	O	O
were	O	O
identified	O	O
in	O	O
a	O	O
sentinel	O	O
lymph	O	O
node	O	O
intra	O	O
.	O	O
hi	O	O
,	O	O
m	O	O
.	O	O
3	O	O
-	O	O
53	O	O
slide	O	O
disposition	O	O
:	O	O
"	O	O
diagnosis	O	O
226	O	O
:	O	O
a	O	O
.	O	O
she	O	O
presents	O	O
with	O	O
a	O	O
two	O	O
history	O	O
of	O	O
upset	O	O
stomach	O	O
with	O	O
nausea	O	O
and	O	O
vomiting	O	O
.	O	O
grossed	O	O
by	O	O
nes	O	O
.	O	O
c	O	O
.	O	O
platelets	O	O
277	O	O
.	O	O
hold	O	O
for	O	O
permanent	O	O
sections	O	O
.	O	O
coping	O	O
and	O	O
living	O	O
with	O	O
breast	O	O
cancer	O	O
mic	O	O
,	O	O
follow	O	O
up	O	O
for	O	O
breast	O	O
cancer	O	O
survivors	O	O
mc	O	O
-	O	O
10	O	O
,	O	O
let	O	O
talk	O	O
about	O	O
clinical	O	O
research	O	O
mc	O	O
-	O	O
12	O	O
,	O	O
a	O	O
guide	O	O
to	O	O
lymph	O	O
mc	O	O
,	O	O
breast	O	O
cancer	O	O
mentor	O	O
bro	O	O
mc	O	O
-	O	O
01	O	O
,	O	O
breast	O	O
mri	O	O
:	O	O
deciding	O	O
who	O	O
needs	O	O
one	O	O
mc	O	O
,	O	O
hope	O	O
and	O	O
healing	O	O
boutique	O	O
mc	O	O
,	O	O
mayo	O	O
clinic	O	O
healthy	O	O
living	O	O
program	O	O
healthy	O	O
living	O	O
classes	O	O
mc	O	O
-	O	O
97	O	O
,	O	O
your	O	O
guide	O	O
to	O	O
pain	O	O
management	O	O
mc	O	O
,	O	O
live	O	O
well	O	O
after	O	O
cancer	O	O
treatment	O	O
mc	O	O
and	O	O
patient	O	O
navigator	O	O
program	O	O
by	O	O
the	O	O
american	O	O
cancer	O	O
society	O	O
)	O	O
,	O	O
mayo	O	O
clinic	O	O
breast	O	O
cancer	O	O
the	O	O
five	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
and	O	O
a	O	O
single	O	O
right	B-laterality-value	B-laterality-value
intra	O	O
sentinel	O	O
lymph	O	O
node	O	O
were	O	O
negative	O	O
for	O	O
metastatic	O	O
disease	O	O
.	O	O
block	O	O
summary	O	O
:	O	O
part	O	O
a	O	O
:	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
wide	O	O
local	O	O
excision	O	O
1	O	O
lt	O	O
inferior	O	O
margin	O	O
2	O	O
lt	O	O
superior	O	O
margin	O	O
3	O	O
lt	O	O
medial	O	O
margin	O	O
4	O	O
lt	O	O
inferior	O	O
margin	O	O
-	O	O
2	O	O
part	O	O
b	O	O
:	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
#	O	O
1	O	O
lt	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
(	O	O
1	O	O
)	O	O
2	O	O
lt	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
(	O	O
2	O	O
)	O	O
part	O	O
c	O	O
:	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
#	O	O
1	O	O
lt	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
l	O	O
#	O	O
part	O	O
d	O	O
:	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
#	O	O
1	O	O
lt	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
l	O	O
#	O	O
ale	O	O
bug	O	O
,	O	O
m	O	O
.	O	[CLS]
a	O	O
.	O	O
june	O	O
19	O	O
,	O	O
2013	O	O
:	O	O
consultation	O	O
with	O	O
dr	O	O
.	O	O
she	O	O
has	O	O
ec	O	O
.	O	O
hold	O	O
over	O	O
for	O	O
grading	O	O
and	O	O
to	O	O
evaluate	O	O
the	O	O
focus	O	O
of	O	O
atypical	O	O
duct	O	O
proliferation	O	O
on	O	O
permanent	O	O
sections	O	O
.	O	O
she	O	O
does	O	O
have	O	O
a	O	O
history	O	O
of	O	O
second	O	O
smoke	O	O
exposure	O	O
.	O	O
we	O	O
talked	O	O
about	O	O
her	O	O
mammogram	O	O
again	O	O
.	O	O
lewis	O	O
,	O	O
m	O	O
.	O	O
3	O	O
-	O	O
44	O	O
report	O	O
electronically	O	O
signed	O	O
by	O	O
jason	O	O
t	O	O
.	O	O
frozen	O	O
section	O	O
histologic	O	O
interpretation	O	O
performed	O	O
by	O	O
:	O	O
fabio	O	O
med	O	O
,	O	O
m	O	O
.	O	O
"	O	O
at	O	O
this	O	O
point	O	O
in	O	O
time	O	O
,	O	O
i	O	O
think	O	O
further	O	O
evaluation	O	O
by	O	O
breast	O	O
mri	O	O
with	O	O
a	O	O
second	O	O
ultrasound	O	O
if	O	O
necessary	O	O
as	O	O
well	O	O
as	O	O
biopsy	O	O
of	O	O
the	O	O
left	B-laterality-value	B-laterality-value
lower	B-site-value	B-site-value
inner	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
mass	O	O
and	O	O
the	O	O
abnormal	O	O
lymph	O	O
node	O	O
in	O	O
the	O	O
left	B-laterality-value	B-laterality-value
axilla	O	O
are	O	O
indicated	O	O
,	O	O
and	O	O
she	O	[CLS]
is	O	O
in	O	O
agreement	O	O
with	O	O
that	O	O
.	O	O
lewis	O	O
,	O	O
m	O	O
.	O	O
participated	O	O
in	O	O
interpretation	O	O
:	O	O
dr	O	O
.	O	O
(	O	O
cr	O	O
-	O	O
87	O	O
)	O	O
tissue	O	O
description	O	O
:	O	O
tissue	O	O
from	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
(	O	O
5	O	O
x	O	O
2	O	O
x	O	O
1	O	O
cm	O	O
)	O	O
,	O	O
separately	O	O
submitted	O	O
superior	O	O
/	O	O
lateral	O	O
margin	O	O
(	O	O
4	O	O
x	O	O
3	O	O
x	O	O
1	O	O
cm	O	O
)	O	O
and	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
lymph	O	O
tissue	O	O
.	O	O
i	O	O
advised	O	O
her	O	O
that	O	O
she	O	O
should	O	O
be	O	O
able	O	O
to	O	O
drive	O	O
herself	O	O
to	O	O
and	O	O
from	O	O
appointments	O	O
as	O	O
long	O	O
as	O	O
she	O	O
does	O	O
not	O	O
become	O	O
overly	O	O
se	O	O
with	O	O
the	O	O
prochlorperazine	O	O
which	O	O
we	O	O
give	O	O
as	O	O
prem	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
(	O	O
no	O	O
.	O	O
2	O	O
)	O	O
deep	O	O
margin	O	O
,	O	O
re	O	O
:	O	O
no	O	O
residual	O	O
tumor	O	O
identified	O	O
.	O	O
all	O	O
surgical	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
(	O	O
minimum	O	O
tumor	O	O
free	O	O
margin	O	O
,	O	O
1	O	O
cm	O	O
,	O	O
anterior	O	O
/	O	O
superior	O	O
margin	O	O
)	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
mass	O	O
,	O	O
short	O	O
;	O	O
long	O	O
\	O	O
"	O	O
is	O	O
a	O	O
4	O	O
(	O	O
m	O	O
)	O	O
x	O	O
4	O	O
(	O	O
a	O	O
)	O	O
x	O	O
3	O	O
(	O	O
s	O	O
)	O	O
cm	O	O
oriented	O	O
wide	O	O
local	O	O
excision	O	O
breast	O	O
specimen	O	O
.	O	O
no	O	O
focal	O	O
pain	O	O
or	O	O
tenderness	O	O
.	O	O
c	O	O
.	O	O
protocol	O	O
ae	O	O
:	O	O
fatigue	O	O
grade	O	B-grade
1	O	B-grade-value
possibly	O	O
related	O	O
to	O	O
radiation	O	O
therapy	O	O
and	O	O
possibly	O	O
related	O	O
to	O	O
chemotherapy	O	O
.	O	O
estrogen	B-receptor	B-receptor
and	O	O
progesterone	B-receptor	B-receptor
receptor	I-receptor	I-receptor
positive	B-receptor-status	B-receptor-status
>	O	O
75	O	O
and	O	O
her	B-receptor	B-receptor
-	I-receptor	I-receptor
2	I-receptor	I-receptor
/	O	O
neu	O	O
negative	B-receptor-status	B-receptor-status
,	O	O
score	O	O
of	O	O
1	B-receptor-value	B-receptor-value
+	I-receptor-value	I-receptor-value
.	O	O
hee	O	O
eun	O	O
lee	O	O
.	O	O
grossed	O	O
by	O	O
cm	O	O
.	O	O
breasts	O	O
:	O	O
large	O	O
symmetrical	O	O
breasts	O	O
.	O	O
hold	O	O
over	O	O
to	O	O
assess	O	O
for	O	O
possible	O	O
atypia	O	O
.	O	O
we	O	O
also	O	O
discussed	O	O
that	O	O
it	O	O
was	O	O
the	O	O
her2	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
status	O	O
that	O	O
is	O	O
a	O	O
major	O	O
component	O	O
in	O	O
the	O	O
decision	O	O
to	O	O
pursue	O	O
chemotherapy	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
new	O	O
anterior	O	O
margin	O	O
,	O	O
re	O	O
:	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
when	O	O
she	O	O
returned	O	O
for	O	O
follow	O	O
in	O	O
december	O	O
,	O	O
he	O	O
noted	O	O
persistence	O	O
of	O	O
the	O	O
lump	O	O
and	O	O
felt	O	O
that	O	O
it	O	O
most	O	O
likely	O	O
represented	O	O
a	O	O
hem	O	O
and	O	O
recommended	O	O
another	O	O
one	O	O
follow	O	O
.	O	O
e	O	O
.	O	O
de	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
63	O	O
slide	O	O
disposition	O	O
:	O	O
"	O	O
diagnosis	O	O
226	O	O
:	O	O
a	O	O
.	O	O
june	O	O
2011	O	O
,	O	O
the	O	O
patient	O	O
undergoes	O	O
planned	O	O
lap	O	O
bilateral	B-laterality-value	B-laterality-value
sal	O	O
and	O	O
d	O	O
&	O	O
c	O	O
.	O	O
a	O	O
nipple	O	O
is	O	O
present	O	O
.	O	O
number	O	O
of	O	O
negative	O	O
l	O	O
:	O	O
6	O	O
.	O	O
mrs	O	O
.	O	O
she	O	O
never	O	O
used	O	O
the	O	O
prem	O	O
cream	O	O
which	O	O
was	O	O
prescribed	O	O
.	O	O
ct	O	O
ur	O	O
performed	O	O
on	O	O
february	O	O
19	O	O
,	O	O
2003	O	O
,	O	O
shows	O	O
a	O	O
4	O	B-size-value
-	O	I-size-value
x	O	I-size-value
3	O	I-size-value
-	O	I-size-value
cm	O	I-size-value
simple	O	O
cyst	O	O
in	O	O
the	O	O
upper	O	B-site-value
pole	O	I-site-value
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
kidney	O	O
.	O	O
this	O	O
occurred	O	O
starting	O	O
two	O	O
to	O	O
three	O	O
months	O	O
ago	O	O
.	O	O
b	O	O
.	O	O
he	O	O
continues	O	O
to	O	O
play	O	O
golf	O	O
3	O	O
times	O	O
a	O	O
week	O	O
.	O	O
the	O	O
patient	O	O
and	O	O
i	O	O
did	O	O
discuss	O	O
the	O	O
situation	O	O
,	O	O
and	O	O
i	O	O
did	O	O
offer	O	O
my	O	O
support	O	O
at	O	O
this	O	O
time	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
,	O	O
excision	O	O
:	O	O
multiple	O	O
(	O	O
2	O	O
)	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
yan	O	O
discussed	O	O
the	O	O
plan	O	O
for	O	O
follow	O	O
up	O	O
,	O	O
including	O	O
a	O	O
visit	O	O
here	O	O
in	O	O
radiation	O	O
oncology	O	O
in	O	O
approximately	O	O
3	O	O
months	O	O
time	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
new	O	O
medial	O	O
margin	O	O
\	O	O
"	O	O
is	O	O
a	O	O
5	O	O
x	O	O
5	O	O
x	O	O
0	O	O
cm	O	O
portion	O	O
of	O	O
fi	O	O
tissue	O	O
.	O	O
however	O	O
,	O	O
i	O	O
did	O	O
discuss	O	O
that	O	O
if	O	O
she	O	O
were	O	O
to	O	O
take	O	O
tamoxifen	O	O
alone	O	O
,	O	O
the	O	O
overall	O	O
10	O	O
-	O	O
year	O	O
survival	O	O
would	O	O
be	O	O
on	O	O
the	O	O
order	O	O
of	O	O
85	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
2	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
multiple	O	O
(	O	O
2	O	O
)	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
without	O	O
blue	O	O
dye	O	O
are	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
overall	O	O
,	O	O
at	O	O
this	O	O
time	O	O
,	O	O
it	O	O
appears	O	O
that	O	O
she	O	O
is	O	O
coping	O	O
fairly	O	O
well	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
03	O	O
/	O	O
17	O	O
/	O	O
2010	O	O
surgical	O	O
pathology	O	O
(	O	O
mr	O	O
-	O	O
2013	O	O
)	O	O
requested	O	O
by	O	O
:	O	O
brian	O	O
t	O	O
.	O	O
all	O	O
questions	O	O
have	O	O
been	O	O
answered	O	O
.	O	O
ki	O	O
-	O	O
67	O	O
(	O	O
mi	O	O
-	O	O
1	O	O
)	O	O
proliferation	O	O
data	O	O
must	O	O
be	O	O
interpreted	O	O
within	O	O
the	O	O
clinical	O	O
context	O	O
for	O	O
which	O	O
the	O	O
test	O	O
was	O	O
ordered	O	O
.	O	O
however	O	O
,	O	O
she	O	O
cannot	O	O
co	O	O
this	O	O
with	O	O
position	O	O
changes	O	O
.	O	O
j	O	O
is	O	O
normal	O	O
.	O	O
abdomen	O	O
:	O	O
examined	O	O
and	O	O
normal	O	O
.	O	O
a	O	O
copy	O	O
of	O	O
this	O	O
document	O	O
was	O	O
provided	O	O
to	O	O
the	O	O
patient	O	O
for	O	O
the	O	O
purposes	O	O
of	O	O
information	O	O
,	O	O
education	O	O
,	O	O
and	O	O
to	O	O
share	O	O
with	O	O
local	O	O
medical	O	O
providers	O	O
.	O	O
h	O	O
.	O	O
recent	O	O
(	O	O
3	O	O
-	O	O
18	O	O
-	O	O
04	O	O
)	O	O
right	O	B-laterality-value
chest	O	O
tube	O	O
thor	O	O
;	O	O
left	O	B-laterality-value
va	O	O
;	O	O
tal	O	O
pl	O	O
for	O	O
bilateral	B-laterality-value	B-laterality-value
malignant	O	O
pl	O	O
ef	O	O
;	O	O
metastatic	O	O
breast	O	O
cancer	O	O
.	O	O
lymph	O	O
:	O	O
there	O	O
is	O	O
no	O	O
axillary	O	O
,	O	O
cervical	O	O
,	O	O
or	O	O
su	O	O
lymphadenopathy	O	O
.	O	O
she	O	O
tolerated	O	O
treatment	O	O
well	O	O
and	O	O
has	O	O
no	O	O
complaints	O	O
at	O	O
this	O	O
time	O	O
within	O	O
the	O	O
treated	O	O
field	O	O
.	O	O
transcribed	O	O
by	O	O
:	O	O
ha	O	O
4	O	O
/	O	O
24	O	O
/	O	O
2012	O	O
11	O	O
:	O	O
21	O	O
:	O	O
04	O	O
signed	O	O
by	O	O
michael	O	O
r	O	O
.	O	O
food	O	O
and	O	O
drug	O	O
administration	O	O
.	O	O
as	O	O
30	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
,	O	O
excision	O	O
:	O	O
a	O	O
single	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
is	O	O
negative	O	O
for	O	O
tumor	O	O
[	O	O
aj	O	O
pn0	B-stage-value	B-stage-value
(	O	O
i	O	O
)	O	O
]	O	O
.	O	O
all	O	O
submitted	O	O
.	O	O
grossed	O	O
by	O	O
t	O	O
.	O	O
she	O	O
used	O	O
this	O	O
for	O	O
maybe	O	O
five	O	O
months	O	O
with	O	O
a	O	O
gap	O	O
of	O	O
two	O	O
to	O	O
three	O	O
months	O	O
in	O	O
between	O	O
doses	O	O
.	O	O
grant	O	O
,	O	O
m	O	O
.	O	O
en	O	O
:	O	O
mu	O	O
membranes	O	O
moist	O	O
.	O	O
angiolymphatic	O	O
invasion	O	O
is	O	O
absent	O	O
.	O	O
ad	O	O
with	O	O
calcifications	O	O
and	O	O
lobular	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
as	O	O
it	O	O
carries	O	O
with	O	O
a	O	O
relative	O	O
risk	O	O
of	O	O
about	O	O
seven	O	O
for	O	O
subsequent	O	O
invasive	O	O
breast	O	O
cancer	O	O
.	O	O
participated	O	O
in	O	O
interpretation	O	O
:	O	O
dr	O	O
.	O	O
:	O	O
ka	O	O
"	O	O
we	O	O
plan	O	O
to	O	O
begin	O	O
the	O	O
radiation	O	O
therapy	O	O
planning	O	O
session	O	O
on	O	O
12	O	O
/	O	O
1	O	O
/	O	O
99	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
given	O	O
an	O	O
appointment	O	O
for	O	O
such	O	O
.	O	O
2011	O	O
:	O	O
general	O	O
:	O	O
well	O	O
,	O	O
well	O	O
female	O	O
in	O	O
no	O	O
apparent	O	O
distress	O	O
.	O	O
lateral	O	O
and	O	O
superior	O	O
margins	O	O
submitted	O	O
shaved	O	O
.	O	O
don	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
620	O	O
tissue	O	O
description	O	O
:	O	O
cr	O	O
-	O	O
85	O	O
a1	O	O
a2	O	O
a	O	O
a	O	O
a	O	O
a	O	O
a	O	O
a	O	O
a	O	O
a1	O	O
a1	O	O
a1	O	O
a1	O	O
a1	O	O
j	O	O
j	O	O
j	O	O
j	O	O
b1	O	O
b	O	O
c1	O	O
c2	O	O
c	O	O
c	O	O
c	O	O
c	O	O
c	O	O
c	O	O
c	O	O
c1	O	O
c1	O	O
c1	O	O
c1	O	O
c1	O	O
c1	O	O
c1	O	O
d	O	O
d	O	O
d	O	O
e	O	O
f1	O	O
f	O	O
g	O	O
g	O	O
h	O	O
h	O	O
i	O	O
i	O	O
i	O	O
i	O	O
i	O	O
i	O	O
i	O	O
i	O	O
i	O	O
i	O	O
grossed	O	O
by	O	O
n	O	O
.	O	O
seen	O	O
in	O	O
consultation	O	O
with	O	O
dr	O	O
.	O	O
the	O	O
traced	O	O
areas	O	O
are	O	O
analyzed	O	O
using	O	O
ape	O	O
software	O	O
,	O	O
an	O	O
fda	O	O
510	O	O
(	O	O
k	O	O
)	O	O
cleared	O	O
application	O	O
for	O	O
precise	O	O
measurement	O	O
of	O	O
the	O	O
level	O	O
of	O	O
her2	B-receptor	B-receptor
protein	O	O
on	O	O
cell	O	O
membranes	O	O
of	O	O
breast	O	O
tumor	O	O
cells	O	O
.	O	O
b	O	O
.	O	O
gross	O	O
description	O	O
226	O	O
:	O	O
a	O	O
.	O	O
she	O	O
was	O	O
informed	O	O
of	O	O
this	O	O
by	O	O
telephone	O	O
by	O	O
jennifer	O	O
hazel	O	O
on	O	O
february	O	O
23	O	O
and	O	O
she	O	O
returns	O	O
today	O	O
for	O	O
a	O	O
repeat	O	O
right	B-laterality-value	B-laterality-value
mammogram	O	O
and	O	O
for	O	O
discussions	O	O
regarding	O	O
her	O	O
follow	O	O
plan	O	O
.	O	O
core	O	O
biopsy	O	O
site	O	O
changes	O	O
extend	O	O
to	O	O
the	O	O
inferior	O	O
margin	O	O
(	O	O
submitted	O	O
perpendicular	O	O
)	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
non	O	O
fibrocystic	O	O
changes	O	O
characterized	O	O
by	O	O
dense	O	O
st	O	O
fibrosis	O	O
and	O	O
duct	O	O
ec	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
5	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
)	O	O
sentinel	O	O
lymph	O	O
node	O	O
with	O	O
blue	O	O
dye	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
all	O	O
controls	O	O
show	O	O
appropriate	O	O
react	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
not	O	O
identified	O	O
in	O	O
lymph	O	O
node	O	O
no	O	O
.	O	O
2	O	O
.	O	O
well	O	O
healed	O	O
lumpectomy	O	O
scar	O	O
left	B-laterality-value	B-laterality-value
upper	O	O
outer	O	O
breast	O	O
.	O	O
she	O	O
was	O	O
taken	O	O
to	O	O
the	O	O
operating	O	O
room	O	O
at	O	O
saint	O	O
mary	O	O
hospital	O	O
on	O	O
may	O	O
5	O	O
,	O	O
2004	O	O
,	O	O
at	O	O
which	O	O
time	O	O
the	O	O
following	O	O
procedures	O	O
were	O	O
performed	O	O
:	O	O
a	O	O
left	B-laterality-value	B-laterality-value
simple	O	O
mastectomy	O	O
with	O	O
implant	O	O
/	O	O
expand	O	O
reconstruction	O	O
.	O	O
we	O	O
remain	O	O
available	O	O
if	O	O
needed	O	O
to	O	O
see	O	O
her	O	O
for	O	O
this	O	O
.	O	O
#	O	[CLS]
hypertension	O	O
ms	O	O
.	O	O
see	O	O
syn	O	O
report	O	O
.	O	O
she	O	O
received	O	O
a	O	O
total	O	O
of	O	O
60	O	O
c	O	O
in	O	O
33	O	O
fraction	O	O
to	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
as	O	O
well	O	O
as	O	O
a	O	O
lower	O	O
dose	O	O
to	O	O
her	O	O
regional	O	O
lymphatics	O	O
.	O	O
this	O	O
led	O	O
to	O	O
an	O	O
ultrasound	O	O
biopsy	O	O
,	O	O
which	O	O
was	O	O
consistent	O	O
with	O	O
b	O	O
non	O	O
lymph	O	O
.	O	O
biopsy	O	O
site	O	O
changes	O	O
present	O	O
.	O	O
macro	O	O
and	O	O
microscopic	O	O
extent	O	O
of	O	O
tumor	O	O
:	O	O
nipple	O	O
:	O	O
not	O	O
involved	O	O
.	O	O
these	O	O
studies	O	O
demonstrated	O	O
increase	O	O
in	O	O
ten	O	O
year	O	O
survival	O	O
and	O	O
did	O	O
treat	O	O
the	O	O
internal	O	O
mammary	O	O
nodes	O	O
.	O	O
lewis	O	O
,	O	O
m	O	O
.	O	O
i	O	O
also	O	O
provided	O	O
her	O	O
with	O	O
written	O	O
information	O	O
about	O	O
ad	O	O
and	O	O
cyto	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
general	O	O
book	O	O
about	O	O
receiving	O	O
chemotherapy	O	O
and	O	O
patient	O	O
information	O	O
.	O	[CLS]
thoroughly	O	O
reviewed	O	O
the	O	O
survivors	O	O
plan	O	O
of	O	O
care	O	O
document	O	O
dated	O	O
today	O	O
and	O	O
available	O	O
in	O	O
the	O	O
electronic	O	O
medical	O	O
records	O	O
under	O	O
cd	O	O
reports	O	O
.	O	O
anterior	O	O
margin	O	O
-	O	O
-	O	O
the	O	O
final	O	O
margins	O	O
of	O	O
excision	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	[CLS]
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
nottingham	O	O
grade	B-grade	B-grade
iii	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
[	O	O
tubule	O	O
3	O	O
/	O	O
3	O	O
,	O	O
nuclei	O	O
3	O	O
/	O	O
3	O	O
,	O	O
mit	O	O
3	O	O
/	O	O
3	O	O
;	O	O
nottingham	O	O
score	O	O
9	O	O
/	O	O
9	O	O
]	O	O
,	O	[CLS]
forming	O	O
a	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
mass	O	O
in	B-site-value	B-site-value
the	I-site-value	I-site-value
lower	I-site-value	I-site-value
inner	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
.	O	O
blue	O	O
dye	O	O
is	O	O
identified	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
new	O	O
superior	O	O
margin	O	O
stitch	O	O
superior	O	O
,	O	O
long	O	O
stitch	O	O
lateral	O	O
\	O	O
"	O	O
is	O	O
a	O	O
5	O	O
gram	O	O
,	O	O
13	O	O
x	O	O
0	O	O
x	O	O
0	O	O
cm	O	O
portion	O	O
of	O	O
fi	O	O
tissue	O	O
with	O	O
a	O	O
13	O	O
x	O	O
0	O	O
cm	O	O
skin	O	O
el	O	O
,	O	O
with	O	O
orientation	O	O
(	O	O
long	O	O
suture	O	O
marks	O	O
lateral	O	O
;	O	O
short	O	O
suture	O	O
marks	O	O
superior	O	O
)	O	O
.	O	O
grossed	O	O
by	O	O
cm	O	O
.	O	O
ex	O	O
and	O	O
intrinsic	O	O
controls	O	O
show	O	O
appropriate	O	O
react	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
identified	O	O
.	O	O
don	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
620	O	O
tissue	O	O
description	O	O
:	O	O
cr	O	O
-	O	O
304	O	O
a1	O	O
a2	O	O
a	O	O
a	O	O
a	O	O
a	O	O
b1	O	O
b	O	O
c1	O	O
c2	O	O
c	O	O
d	O	O
d	O	O
e	O	O
f1	O	O
f	O	O
f	O	O
f	O	O
f	O	O
f	O	O
f	O	O
f	O	O
f	O	O
f1	O	O
f1	O	O
f1	O	O
f1	O	O
f1	O	O
f1	O	O
f1	O	O
f1	O	O
f1	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
(	O	O
70	O	O
grams	O	O
,	O	O
23	O	O
x	O	O
17	O	O
x	O	O
6	O	O
cm	O	O
with	O	O
skin	O	O
el	O	O
15	O	O
x	O	O
5	O	O
cm	O	O
)	O	O
,	O	O
separately	O	O
submitted	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
[	O	O
no	O	O
.	O	O
1	O	O
(	O	O
2	B-size-value	O
h	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
new	O	O
inferior	O	O
skin	O	O
margin	O	O
,	O	O
no	O	O
.	O	O
3	O	O
,	O	O
excision	O	O
:	O	O
focally	O	O
positive	O	O
at	O	O
the	O	O
lateral	O	O
margin	O	O
.	O	O
be	O	O
is	O	O
due	O	O
to	O	O
receive	O	O
her	O	O
fourth	O	O
and	O	O
last	O	O
treatment	O	O
of	O	O
ad	O	O
and	O	O
cyto	O	O
today	O	O
for	O	O
neoadjuvant	O	O
treatment	O	O
of	O	O
her	O	O
breast	O	O
cancer	O	O
.	O	O
she	O	O
is	O	O
post	O	O
and	O	O
er	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
and	O	O
pr	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
.	O	O
stomach	O	O
cancer	O	O
in	O	O
a	O	O
paternal	O	O
grandpa	O	O
after	O	O
the	O	O
age	O	O
of	O	O
50	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
stage	B-stage	B-stage
i	B-stage-value	B-stage-value
(	O	O
t1	B-stage-value	B-stage-value
,	O	O
n0	B-stage-value	B-stage-value
,	O	O
m0	B-stage-value	B-stage-value
)	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
cancer	O	O
,	O	O
status	O	O
post	O	O
mastectomy	O	O
#	O	O
history	O	O
of	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
cancer	O	O
,	O	O
status	O	O
post	O	O
mastectomy	O	O
#	O	O
ind	O	O
skin	O	O
rash	O	O
left	B-laterality-value	B-laterality-value
chest	O	O
wall	O	O
#	O	O
possible	O	O
lymph	O	O
/	O	O
ser	O	O
left	B-laterality-value	B-laterality-value
chest	O	O
wall	O	O
2011	O	O
:	O	O
#	O	O
stage	B-stage	B-stage
i	B-stage-value	B-stage-value
(	O	O
t1	B-stage-value	B-stage-value
,	O	O
n0	B-stage-value	B-stage-value
,	O	O
m0	B-stage-value	B-stage-value
)	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
cancer	O	O
,	O	O
status	O	O
post	O	O
mastectomy	O	O
#	O	O
history	O	O
of	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
cancer	O	O
,	O	O
status	O	O
post	O	O
mastectomy	O	O
#	O	O
ind	O	O
skin	O	O
rash	O	O
left	B-laterality-value	B-laterality-value
chest	O	O
wall	O	O
#	O	O
possible	O	O
lymph	O	O
/	O	O
ser	O	O
left	B-laterality-value	B-laterality-value
chest	O	O
wall	O	O
i	O	O
reassured	O	O
mrs	O	O
.	O	O
shah	O	O
,	O	O
m	O	O
.	O	O
4	O	O
/	O	O
19	O	O
/	O	O
2017	O	O
15	O	O
:	O	O
57	O	O
:	O	O
15	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
a	O	O
.	O	O
lewis	O	O
,	O	O
m	O	O
.	O	O
histologic	B-htype	B-htype
type	I-htype	I-htype
:	O	O
invasive	B-htype-value	B-htype-value
mammary	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
with	O	O
mixed	O	O
ductal	O	O
and	O	O
lobular	O	O
features	O	O
.	O	O
lewis	O	O
,	O	O
m	O	O
.	O	O
"	O	O
the	O	O
margins	O	O
of	O	O
excision	O	O
are	O	O
free	O	O
of	O	O
tumor	O	O
(	O	O
nearest	O	O
0	O	O
cm	O	O
)	O	O
.	O	O
linda	O	O
n	O	O
.	O	O
no	O	O
overly	O	O
skin	O	O
changes	O	O
noted	O	O
.	O	O
this	O	O
final	O	O
pathology	O	O
report	O	O
is	O	O
based	O	O
on	O	O
the	O	O
gross	O	O
/	O	O
macro	O	O
examination	O	O
and	O	O
the	O	O
frozen	O	O
section	O	O
histologic	O	O
evaluation	O	O
of	O	O
the	O	O
specimen	O	O
(	O	O
s	O	O
)	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
not	O	O
grade	B-grade	B-grade
i	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
,	O	[CLS]
forming	O	O
a	O	O
3	B-size-value	B-size-value
x	I-size-value	I-size-value
2	I-size-value	I-size-value
x	I-size-value	I-size-value
2	I-size-value	I-size-value
cm	I-size-value	I-size-value
mass	O	O
associated	O	O
with	O	O
extensive	O	B-htype-value
ductal	B-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
at	O	O
1	B-site-value	B-site-value
o	I-site-value	I-site-value
.	O	O
lo	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
60	O	O
"	O	O
diagnosis	O	O
226	O	O
:	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
needle	O	O
biopsy	O	O
:	O	O
invasive	B-htype-value	O
grade	B-grade	B-grade
3	B-grade-value	B-grade-value
(	O	O
of	O	O
3	O	O
)	O	O
ductal	B-htype-value	B-htype-value
adenocarcinoma	I-htype-value	I-htype-value
.	O	O
"	O	O
patient	O	O
verbal	O	O
understanding	O	O
of	O	O
instructions	O	O
,	O	O
and	O	O
all	O	O
questions	O	O
were	O	O
answered	O	O
.	O	O
margins	O	O
were	O	O
negative	O	O
.	O	O
a	O	O
techno	O	O
views	O	O
the	O	O
digit	O	O
image	O	O
on	O	O
a	O	O
computer	O	O
monitor	O	O
and	O	O
using	O	O
a	O	O
tracing	O	O
tool	O	O
available	O	O
in	O	O
images	O	O
(	O	O
ape	O	O
technologies	O	O
inc	O	O
)	O	O
,	O	O
traces	O	O
around	O	O
areas	O	O
of	O	O
invasive	O	O
or	O	O
metastatic	O	O
cancer	O	O
capturing	O	O
no	O	O
less	O	O
than	O	O
75	O	O
of	O	O
the	O	O
total	O	O
cancer	O	O
within	O	O
the	O	O
image	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
not	O	O
identified	O	O
in	O	O
lymph	O	O
nodes	O	O
nos	O	O
.	O	O
2a	O	O
,	O	O
2	O	O
,	O	O
3a	O	O
,	O	O
3	O	O
,	O	O
or	O	O
4	O	O
.	O	O
d	O	O
,	O	O
f	O	O
,	O	O
g	O	O
.	O	O
kirby	O	O
is	O	O
a	O	O
very	O	O
pleasant	O	O
46	O	O
-	O	O
year	O	O
,	O	O
right	O	B-laterality-value
,	O	O
shop	O	O
from	O	O
saint	O	O
charles	O	O
,	O	O
minnesota	O	O
.	O	O
please	O	O
see	O	O
dr	O	O
.	O	O
she	O	O
has	O	O
a	O	O
central	O	O
line	O	O
in	O	O
place	O	O
;	O	O
and	O	O
due	O	O
to	O	O
a	O	O
high	O	O
in	O	O
,	O	O
she	O	O
was	O	O
given	O	O
vitamin	O	O
k	O	O
.	O	O
the	O	O
ultrasound	O	O
at	O	O
1	B-site-value	B-site-value
o	I-site-value	I-site-value
showed	O	O
an	O	O
area	O	O
of	O	O
abnormality	O	O
over	O	O
about	O	O
2	B-size-value	B-size-value
cm	I-size-value	I-size-value
with	I-size-value	O
a	I-size-value	O
9	I-size-value	B-size-value
-	I-size-value	I-size-value
mm	I-size-value	I-size-value
mass	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
wide	O	O
local	O	O
excision	O	O
:	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
,	O	O
intermediate	B-grade-value	B-grade-value
to	I-grade-value	I-grade-value
high	I-grade-value	I-grade-value
nuclear	O	O
grade	B-grade	B-grade
,	O	O
involving	O	O
an	O	O
area	O	O
3	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
.	O	O
ya	O	O
oz	O	O
who	O	O
is	O	O
here	O	O
for	O	O
further	O	O
evaluation	O	O
and	O	O
recommendations	O	O
regarding	O	O
new	O	O
diagnosis	O	O
of	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
cancer	O	O
.	O	O
the	O	O
specimen	O	O
is	O	O
ink	O	O
black	O	O
and	O	O
serial	O	O
section	O	O
from	O	O
medial	O	O
to	O	O
lateral	O	O
.	O	O
there	O	O
is	O	O
no	O	O
red	O	O
to	O	O
it	O	O
.	O	[CLS]
2011	O	O
:	O	O
#	O	O
stage	B-stage	B-stage
i	B-stage-value	B-stage-value
,	O	O
t1c	B-stage-value	B-stage-value
(	O	O
1	B-size-value	B-size-value
cm	I-size-value	I-size-value
)	O	O
,	O	O
n0	B-stage-value	B-stage-value
(	O	O
0	O	O
/	O	O
3	O	O
)	O	O
,	O	O
m0	B-stage-value	B-stage-value
,	O	O
grade	B-grade	B-grade
1	B-grade-value	B-grade-value
to	I-grade-value	O
2	I-grade-value	O
mixed	O	O
infiltrating	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
/	O	O
infiltrating	B-htype-value	B-htype-value
lobular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
;	O	O
status	O	O
post	O	O
wide	O	O
local	O	O
excision	O	O
september	O	O
23	O	O
,	O	O
2008	O	O
,	O	O
er	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
,	O	O
pr	B-receptor	B-receptor
and	O	O
her	B-receptor	B-receptor
-	I-receptor	I-receptor
2	I-receptor	I-receptor
/	O	O
neu	O	O
negative	B-receptor-status	B-receptor-status
2011	O	O
:	O	O
#	O	O
stage	B-stage	B-stage
i	B-stage-value	B-stage-value
,	O	O
t1c	B-stage-value	B-stage-value
(	O	O
1	B-size-value	B-size-value
cm	I-size-value	I-size-value
)	O	O
,	O	O
n0	B-stage-value	B-stage-value
(	O	O
0	O	O
/	O	O
3	O	O
)	O	O
,	O	O
m0	B-stage-value	B-stage-value
,	O	O
grade	B-grade	B-grade
1	B-grade-value	B-grade-value
to	I-grade-value	O
2	I-grade-value	O
mixed	O	O
infiltrating	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
/	O	O
infiltrating	B-htype-value	B-htype-value
lobular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
;	O	O
status	O	O
post	O	O
wide	O	O
local	O	O
excision	O	O
september	O	O
23	O	O
,	O	O
2008	O	O
,	O	O
er	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
,	O	O
pr	B-receptor	B-receptor
lymph	O	O
node	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
3	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
)	O	O
sentinel	O	O
lymph	O	O
node	O	O
with	O	O
blue	O	O
dye	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
we	O	O
discussed	O	O
with	O	O
her	O	O
that	O	O
she	O	O
would	O	O
be	O	O
a	O	O
good	O	O
candidate	O	O
for	O	O
either	O	O
a	O	O
lumpectomy	O	O
or	O	O
a	O	O
mastectomy	O	O
.	O	O
she	O	O
underwent	O	O
an	O	O
excision	O	O
biopsy	O	O
on	O	O
march	O	O
1	O	O
which	O	O
confirmed	O	O
the	O	O
diagnosis	O	O
of	O	O
an	O	O
invasive	B-htype-value	B-htype-value
,	O	O
nottingham	O	O
grade	B-grade	B-grade
2	B-grade-value	B-grade-value
of	O	O
3	O	O
,	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
forming	O	O
a	O	O
mass	O	O
1	B-size-value	B-size-value
cm	I-size-value	I-size-value
at	O	O
greatest	O	O
dimension	O	O
.	O	O
a	O	O
techno	O	O
views	O	O
the	O	O
digit	O	O
image	O	O
on	O	O
a	O	O
computer	O	O
monitor	O	O
and	O	O
using	O	O
a	O	O
tracing	O	O
tool	O	O
available	O	O
in	O	O
images	O	O
(	O	O
ape	O	O
technologies	O	O
inc	O	O
)	O	O
,	O	O
traces	O	O
around	O	O
areas	O	O
of	O	O
invasive	O	O
or	O	O
metastatic	O	O
cancer	O	O
capturing	O	O
no	O	O
less	O	O
than	O	O
75	O	O
of	O	O
the	O	O
total	O	O
cancer	O	O
within	O	O
the	O	O
image	O	O
.	O	O
lynn	O	O
c	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
wide	O	O
local	O	O
excision	O	O
:	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
,	O	O
intermediate	B-grade-value	B-grade-value
to	I-grade-value	I-grade-value
high	I-grade-value	I-grade-value
nuclear	O	O
grade	B-grade	B-grade
,	O	O
involving	O	O
an	O	O
area	O	O
3	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
.	O	O
she	O	O
is	O	O
psychological	O	O
very	O	O
well	O	O
adjusted	O	O
to	O	O
the	O	O
diagnosis	O	O
.	O	O
i	O	O
think	O	O
that	O	O
she	O	O
is	O	O
at	O	O
acceptable	O	O
cardiovascular	O	O
risk	O	O
to	O	O
proceed	O	O
with	O	O
surgery	O	O
.	O	O
bilateral	O	O
well	O	O
horizontal	O	O
mastectomy	O	O
inc	O	O
present	O	O
.	O	O
however	O	O
,	O	O
she	O	O
describes	O	O
two	O	O
different	O	O
types	O	O
of	O	O
pain	O	O
over	O	O
both	O	O
breasts	O	O
.	O	O
discussed	O	O
the	O	O
schedule	O	O
of	O	O
radiation	O	O
therapy	O	O
.	O	O
this	O	O
patient	O	O
completed	O	O
radiation	O	O
approximately	O	O
four	O	O
weeks	O	O
ago	O	O
.	O	O
the	O	O
left	B-laterality-value	B-laterality-value
lateral	O	O
(	O	O
palpable	O	O
)	O	O
breast	O	O
mass	O	O
and	O	O
right	B-laterality-value	B-laterality-value
upper	B-site-value	B-site-value
outer	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
screen	O	O
mass	O	O
both	O	O
showed	O	O
grade	B-grade	B-grade
i	B-grade-value	B-grade-value
invasive	B-htype-value	B-htype-value
lobular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
er	B-receptor	B-receptor
and	O	O
pr	B-receptor	B-receptor
positive	B-receptor-status	B-receptor-status
>	O	O
75	O	O
,	O	O
her2	B-receptor	B-receptor
0	B-receptor-value	B-receptor-status
,	O	O
ki	O	O
16	O	O
(	O	O
right	O	B-laterality-value
)	O	O
,	O	O
ki	O	O
12	O	O
(	O	O
left	O	B-laterality-value
)	O	O
.	O	O
it	O	O
is	O	O
non	O	O
.	O	O
women	O	O
with	O	O
dense	O	O
breasts	O	O
are	O	O
also	O	O
considered	O	O
at	O	O
increased	O	O
breast	O	O
cancer	O	O
risk	O	O
compared	O	O
with	O	O
women	O	O
with	O	O
non	O	O
breasts	O	O
.	O	O
i	O	O
will	O	O
discuss	O	O
the	O	O
results	O	O
of	O	O
the	O	O
ultrasound	O	O
with	O	O
mrs	O	O
.	O	O
immunohistochemical	O	O
cyto	O	O
stain	O	O
was	O	O
performed	O	O
on	O	O
the	O	O
paraffin	O	O
embedded	O	O
sentinel	O	O
lymph	O	O
node	O	O
tissue	O	O
and	O	O
confirms	O	O
the	O	O
h	O	O
&	O	O
e	O	O
impression	O	O
.	O	O
proliferation	O	O
index	O	O
ki	O	O
-	O	O
67	O	O
(	O	O
mi	O	O
-	O	O
1	O	O
)	O	O
=	O	O
26	O	O
.	O	O
"	O	O
page	O	O
:	O	O
127	O	O
-	O	O
1858	O	O
and	O	O
dr	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
2	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
multiple	O	O
(	O	O
2	O	O
)	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
no	O	O
evidence	O	O
of	O	O
additional	O	O
breast	O	O
disease	O	O
or	O	O
axillary	O	O
metastases	O	O
were	O	O
identified	O	O
on	O	O
other	O	O
imaging	O	O
.	O	O
both	O	O
nipples	O	O
ever	O	O
.	O	O
ok	O	O
,	O	O
supervising	O	O
on	O	O
today	O	O
,	O	O
who	O	O
was	O	O
essential	O	O
in	O	O
the	O	O
formation	O	O
of	O	O
the	O	O
assessment	O	O
and	O	O
plan	O	O
.	O	O
we	O	O
reviewed	O	O
that	O	O
tamoxifen	O	O
is	O	O
fda	O	O
to	O	O
reduce	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
invasive	O	O
breast	O	O
cancer	O	O
in	O	O
women	O	O
recently	O	O
treated	O	O
for	O	O
er	B-receptor-status	B-receptor
dcis	B-htype-value	B-htype-value
.	O	O
inward	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
68	O	O
preliminary	O	O
frozen	O	O
section	O	O
consultation	O	O
:	O	O
lymph	O	O
nodes	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
,	O	O
excision	O	O
:	O	O
multiple	O	O
(	O	O
2	O	O
)	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
(	O	O
blue	O	O
dye	O	O
identified	O	O
in	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
no	O	O
.	O	O
1	O	O
only	O	O
)	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
high	O	O
and	O	O
mid	O	O
/	O	O
low	O	O
axillary	O	O
,	O	O
modified	O	O
radical	O	O
mastectomy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
of	O	O
28	O	O
)	O	O
mid	O	O
/	O	O
low	O	O
axillary	O	O
lymph	O	O
node	O	O
is	O	O
involved	O	O
by	O	O
metastatic	B-htype-value	B-htype-value
breast	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
at	O	O
1	I-site-value	O
:	I-site-value	O
00	I-site-value	O
,	I-site-value	O
7	I-site-value	O
cm	I-site-value	O
from	I-site-value	I-site-value
nipple	I-site-value	I-site-value
,	O	O
ultrasound	O	O
guided	O	O
needle	O	O
biopsy	O	O
(	O	O
r	O	O
-	O	O
77	O	O
;	O	O
11	O	O
/	O	O
10	O	O
/	O	O
11	O	O
)	O	O
:	O	O
low	B-grade-value	B-grade-value
grade	B-grade	B-grade
b	O	O
lymph	O	O
,	O	O
most	O	O
consistent	O	O
with	O	O
extra	O	O
marginal	O	O
zone	O	O
lymph	O	O
of	O	O
mu	O	O
lymph	O	O
tissue	O	O
(	O	O
mal	O	O
)	O	O
.	O	O
progesterone	B-receptor	B-receptor
:	O	O
focally	O	O
positive	B-receptor-status	B-receptor-status
,	O	O
1	O	O
-	O	O
10	O	O
tumor	O	O
nuclei	O	O
staining	O	O
.	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
with	O	O
a	O	O
palpable	O	O
3	B-size-value	B-size-value
-	I-size-value	I-size-value
cm	I-size-value	I-size-value
mass	O	O
at	O	O
the	O	O
11	B-site-value	B-site-value
o	I-site-value	I-site-value
position	I-site-value	I-site-value
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
4	B-site-value	B-site-value
cm	I-site-value	I-site-value
from	I-site-value	I-site-value
the	I-site-value	I-site-value
edge	I-site-value	I-site-value
of	I-site-value	I-site-value
the	I-site-value	I-site-value
nipple	I-site-value	I-site-value
complex	I-site-value	I-site-value
.	O	O
the	O	O
patient	O	O
was	O	O
provided	O	O
with	O	O
my	O	O
business	O	O
card	O	O
.	O	O
2011	O	O
:	O	O
general	O	O
:	O	O
physical	O	O
examination	O	O
reveals	O	O
a	O	O
pleasant	O	O
lady	O	O
in	O	O
no	O	O
apparent	O	O
distress	O	O
.	O	O
submitted	O	O
as	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
consisting	O	O
of	O	O
a	O	O
3	O	B-size-value
x	O	I-size-value
2	O	I-size-value
cm	O	I-size-value
yellow	O	O
fatty	O	O
tissue	O	O
fragment	O	O
.	O	O
mrs	O	O
.	O	O
the	O	O
specimen	O	O
is	O	O
ink	O	O
and	O	O
the	O	O
margins	O	O
are	O	O
taken	O	O
perpendicular	O	O
.	O	O
discussed	O	O
follow	O	O
recommendations	O	O
for	O	O
breast	O	O
cancer	O	O
surveillance	O	O
as	O	O
detailed	O	O
in	O	O
the	O	O
survivors	O	O
plan	O	O
of	O	O
care	O	O
.	O	O
i	O	O
provided	O	O
her	O	O
with	O	O
a	O	O
list	O	O
of	O	O
cy	O	O
inhibitors	O	O
.	O	O
diagnosis	O	O
226	O	O
:	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
tu	B-htype-value	O
ductal	I-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
,	O	O
solid	O	O
,	O	O
papillary	O	O
,	O	O
and	O	O
come	O	O
types	O	O
,	O	O
high	B-grade-value	B-grade-value
nuclear	O	O
grade	B-grade	B-grade
with	O	O
intra	O	O
necrosis	O	O
and	O	O
extensive	O	O
cancer	O	O
of	O	O
lobular	O	O
units	O	O
involving	O	O
an	O	O
area	O	O
covering	O	O
an	O	O
estimated	O	O
4	B-size-value	B-size-value
x	I-size-value	I-size-value
3	I-size-value	I-size-value
x	I-size-value	I-size-value
2	I-size-value	I-size-value
cm	I-size-value	I-size-value
[	O	O
aj	O	O
ptis	B-stage-value	B-stage-value
]	O	O
located	B-site	B-site
in	B-site-value	B-site-value
the	I-site-value	I-site-value
inferior	I-site-value	I-site-value
medial	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
of	I-site-value	I-site-value
the	I-site-value	I-site-value
breast	I-site-value	I-site-value
.	O	O
representative	O	O
sections	O	O
submitted	O	O
.	O	O
tumor	O	O
location	B-site	B-site
(	O	O
mastectomy	O	O
)	O	O
:	O	O
upper	B-site-value	B-site-value
outer	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
.	O	O
g	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
,	O	O
excision	O	O
:	O	O
multiple	O	O
(	O	O
2	O	O
)	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
(	O	O
blue	O	O
dye	O	O
identified	O	O
in	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
no	O	O
.	O	O
1	O	O
only	O	O
)	O	O
.	O	O
(	O	O
cr	O	O
-	O	O
103	O	O
)	O	O
tissue	O	O
description	O	O
:	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
(	O	O
wide	O	O
local	O	O
excision	O	O
,	O	O
5	O	O
x	O	O
5	O	O
x	O	O
2	O	O
cm	O	O
)	O	O
,	O	O
and	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
(	O	O
1	O	O
-	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
;	O	O
2	O	O
-	O	O
4	B-size-value	B-size-value
x	I-size-value	I-size-value
4	I-size-value	I-size-value
x	I-size-value	I-size-value
4	I-size-value	I-size-value
mm	I-size-value	I-size-value
)	O	O
.	O	O
as	O	O
the	O	O
signing	O	O
path	O	O
,	O	O
i	O	O
verify	O	O
that	O	O
i	O	O
have	O	O
examined	O	O
all	O	O
relevant	O	O
slides	O	O
/	O	O
materials	O	O
for	O	O
the	O	O
specimen	O	O
(	O	O
s	O	O
)	O	O
and	O	O
rendered	O	O
or	O	O
confirmed	O	O
the	O	O
diagnosis	O	O
.	O	O
7	O	O
/	O	O
1	O	O
/	O	O
2016	O	O
11	O	O
:	O	O
59	O	O
interpreted	O	O
by	O	O
:	O	O
joanne	O	O
yi	O	O
,	O	O
m	O	O
.	O	O
8	O	O
-	O	O
99	O	O
report	O	O
electronically	O	O
signed	O	O
by	O	O
joanne	O	O
yi	O	O
,	O	O
m	O	O
.	O	O
there	O	O
is	O	O
no	O	O
angiolymphatic	O	O
invasion	O	O
.	O	O
g	O	O
.	O	O
all	O	O
controls	O	O
show	O	O
appropriate	O	O
react	O	O
.	O	O
it	O	O
will	O	O
be	O	O
determined	O	O
whether	O	O
she	O	O
would	O	O
like	O	O
to	O	O
pursue	O	O
radiation	O	O
here	O	O
in	O	O
rochester	O	O
or	O	O
get	O	O
her	O	O
radiation	O	O
in	O	O
albert	O	O
lea	O	O
.	O	O
there	O	O
is	O	O
no	O	O
disco	O	O
or	O	O
abnormality	O	O
of	O	O
the	O	O
skin	O	O
visible	O	O
in	O	O
this	O	O
region	O	O
.	O	O
otherwise	O	O
,	O	O
the	O	O
patient	O	O
denies	O	O
any	O	O
prior	O	O
radiation	O	O
history	O	O
and	O	O
denies	O	O
any	O	O
history	O	O
of	O	O
col	O	O
vascular	O	O
disease	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
stage	B-stage	B-stage
i	B-stage-value	B-stage-value
(	O	O
t1bn0m0	B-stage-value	B-stage-value
)	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
s	O	O
/	O	O
p	O	O
wide	O	O
local	O	O
excision	O	O
and	O	O
sentinel	O	O
lymph	O	O
node	O	O
biopsy	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
stage	B-stage	B-stage
i	B-stage-value	B-stage-value
(	O	O
t1bn0m0	B-stage-value	B-stage-value
)	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
s	O	O
/	O	O
p	O	O
wide	O	O
local	O	O
excision	O	O
and	O	O
sentinel	O	O
lymph	O	O
node	O	O
biopsy	O	O
.	O	O
in	O	O
no	O	O
acute	O	O
distress	O	O
.	O	O
grossed	O	O
by	O	O
cl	O	O
.	O	O
a	O	O
chest	O	O
x	O	O
dated	O	O
august	O	O
11	O	O
showed	O	O
a	O	O
tiny	O	O
cal	O	O
gran	O	O
in	O	O
the	O	O
right	B-laterality-value	B-laterality-value
lower	O	O
lung	O	O
medial	O	O
and	O	O
a	O	O
fibrotic	O	O
strand	O	O
in	O	O
the	O	O
right	B-laterality-value	B-laterality-value
upper	O	O
lung	O	O
.	O	O
men	O	O
at	O	O
age	O	O
11	O	O
.	O	O
however	O	O
,	O	O
she	O	O
wakes	O	O
up	O	O
at	O	O
night	O	O
and	O	O
the	O	O
pillows	O	O
have	O	O
fallen	O	O
away	O	O
and	O	O
the	O	O
pain	O	O
returns	O	O
.	O	O
she	O	O
has	O	O
good	O	O
range	O	O
of	O	O
motion	O	O
of	O	O
her	O	O
arm	O	O
other	O	O
than	O	O
tenderness	O	O
when	O	O
she	O	O
brings	O	O
her	O	O
right	B-laterality-value	B-laterality-value
arm	O	O
into	O	O
her	O	O
right	O	B-laterality-value
side	O	O
,	O	[CLS]
and	O	O
i	O	O
shared	O	O
with	O	O
her	O	O
that	O	O
she	O	O
should	O	O
have	O	O
full	O	O
recovery	O	O
of	O	O
her	O	O
arm	O	O
without	O	O
difficulty	O	O
in	O	O
range	O	O
of	O	O
motion	O	O
.	O	O
patient	O	O
presents	O	O
today	O	O
in	O	O
consultation	O	O
with	O	O
her	O	O
family	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
cancer	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
cancer	O	O
.	O	O
nipples	O	O
are	O	O
ever	O	O
without	O	O
lesion	O	O
.	O	O
we	O	O
discussed	O	O
the	O	O
treatment	O	O
schedule	O	O
which	O	O
will	O	O
be	O	O
three	O	O
weeks	O	O
on	O	O
and	O	O
one	O	O
week	O	O
off	O	O
.	O	O
2010	O	O
:	O	O
ms	O	O
.	O	O
cardiac	O	O
:	O	O
regular	O	O
rate	O	O
and	O	O
rhythm	O	O
.	O	O
gross	O	O
,	O	O
there	O	O
is	O	O
a	O	O
2	B-size-value	B-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
cm	I-size-value	I-size-value
irregular	O	O
mass	O	O
with	O	O
core	O	O
biopsy	O	O
site	O	O
which	O	O
is	O	O
located	O	O
at	B-site-value	O
the	I-site-value	O
anterior	I-site-value	O
margin	I-site-value	O
(	O	O
submitted	O	O
perpendicular	O	O
)	O	O
,	O	O
0	B-site-value	O
cm	I-site-value	O
from	I-site-value	I-site-value
the	I-site-value	I-site-value
superior	I-site-value	I-site-value
margin	I-site-value	I-site-value
(	O	O
submitted	O	O
perpendicular	O	O
)	O	O
,	O	O
and	O	O
1	B-site-value	O
cm	I-site-value	I-site-value
from	I-site-value	I-site-value
the	I-site-value	I-site-value
lateral	I-site-value	I-site-value
margin	I-site-value	I-site-value
(	O	O
submitted	O	O
shaved	O	O
)	O	O
.	O	O
the	O	O
patient	O	O
and	O	O
her	O	O
husband	O	O
come	O	O
to	O	O
mayo	O	O
for	O	O
a	O	O
second	O	O
opinion	O	O
consultation	O	O
.	O	O
no	O	O
er	O	O
or	O	O
signs	O	O
of	O	O
infection	O	O
.	O	O
page	O	O
disease	O	O
of	O	O
the	O	O
nipple	O	O
is	O	O
not	O	O
present	O	O
.	O	O
there	O	O
are	O	O
no	O	O
abnormalities	O	O
of	O	O
the	O	O
color	O	O
or	O	O
con	O	O
of	O	O
the	O	O
left	O	B-laterality-value
breast	O	O
.	O	O
heart	O	O
:	O	O
examined	O	O
and	O	O
normal	O	O
.	O	O
shu	O	O
is	O	O
recovering	O	O
well	O	O
from	O	O
surgery	O	O
and	O	O
is	O	O
returning	O	O
to	O	O
michigan	O	O
tomorrow	O	O
.	O	O
non	O	O
axillary	O	O
nodes	O	O
,	O	O
total	O	O
number	O	O
examined	O	O
:	O	O
0	O	O
.	O	O
sentinel	O	O
lymph	O	O
node	O	O
biopsy	O	O
was	O	O
not	O	O
performed	O	O
.	O	O
transcribed	O	O
by	O	O
:	O	O
k	O	O
10	O	O
/	O	O
9	O	O
/	O	O
2014	O	O
19	O	O
:	O	O
24	O	O
:	O	O
36	O	O
addendum	O	O
:	O	O
immunohistochemical	O	O
studies	O	O
were	O	O
performed	O	O
on	O	O
block	O	O
a	O	O
.	O	O
es	O	O
2	O	O
cassette	O	O
.	O	O
family	O	O
cancer	O	O
history	O	O
breast	O	O
cancer	O	O
in	O	O
a	O	O
sister	O	O
after	O	O
the	O	O
age	O	O
of	O	O
50	O	O
.	O	O
patient	O	O
was	O	O
seen	O	O
by	O	O
dr	O	O
.	O	O
sad	O	O
say	O	O
,	O	O
m	O	O
.	O	O
"	O	O
july	O	O
2	O	O
,	O	O
2013	O	O
:	O	O
consultation	O	O
with	O	O
dr	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
contents	O	O
,	O	O
dissection	O	O
:	O	O
a	O	O
focus	O	O
of	O	O
metastatic	O	O
tumor	O	O
with	O	O
treatment	O	O
effect	O	O
found	O	O
in	O	O
a	O	O
single	O	O
(	O	O
1	O	O
of	O	O
35	O	O
)	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
lymph	O	O
node	O	O
.	O	O
mild	O	O
pau	O	O
de	O	O
orange	O	O
skin	O	O
texture	O	O
noted	O	O
left	B-laterality-value	B-laterality-value
central	O	O
breast	O	O
including	O	O
edema	O	O
nipple	O	O
.	O	O
anticipated	O	O
date	O	O
of	O	O
completion	O	O
is	O	O
october	O	O
10	O	O
,	O	O
2017	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
,	O	O
excision	O	O
:	O	O
multiple	O	O
(	O	O
9	O	O
)	O	O
axillary	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
inward	O	O
,	O	O
m	O	O
.	O	O
as	O	O
a	O	O
post	O	O
woman	O	O
she	O	O
would	O	O
clearly	O	O
be	O	O
a	O	O
good	O	O
candidate	O	O
for	O	O
consideration	O	O
of	O	O
the	O	O
star	O	O
trial	O	O
.	O	O
en	O	O
:	O	O
oral	O	O
cavity	O	O
-	O	O
-	O	O
no	O	O
lesions	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
high	O	O
,	O	O
excision	O	O
:	O	O
multiple	O	O
(	O	O
11	O	O
of	O	O
11	O	O
)	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
high	O	O
lymph	O	O
nodes	O	O
are	O	O
positive	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
adenocarcinoma	I-htype-value	I-htype-value
.	O	O
delay	O	O
to	O	O
fixation	O	O
,	O	O
under	O	O
fixation	O	O
or	O	O
over	O	O
fixation	O	O
fall	O	O
outside	O	O
of	O	O
cap	O	O
/	O	O
as	O	O
guidelines	O	O
and	O	O
may	O	O
affect	O	O
these	O	O
results	O	O
.	O	O
she	O	O
has	O	O
noted	O	O
some	O	O
drying	O	O
of	O	O
the	O	O
left	B-laterality-value	B-laterality-value
eye	O	O
but	O	O
no	O	O
other	O	O
visual	O	O
symptoms	O	O
such	O	O
as	O	O
dip	O	O
or	O	O
visual	O	O
loss	O	O
.	O	O
sim	O	O
surgical	O	O
note	O	O
for	O	O
further	O	O
details	O	O
.	O	O
she	O	O
has	O	O
a	O	O
network	O	O
of	O	O
support	O	O
including	O	O
family	O	O
and	O	O
friends	O	O
.	O	O
reynolds	O	O
,	O	O
m	O	O
.	O	O
the	O	O
tamoxifen	O	O
side	O	O
effect	O	O
profile	O	O
on	O	O
up	O	O
states	O	O
that	O	O
up	O	O
to	O	O
8	O	O
of	O	O
patients	O	O
can	O	O
have	O	O
di	O	O
.	O	O
the	O	O
nipple	O	O
and	O	O
skin	O	O
are	O	O
without	O	O
diagnostic	O	O
abnormality	O	O
.	O	O
2010	O	O
:	O	O
this	O	O
37	O	O
-	O	O
year	O	O
white	O	O
female	O	O
from	O	O
ow	O	O
,	O	O
minnesota	O	O
,	O	O
has	O	O
a	O	O
history	O	O
of	O	O
breast	O	O
cancer	O	O
.	O	O
uterus	O	O
and	O	O
o	O	O
are	O	O
intact	O	O
.	O	O
photographed	O	O
.	O	O
a	O	O
nipple	O	O
is	O	O
present	O	O
.	O	O
i	O	O
discussed	O	O
this	O	O
case	O	O
at	O	O
length	O	O
with	O	O
dr	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
lumpectomy	O	O
:	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
forming	O	O
a	O	O
0	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
mass	O	O
,	O	O
associated	O	O
with	O	O
prominent	O	O
biopsy	O	O
site	O	O
changes	O	O
.	O	[CLS]
angiolymphatic	O	O
invasion	O	O
is	O	O
absent	O	O
.	O	O
discussed	O	O
the	O	O
indications	O	O
,	O	O
cost	O	O
,	O	O
the	O	O
limitations	O	O
,	O	O
and	O	O
the	O	O
benefits	O	O
and	O	O
risks	O	O
of	O	O
these	O	O
tests	O	O
.	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
showed	O	O
focal	O	O
atypical	O	O
ductal	O	O
proliferation	O	O
with	O	O
prominent	O	O
sc	O	O
aden	O	O
with	O	O
features	O	O
consistent	O	O
with	O	O
low	B-grade-value	B-grade-value
ductal	B-htype-value	B-htype-value
tubular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
pathology	O	O
from	O	O
the	O	O
biopsies	O	O
has	O	O
been	O	O
reviewed	O	O
at	O	O
mayo	O	O
.	O	O
next	O	O
closest	O	O
margin	O	O
0	O	O
cm	O	O
to	O	O
inferior	O	O
.	O	O
vessels	O	O
:	O	O
2	O	O
+	O	O
radial	O	O
,	O	O
pedal	O	O
,	O	O
and	O	O
car	O	O
pulses	O	O
.	O	O
b	O	O
.	O	O
ur	O	O
a	O	O
,	O	O
smith	O	O
ie	O	O
,	O	O
dow	O	O
m	O	O
.	O	O
histologic	B-htype	B-htype
type	I-htype	I-htype
of	O	O
invasive	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
:	O	O
no	O	O
residual	B-htype-value	B-htype-value
invasive	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
after	O	O
neoadjuvant	O	O
therapy	O	O
.	O	O
small	O	O
lymph	O	O
nodes	O	O
,	O	O
bisected	O	O
.	O	O
it	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
any	O	O
pain	O	O
,	O	O
skin	O	O
changes	O	O
,	O	O
nipple	O	O
changes	O	O
,	O	O
discharge	O	O
,	O	O
lymphadenopathy	O	O
,	O	O
fever	O	O
,	O	O
chill	O	O
,	O	O
or	O	O
night	O	O
sweat	O	O
.	O	O
this	O	O
extends	O	O
over	O	O
probably	O	O
4	B-size-value	O
cm	I-size-value	O
and	O	O
is	O	O
located	O	O
5	B-site-value	B-site-value
cm	I-site-value	I-site-value
from	I-site-value	I-site-value
the	I-site-value	I-site-value
nipple	I-site-value	I-site-value
.	O	O
d	O	O
.	O	O
one	O	O
lymph	O	O
node	O	O
was	O	O
examined	O	O
and	O	O
negative	O	O
.	O	[CLS]
4	O	O
.	O	O
the	O	O
traced	O	O
areas	O	O
are	O	O
analyzed	O	O
using	O	O
ape	O	O
software	O	O
,	O	O
an	O	O
fda	O	O
510	O	O
(	O	O
k	O	O
)	O	O
cleared	O	O
application	O	O
for	O	O
precise	O	O
measurement	O	O
of	O	O
the	O	O
level	O	O
of	O	O
her2	B-receptor	B-receptor
protein	O	O
on	O	O
cell	O	O
membranes	O	O
of	O	O
breast	O	O
tumor	O	O
cells	O	O
.	O	O
we	O	O
discussed	O	O
that	O	O
the	O	O
biopsy	O	O
from	O	O
the	O	O
area	O	O
posterior	O	O
to	O	O
her	O	O
cancer	O	O
does	O	O
show	O	O
dcis	B-htype-value	B-htype-value
which	O	O
was	O	O
low	B-grade-value	B-grade-value
.	O	O
she	O	O
had	O	O
her	O	O
most	O	O
recent	O	O
colonoscopy	O	O
screening	O	O
at	O	O
the	O	O
age	O	O
of	O	O
47	O	O
(	O	O
two	O	O
years	O	O
ago	O	O
)	O	O
.	O	O
2011	O	O
:	O	O
ms	O	O
.	O	O
lungs	O	O
:	O	O
clinical	O	O
clear	O	O
.	O	O
her	O	O
past	O	O
medical	O	O
history	O	O
is	O	O
also	O	O
remarkable	O	O
for	O	O
auto	O	O
thyroid	O	O
disease	O	O
(	O	O
hash	O	O
)	O	O
for	O	O
which	O	O
she	O	O
takes	O	O
thyroid	O	O
replacement	O	O
.	O	O
she	O	O
can	O	O
walk	O	O
on	O	O
toes	O	O
and	O	O
heels	O	O
without	O	O
difficulty	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
no	O	O
.	O	O
4	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
with	O	O
blue	O	O
dye	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	[CLS]
discussed	O	O
breast	O	O
mri	O	O
indications	O	O
,	O	O
risks	O	O
,	O	O
limitations	O	O
,	O	O
costs	O	O
and	O	O
benefits	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
set	O	O
#	O	O
,	O	O
biopsy	O	O
:	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
is	O	O
identified	O	O
in	O	O
a	O	O
single	O	O
(	O	O
1	O	O
of	O	O
3	O	O
)	O	O
lymph	O	O
node	O	O
.	O	O
she	O	O
denies	O	O
any	O	O
breast	O	O
tenderness	O	O
.	O	O
provided	O	O
assurance	O	O
that	O	O
,	O	O
as	O	O
a	O	O
team	O	O
of	O	O
care	O	O
providers	O	O
,	O	O
we	O	O
will	O	O
continue	O	O
to	O	O
be	O	O
available	O	O
for	O	O
questions	O	O
and	O	O
will	O	O
evaluate	O	O
new	O	O
concerns	O	O
.	O	O
will	O	O
also	O	O
refer	O	O
patient	O	O
to	O	O
on	O	O
for	O	O
further	O	O
management	O	O
of	O	O
this	O	O
breast	O	O
cancer	O	O
.	O	O
b	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
wide	O	O
local	O	O
excision	O	O
:	O	O
infiltrating	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
with	O	O
micro	O	O
features	O	O
,	O	O
nottingham	O	O
grade	B-grade	B-grade
ii	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
[	O	O
tubule	O	O
2	O	O
/	O	O
3	O	O
,	O	O
nuclei	O	O
2	O	O
/	O	O
3	O	O
,	O	O
mit	O	O
2	O	O
/	O	O
3	O	O
;	O	O
nottingham	O	O
score	O	O
6	O	O
/	O	O
9	O	O
]	O	O
is	O	[CLS]
identified	O	O
forming	O	O
a	O	O
2	B-size-value	B-size-value
cm	I-size-value	I-size-value
mass	O	O
.	O	O
men	O	O
was	O	O
natural	O	O
sometime	O	O
during	O	O
her	O	O
50	O	O
.	O	O
reviewed	O	O
the	O	O
role	O	O
of	O	O
a	O	O
complete	O	O
axillary	O	O
node	O	O
dissection	O	O
if	O	O
the	O	O
sentinel	O	O
lymph	O	O
node	O	O
is	O	O
positive	O	O
.	O	O
lymph	O	O
node	O	O
sampling	O	O
:	O	O
no	O	O
lymph	O	O
nodes	O	O
submitted	O	O
.	O	O
the	O	O
closest	O	O
margin	O	O
is	O	O
anterior	O	O
at	O	O
0	O	O
cm	O	O
.	O	O
she	O	O
has	O	O
not	O	O
started	O	O
experiencing	O	O
any	O	O
hot	O	O
flashes	O	O
yet	O	O
.	O	O
d	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
,	O	O
lymph	O	O
:	O	O
multiple	O	O
(	O	O
2	O	O
)	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
2010	O	O
:	O	O
mrs	O	O
.	O	O
sk	O	O
undergoes	O	O
a	O	O
wide	O	O
local	O	O
excision	O	O
and	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
biopsy	O	O
under	O	O
the	O	O
care	O	O
of	O	O
dr	O	O
.	O	O
hold	O	O
over	O	O
for	O	O
further	O	O
evaluation	O	O
on	O	O
permanent	O	O
sections	O	O
.	O	O
lymph	O	O
:	O	O
no	O	O
evidence	O	O
of	O	O
su	O	O
,	O	O
in	O	O
,	O	O
or	O	O
axillary	O	O
adenopathy	O	O
bilaterally	B-laterality-value	B-laterality-value
.	O	O
grossed	O	O
by	O	O
rs	O	O
.	O	O
i	O	O
will	O	O
discuss	O	O
breast	O	O
mri	O	O
with	O	O
our	O	O
breast	O	O
radio	O	O
to	O	O
see	O	O
about	O	O
evaluating	O	O
the	O	O
margins	O	O
.	O	O
pathologic	O	O
stage	B-stage	B-stage
ia	B-stage-value	B-stage-value
(	O	O
t1b	B-stage-value	B-stage-value
,	O	O
n0	B-stage-value	B-stage-value
,	O	O
m0	B-stage-value	B-stage-value
)	O	O
.	O	O
6	O	O
.	O	O
about	O	O
a	O	O
week	O	O
later	O	O
she	O	O
received	O	O
biopsy	O	O
report	O	O
that	O	O
this	O	O
showed	O	O
an	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
tiny	O	O
low	O	O
lesions	O	O
in	O	O
the	O	O
medial	O	O
segment	O	O
of	O	O
the	O	O
left	B-laterality-value	B-laterality-value
lobe	O	O
of	O	O
the	O	O
liver	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
dome	O	O
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
lobe	O	O
of	O	O
the	O	O
liver	O	O
.	O	O
the	O	O
second	O	O
inc	O	O
,	O	O
sentinel	O	O
node	O	O
biopsy	O	O
inc	O	O
,	O	O
is	O	O
slightly	O	O
er	O	O
with	O	O
a	O	O
small	O	O
amount	O	O
of	O	O
yellowish	O	O
drainage	O	O
,	O	O
red	O	O
,	O	O
and	O	O
tender	O	O
to	O	O
touch	O	O
.	O	[CLS]
su	O	O
,	O	O
m	O	O
.	O	O
garcia	O	O
,	O	O
m	O	O
"	O	O
gross	O	O
description	O	O
226	O	O
:	O	O
a	O	O
.	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
scar	O	O
is	O	O
appropriately	O	O
firm	O	O
but	O	O
there	O	O
are	O	O
no	O	O
wo	O	O
masses	O	O
within	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
scar	O	O
nor	O	O
elsewhere	O	O
within	O	O
the	O	O
breasts	O	O
.	O	O
diagnosis	O	O
226	O	O
:	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
infiltrating	B-htype-value	B-htype-value
lobular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
nottingham	O	O
grade	B-grade	B-grade
i	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
[	O	O
tubule	O	O
3	O	O
/	O	O
3	O	O
,	O	O
nuclei	O	O
1	O	O
/	O	O
3	O	O
,	O	O
mit	O	O
1	O	O
/	O	O
3	O	O
;	O	O
nottingham	O	O
score	O	O
5	O	O
/	O	O
9	O	O
]	O	O
,	O	O
forming	O	O
a	O	O
mass	O	O
(	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
)	O	O
located	B-site	B-site
in	B-site-value	B-site-value
the	I-site-value	I-site-value
upper	I-site-value	I-site-value
inner	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
of	I-site-value	I-site-value
the	I-site-value	I-site-value
breast	I-site-value	I-site-value
adjacent	I-site-value	I-site-value
to	I-site-value	I-site-value
the	I-site-value	I-site-value
prior	I-site-value	O
biopsy	I-site-value	O
site	I-site-value	I-site-value
[	O	O
aj	O	O
pt1c	B-stage-value	B-stage-value
]	O	O
.	O	O
i	O	O
discussed	O	O
the	O	O
pro	O	O
,	O	O
risks	O	O
of	O	O
rt	O	O
and	O	O
alternative	O	O
(	O	O
no	O	O
rt	O	O
)	O	O
,	O	O
with	O	O
the	O	O
patient	O	O
and	O	O
the	O	O
patients	O	O
sister	O	O
marsh	O	O
in	O	O
detail	O	O
.	O	O
ac	O	O
(	O	O
r	O	O
)	O	O
iii	O	O
her	O	O
(	O	O
t	O	O
)	O	O
application	O	O
software	O	O
is	O	O
an	O	O
fda	O	O
510	O	O
(	O	O
k	O	O
)	O	O
cleared	O	O
application	O	O
for	O	O
precise	O	O
measurement	O	O
for	O	O
assessing	O	O
the	O	O
level	O	O
of	O	O
her2	B-receptor	B-receptor
protein	O	O
on	O	O
cell	O	O
membranes	O	O
of	O	O
breast	O	O
tumor	O	O
cells	O	O
.	O	O
her	B-receptor	B-receptor
-	I-receptor	I-receptor
2	I-receptor	I-receptor
/	O	O
neu	O	O
has	O	O
been	O	O
ordered	O	O
on	O	O
paraffin	O	O
embedded	O	O
tissue	O	O
.	O	O
membrane	O	O
staining	O	O
for	O	O
her2	B-receptor	B-receptor
protein	O	O
in	O	O
breast	O	B-htype-value
carcinoma	O	I-htype-value
is	O	O
scored	O	O
on	O	O
a	O	O
0	O	O
to	O	O
3	O	O
+	O	O
scale	O	O
.	O	O
specimen	O	O
is	O	O
oriented	O	O
.	O	O
breast	O	O
,	O	O
new	O	O
right	B-laterality-value	B-laterality-value
lateral	O	O
margin	O	O
,	O	O
excision	O	O
:	O	O
negative	O	O
for	O	O
carcinoma	O	O
.	O	O
men	O	O
at	O	O
age	O	O
14	O	O
.	O	O
immunohistochemical	O	O
cyto	O	O
stain	O	O
was	O	O
performed	O	O
on	O	O
the	O	O
paraffin	O	O
embedded	O	O
sentinel	O	O
lymph	O	O
node	O	O
tissue	O	O
and	O	O
confirms	O	O
the	O	O
h	O	O
&	O	O
e	O	O
impression	O	O
[	O	O
aj	O	O
pn0	O	B-stage-value
(	O	O
i	O	O
-	O	O
)	O	O
(	O	O
s	O	O
)	O	O
]	O	O
.	O	O
in	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
at	O	O
3	B-site-value	B-site-value
o	I-site-value	I-site-value
and	I-site-value	O
6	I-site-value	I-site-value
o	I-site-value	I-site-value
in	I-site-value	O
the	I-site-value	I-site-value
per	I-site-value	I-site-value
region	I-site-value	I-site-value
,	O	O
she	O	O
has	O	O
0	B-size-value	B-size-value
-	I-size-value	I-size-value
to	I-size-value	I-size-value
0	I-size-value	I-size-value
-	I-size-value	I-size-value
cm	I-size-value	I-size-value
areas	O	O
of	O	O
nod	O	O
which	O	O
are	O	O
also	O	O
marked	O	O
.	O	O
breast	O	O
,	O	O
new	O	O
right	B-laterality-value	B-laterality-value
medial	O	O
margin	O	O
,	O	O
excision	O	O
:	O	O
negative	O	O
for	O	O
carcinoma	O	O
.	O	O
all	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
following	O	O
re	O	O
of	O	O
the	O	O
medial	O	O
and	O	O
lateral	O	O
margins	O	O
(	O	O
see	O	O
parts	O	O
b	O	O
and	O	O
c	O	O
)	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
identified	O	O
in	O	O
the	O	O
lymph	O	O
node	O	O
.	O	O
potential	O	O
late	O	O
radiation	O	O
side	O	O
effects	O	O
include	O	O
,	O	O
but	O	O
are	O	O
not	O	O
limited	O	O
to	O	O
,	O	O
the	O	O
radiation	O	O
fibrosis	O	O
of	O	O
the	O	O
anterior	O	O
portion	O	O
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
lung	O	O
,	O	O
and	O	O
the	O	O
fibrotic	O	O
change	O	O
of	O	O
the	O	O
breast	O	O
tissue	O	O
.	O	[CLS]
heart	O	O
:	O	O
examined	O	O
and	O	O
normal	O	O
.	O	O
this	O	O
was	O	O
removed	O	O
.	O	O
she	O	O
has	O	O
no	O	O
sore	O	O
or	O	O
change	O	O
in	O	O
mobility	O	O
in	O	O
the	O	O
left	B-laterality-value	B-laterality-value
shoulder	O	O
/	O	O
axilla	O	O
.	O	O
r	O	O
patient	O	O
underwent	O	O
screening	O	O
mammogram	O	O
which	O	O
showed	O	O
an	O	O
area	O	O
of	O	O
concern	O	O
in	O	O
the	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
which	O	O
was	O	O
then	O	O
further	O	O
evaluated	O	O
on	O	O
a	O	O
diagnostic	O	O
mammogram	O	O
april	O	O
27	O	O
,	O	O
2004	O	O
.	O	O
they	O	O
would	O	O
like	O	O
to	O	O
get	O	O
these	O	O
appointments	O	O
moved	O	O
together	O	O
.	O	O
hold	O	O
over	O	O
for	O	O
grading	O	O
on	O	O
permanent	O	O
sections	O	O
.	O	O
rosa	O	O
sand	O	O
.	O	O
one	O	O
margin	O	O
was	O	O
positive	O	O
,	O	O
and	O	O
further	O	O
evaluation	O	O
and	O	O
surgery	O	O
was	O	O
recommended	O	O
.	O	O
will	O	O
see	O	O
her	O	O
back	O	O
approximately	O	O
five	O	O
months	O	O
from	O	O
now	O	O
with	O	O
a	O	O
repeat	O	O
evaluation	O	O
.	O	O
abdomen	O	O
:	O	O
soft	O	O
,	O	O
non	O	O
,	O	O
non	O	O
,	O	O
no	O	O
he	O	O
.	O	O
jean	O	O
ec	O	O
is	O	O
a	O	O
70	O	O
-	O	O
year	O	O
lady	O	O
,	O	O
who	O	O
returns	O	O
today	O	O
for	O	O
follow	O	O
of	O	O
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
situ	I-htype-value	I-htype-value
,	O	O
er	B-receptor	B-receptor
/	O	O
pr	B-receptor	B-receptor
negative	B-receptor-status	B-receptor-status
with	O	O
a	O	O
small	O	O
component	O	O
of	O	O
invasive	B-htype-value	B-htype-value
ductal	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
patient	O	O
expressed	O	O
understanding	O	O
of	O	O
the	O	O
content	O	O
.	O	O
proliferation	O	O
index	O	O
ki	O	O
-	O	O
67	O	O
(	O	O
mi	O	O
-	O	O
1	O	O
)	O	O
=	O	O
6	O	O
.	O	O
pal	O	O
over	O	O
the	O	O
anterior	O	O
chest	O	O
wall	O	O
revealed	O	O
no	O	O
nodule	O	O
and	O	O
with	O	O
patient	O	O
lying	O	O
down	O	O
,	O	O
the	O	O
redundant	O	O
tissue	O	O
did	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
as	O	O
obvious	O	O
.	O	O
lymphovascular	O	O
invasion	O	O
is	O	O
present	O	O
with	O	O
negative	O	O
surgical	O	O
margins	O	O
with	O	O
7	O	O
/	O	O
19	O	O
lymph	O	O
nodes	O	O
positive	O	O
.	O	O
2011	O	O
:	O	O
#	O	O
breast	O	O
cancer	O	O
#	O	O
sub	O	O
nodule	O	O
,	O	O
et	O	O
to	O	O
be	O	O
determined	O	O
.	O	O
2011	O	O
:	O	O
supervisory	O	O
note	O	O
by	O	O
diana	O	O
f	O	O
.	O	O
chemotherapy	O	O
likely	O	O
will	O	O
be	O	O
helpful	O	O
in	O	O
shrinking	O	O
the	O	O
size	O	O
of	O	O
the	O	O
involved	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
lymph	O	O
nodes	O	O
.	O	O
(	O	O
05	O	O
/	O	O
28	O	O
/	O	O
2004	O	O
)	O	O
ka	O	O
jean	O	O
e	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
identified	O	O
in	O	O
the	O	O
lymph	O	O
node	O	O
(	O	O
s	O	O
)	O	O
.	O	O
treatment	O	O
effect	O	O
:	O	O
tumor	O	O
bed	O	O
3	O	O
x	O	O
1	O	O
x	O	O
1	O	O
cm	O	O
.	O	O
she	O	O
has	O	O
never	O	O
had	O	O
a	O	O
breast	O	O
cyst	O	O
as	O	O
,	O	O
and	O	O
her	O	O
recent	O	O
breast	O	O
and	O	O
axillary	O	O
biopsies	O	O
have	O	O
been	O	O
her	O	O
only	O	O
biopsies	O	O
.	O	O
be	O	O
returns	O	O
for	O	O
additional	O	O
evaluation	O	O
of	O	O
the	O	O
above	O	O
concerns	O	O
.	O	O
anticipated	O	O
date	O	O
of	O	O
completion	O	O
is	O	O
august	O	O
7th	O	O
,	O	O
2015	O	O
.	O	O
2011	O	O
:	O	O
supervised	O	O
by	O	O
dr	O	O
.	O	O
in	O	O
2008	O	O
,	O	O
she	O	O
had	O	O
a	O	O
pet	O	O
scan	O	O
,	O	O
breast	O	O
mri	O	O
,	O	O
mammogram	O	O
,	O	O
and	O	O
ultrasound	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
no	O	O
.	O	O
1	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
(	O	O
1	O	O
)	O	O
sentinel	O	O
lymph	O	O
node	O	O
with	O	O
blue	O	O
dye	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
sand	O	O
,	O	O
m	O	O
.	O	O
"	O	O
john	O	O
van	O	O
ar	O	O
.	O	O
grossed	O	O
by	O	O
cm	O	O
.	O	O
l	O	O
within	O	O
normal	O	O
limits	O	O
including	O	O
al	O	O
ph	O	O
178	O	O
with	O	O
normal	O	O
liver	O	O
,	O	O
bone	O	O
,	O	O
and	O	O
int	O	O
fraction	O	O
.	O	O
overall	O	O
,	O	O
if	O	O
she	O	O
were	O	O
to	O	O
undergo	O	O
standard	O	O
chemotherapy	O	O
as	O	O
described	O	O
,	O	O
this	O	O
could	O	O
improve	O	O
her	O	O
survival	O	O
to	O	O
about	O	O
83	O	O
.	O	O
frozen	O	O
section	O	O
histologic	O	O
interpretation	O	O
performed	O	O
by	O	O
:	O	O
karen	O	O
fr	O	O
,	O	O
m	O	O
.	O	O
"	O	O
ex	O	O
:	O	O
no	O	O
edema	O	O
.	O	O
laboratory	O	O
developed	O	O
test	O	O
transcribed	O	O
by	O	O
:	O	O
san	O	O
9	O	O
/	O	O
11	O	O
/	O	O
2017	O	O
09	O	O
:	O	O
38	O	O
:	O	O
57	O	O
signed	O	O
by	O	O
jo	O	O
m	O	O
.	O	O
the	O	O
prior	O	O
lumpectomy	O	O
site	O	O
is	O	O
located	O	O
sub	O	O
to	O	O
the	O	O
skin	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
29	O	O
surgical	O	O
pathology	O	O
requested	O	O
by	O	O
:	O	O
michael	O	O
b	O	O
.	O	O
chest	O	O
x	O	O
of	O	O
march	O	O
9	O	O
is	O	O
negative	O	O
.	O	O
diagnosis	O	O
226	O	O
:	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
no	O	O
residual	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
is	O	O
identified	O	O
at	O	O
the	O	O
previous	O	O
biopsy	O	O
cavity	O	O
,	O	O
which	O	O
shows	O	O
reactive	O	O
changes	O	O
.	O	O
pathologic	O	O
staging	B-stage	B-stage
(	O	O
aj	O	O
,	O	O
7th	O	O
edition	O	O
)	O	O
:	O	O
primary	O	O
tumor	O	O
:	O	O
pt2	B-stage-value	B-stage-value
.	O	O
in	O	O
situ	O	O
component	O	O
:	O	O
dcis	B-htype-value	B-htype-value
absent	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
09	O	O
/	O	O
14	O	O
/	O	O
2004	O	O
surgical	O	O
pathology	O	O
(	O	O
cr	O	O
-	O	O
71	O	O
)	O	O
revised	O	O
report	O	O
(	O	O
addendum	O	O
/	O	O
procedure	O	O
included	O	O
)	O	O
requested	O	O
by	O	O
:	O	O
amy	O	O
c	O	O
.	O	O
the	O	O
average	O	O
intensity	O	O
of	O	O
the	O	O
positively	O	O
staining	O	O
tumor	O	O
nuclei	O	O
is	O	O
strong	O	O
.	O	O
ki	O	O
-	O	O
67	O	O
(	O	O
mi	O	O
-	O	O
1	O	O
)	O	O
-	O	O
stained	O	O
slides	O	O
are	O	O
scanned	O	O
using	O	O
the	O	O
ape	O	O
scans	O	O
instrument	O	O
,	O	O
which	O	O
captures	O	O
digital	O	O
images	O	O
of	O	O
the	O	O
patient	O	O
slide	O	O
.	O	O
d	O	O
.	O	O
the	O	O
area	O	O
of	O	O
er	O	O
towards	O	O
the	O	O
medial	O	O
portion	O	O
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
measures	O	B-size
3	O	B-size-value
x	O	I-size-value
4	O	I-size-value
cm	O	I-size-value
.	O	O
all	O	O
submitted	O	O
.	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
new	O	O
anterior	O	O
margin	O	O
,	O	O
re	O	O
:	O	O
benign	O	O
breast	O	O
par	O	O
.	O	O
"	O	O
advance	O	O
directive	O	O
information	O	O
packet	O	O
provided	O	O
to	O	O
the	O	O
patient	O	O
.	O	O
i	O	O
do	O	O
not	O	O
pal	O	O
any	O	O
other	O	O
discrete	O	O
masses	O	O
within	O	O
the	O	O
left	O	B-laterality-value
breast	O	O
.	O	O
eyes	O	O
:	O	O
pupils	O	O
equal	O	O
,	O	O
round	O	O
,	O	O
and	O	O
reactive	O	O
to	O	O
light	O	O
and	O	O
accommodation	O	O
.	O	O
page	O	O
:	O	O
127	O	O
-	O	O
00	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
04	O	O
/	O	O
22	O	O
/	O	O
2004	O	O
surgical	O	O
pathology	O	O
(	O	O
cr	O	O
-	O	O
305	O	O
)	O	O
requested	O	O
by	O	O
:	O	O
amy	O	O
c	O	O
.	O	O
psycho	O	O
mrs	O	O
.	O	O
the	O	O
cr	O	O
nerve	O	O
exam	O	O
reveals	O	O
a	O	O
near	O	O
complete	O	O
peripheral	O	O
left	O	B-laterality-value
seventh	O	O
nerve	O	O
pal	O	O
.	O	O
rachel	O	O
rick	O	O
her	O	O
presentation	O	O
with	O	O
a	O	O
clinical	O	O
t2	B-stage-value	B-stage-value
,	O	O
n0	B-stage-value	B-stage-value
right	B-laterality-value	B-laterality-value
breast	O	O
cancer	O	O
.	O	O
the	O	O
overall	O	O
invasive	O	O
tumor	O	O
cellular	O	O
is	O	O
approximately	O	O
50	O	O
.	O	O
otherwise	O	O
,	O	O
protocol	O	O
adverse	O	O
events	O	O
are	O	O
grade	O	B-grade
0	O	B-grade-value
.	O	O
2011	O	O
:	O	O
general	O	O
:	O	O
pleasant	O	O
woman	O	O
in	O	O
no	O	O
apparent	O	O
distress	O	O
.	O	O
e	O	O
.	O	O
her	O	O
hips	O	O
demonstrate	O	O
normal	O	O
range	O	O
of	O	O
motion	O	O
;	O	O
however	O	O
,	O	O
the	O	O
left	O	B-laterality-value
is	O	O
somewhat	O	O
diminished	O	O
secondary	O	O
to	O	O
the	O	O
pain	O	O
of	O	O
the	O	O
fracture	O	O
.	O	O
all	O	O
surgical	O	O
resection	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
(	O	O
minimum	O	O
tumor	O	O
free	O	O
margin	O	O
,	O	O
0	O	O
cm	O	O
,	O	O
anterior	O	O
inferior	O	O
margin	O	O
)	O	O
.	O	O
mitotic	O	O
rate	O	O
:	O	O
21	O	O
/	O	O
10	O	O
high	O	O
fields	O	O
(	O	O
most	O	O
pro	O	O
area	O	O
)	O	O
.	O	O
inward	O	O
,	O	O
m	O	O
.	O	[CLS]
4	O	O
-	O	O
68	O	O
report	O	O
electronically	O	O
signed	O	O
by	O	O
carrie	O	O
y	O	O
.	O	O
she	O	O
did	O	O
talk	O	O
with	O	O
a	O	O
radiation	O	O
on	O	O
at	O	O
home	O	O
who	O	O
suggested	O	O
that	O	O
it	O	O
might	O	O
be	O	O
better	O	O
for	O	O
her	O	O
to	O	O
not	O	O
have	O	O
radiation	O	O
because	O	O
of	O	O
the	O	O
potential	O	O
risks	O	O
for	O	O
development	O	O
of	O	O
second	O	O
cancers	O	O
after	O	O
radiation	O	O
therapy	O	O
.	O	O
hartman	O	O
to	O	O
let	O	O
her	O	O
know	O	O
the	O	O
progress	O	O
that	O	O
mrs	O	O
.	O	O
lymph	O	O
nodes	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
and	O	O
right	B-laterality-value	B-laterality-value
intra	O	O
sentinel	O	O
,	O	O
excision	O	O
:	O	O
multiple	O	O
(	O	O
5	O	O
)	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
and	O	O
a	O	O
single	O	O
right	B-laterality-value	B-laterality-value
intra	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
a	O	O
prescription	O	O
for	O	O
z	O	O
was	O	O
prescribed	O	O
to	O	O
weber	O	O
and	O	O
judd	O	O
in	O	O
stewart	O	O
.	O	O
af	O	O
frozen	O	O
section	O	O
a	O	O
.	O	O
there	O	O
,	O	O
it	O	O
was	O	O
proposed	O	O
to	O	O
the	O	O
patient	O	O
to	O	O
do	O	O
radiation	O	O
to	O	O
the	O	O
mammary	O	O
and	O	O
axillary	O	O
area	O	O
where	O	O
the	O	O
lymph	O	O
nodes	O	O
were	O	O
positive	O	O
.	O	O
she	O	O
had	O	O
initially	O	O
noted	O	O
some	O	O
pink	O	O
of	O	O
her	O	O
skin	O	O
in	O	O
her	O	O
initial	O	O
radiation	O	O
sessions	O	O
.	O	O
she	O	O
was	O	O
seen	O	O
by	O	O
her	O	O
primary	O	O
physician	O	O
,	O	O
dr	O	O
.	O	O
patient	O	O
underwent	O	O
a	O	O
screening	O	O
mammogram	O	O
on	O	O
january	O	O
10	O	O
,	O	O
2007	O	O
,	O	O
and	O	O
additional	O	O
mag	O	O
views	O	O
were	O	O
performed	O	O
on	O	O
january	O	O
25	O	O
of	O	O
2007	O	O
.	O	O
no	O	O
coughing	O	O
in	O	O
the	O	O
office	O	O
.	O	O
bo	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
75	O	O
slide	O	O
disposition	O	O
:	O	O
"	O	O
diagnosis	O	O
226	O	O
:	O	O
a	O	O
.	O	O
flow	O	O
cyto	O	O
im	O	O
,	O	O
bone	O	O
marrow	O	O
as	O	O
,	O	O
by	O	O
report	O	O
:	O	O
no	O	O
mono	O	O
b	O	O
were	O	O
identified	O	O
.	O	O
4	O	O
.	O	O
at	O	O
the	O	O
time	O	O
of	O	O
follow	O	O
with	O	O
the	O	O
surgeon	O	O
on	O	O
january	O	O
24	O	O
,	O	O
he	O	O
recommended	O	O
partial	O	O
mastectomy	O	O
versus	O	O
total	O	O
mastectomy	O	O
and	O	O
referred	O	O
her	O	O
on	O	O
to	O	O
radiology	O	O
for	O	O
bilateral	O	B-laterality-value
whole	O	O
breast	O	O
ultrasound	O	O
.	O	O
pathologic	O	O
staging	B-stage	B-stage
des	O	O
:	O	O
s	O	O
,	O	O
y	O	O
pathologic	O	O
staging	B-stage	B-stage
(	O	O
aj	O	O
,	O	O
7th	O	O
edition	O	O
)	O	O
:	O	O
primary	O	O
tumor	O	O
:	O	O
pt	B-stage-value	B-stage-value
regional	O	O
lymph	O	O
nodes	O	O
:	O	O
pn0	B-stage-value	B-stage-value
sentinel	O	O
nodes	O	O
,	O	O
total	O	O
number	O	O
examined	O	O
:	O	O
3	O	O
non	O	O
axillary	O	O
nodes	O	O
,	O	O
total	O	O
number	O	O
examined	O	O
:	O	O
0	O	O
all	O	O
(	O	O
sentinel	O	O
plus	O	O
non	O	O
)	O	O
nodes	O	O
,	O	O
total	O	O
number	O	O
:	O	O
3	O	O
number	O	O
of	O	O
negative	O	O
l	O	O
:	O	O
3	O	O
number	O	O
of	O	O
l	O	O
with	O	O
isolated	O	O
tumor	O	O
cells	O	O
:	O	O
0	O	O
number	O	O
of	O	O
l	O	O
with	O	O
micro	O	O
:	O	O
0	O	O
number	O	O
of	O	O
l	O	O
with	O	O
macrometastases	O	O
:	O	O
0	O	O
treatment	O	O
effect	O	O
(	O	O
lymph	O	O
nodes	O	O
)	O	O
:	O	O
no	O	O
evidence	O	O
of	O	O
therapeutic	O	O
response	O	O
.	O	O
i	O	O
also	O	O
provided	O	O
her	O	O
with	O	O
a	O	O
prescription	O	O
for	O	O
cr	O	O
pro	O	O
as	O	O
well	O	O
as	O	O
\	O	O
"	O	O
understanding	O	O
chemotherapy	O	O
\	O	O
"	O	O
booklet	O	O
for	O	O
review	O	O
.	O	O
immunohistochemical	O	O
cyto	O	O
stain	O	O
was	O	O
performed	O	O
on	O	O
the	O	O
paraffin	O	O
embedded	O	O
sentinel	O	O
lymph	O	O
node	O	O
tissue	O	O
and	O	O
confirms	O	O
the	O	O
h	O	O
&	O	O
e	O	O
impression	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
new	O	O
anterior	O	O
margin	O	O
,	O	O
excision	O	O
:	O	O
benign	O	O
breast	O	O
tissue	O	O
,	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
2	O	O
/	O	O
10	O	O
/	O	O
2012	O	O
16	O	O
:	O	O
37	O	O
interpreted	O	O
by	O	O
:	O	O
rafael	O	O
e	O	O
.	O	O
low	B-grade-value	B-grade-value
nuclear	O	O
grade	B-grade	B-grade
ductal	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
in	I-htype-value	I-htype-value
,	O	O
predominantly	O	O
solid	O	O
type	O	O
,	O	O
comprises	O	O
less	O	O
than	O	O
10	O	O
of	O	O
the	O	O
tumor	O	O
mass	O	O
.	O	[CLS]
ki	O	O
-	O	O
67	O	O
(	O	O
mi	O	O
-	O	O
1	O	O
)	O	O
-	O	O
stained	O	O
slides	O	O
are	O	O
scanned	O	O
using	O	O
the	O	O
ape	O	O
scans	O	O
instrument	O	O
,	O	O
which	O	O
captures	O	O
digital	O	O
images	O	O
of	O	O
the	O	O
patient	O	O
slide	O	O
.	O	O
eyes	O	O
:	O	O
appearance	O	O
of	O	O
the	O	O
eyes	O	O
looks	O	O
somewhat	O	O
dry	O	O
.	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
over	O	O
the	O	O
area	O	O
of	O	O
the	O	O
surgical	O	O
scar	O	O
is	O	O
slightly	O	O
warm	O	O
to	O	O
touch	O	O
.	O	O
the	O	O
surgical	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
she	O	O
reports	O	O
nighttime	O	O
hot	O	O
flashes	O	O
,	O	O
however	O	O
,	O	O
she	O	O
is	O	O
not	O	O
experiencing	O	O
hot	O	O
flashes	O	O
during	O	O
the	O	O
day	O	O
.	O	O
medical	O	O
oncology	O	O
has	O	O
recommended	O	O
adjuvant	O	O
chemotherapy	O	O
with	O	O
standard	O	O
dose	O	O
ac	O	O
followed	O	O
by	O	O
taxol	O	O
.	O	O
given	O	O
that	O	O
the	O	O
majority	O	O
of	O	O
the	O	O
patient	O	O
tumor	O	O
was	O	O
not	O	O
visible	O	O
with	O	O
ultrasound	O	O
,	O	O
re	O	O
with	O	O
mr	O	O
scanning	O	O
could	O	O
be	O	O
performed	O	O
if	O	O
clinical	O	O
relevant	O	O
.	O	O
the	O	O
surgical	O	O
margins	O	O
,	O	O
after	O	O
re	O	O
-	O	O
excision	O	O
,	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
far	O	O
,	O	O
m	O	O
.	O	O
she	O	O
does	O	O
garden	O	O
as	O	O
well	O	O
as	O	O
do	O	O
all	O	O
of	O	O
her	O	O
house	O	O
including	O	O
vacuum	O	O
,	O	O
laundry	O	O
,	O	O
going	O	O
up	O	O
and	O	O
down	O	O
the	O	O
stairs	O	O
with	O	O
no	O	O
chest	O	O
pain	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
new	O	O
anterior	O	O
margin	O	O
,	O	O
re	O	O
:	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
d	O	O
.	O	O
axillary	O	O
lymph	O	O
nodes	O	O
are	O	O
not	O	O
identified	O	O
.	O	O
lymph	O	O
node	O	O
,	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
,	O	O
biopsy	O	O
:	O	O
a	O	O
single	O	O
right	B-laterality-value	B-laterality-value
axillary	O	O
lymph	O	O
node	O	O
is	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
is	O	O
a	O	O
former	O	O
smoke	O	O
with	O	O
no	O	O
second	O	O
smoke	O	O
exposure	O	O
.	O	O
all	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
carcinoma	O	O
.	O	O
bo	O	O
,	O	O
m	O	O
.	O	O
4	O	O
-	O	O
75	O	O
slide	O	O
disposition	O	O
:	O	O
"	O	O
diagnosis	O	O
226	O	O
:	O	O
a	O	O
.	O	O
she	O	O
has	O	O
used	O	O
no	O	O
med	O	O
cream	O	O
.	O	O
hi	O	O
is	O	O
ready	O	O
to	O	O
undergo	O	O
simulation	O	O
with	O	O
intention	O	O
to	O	O
initiate	O	O
radiation	O	O
therapy	O	O
to	O	O
the	O	O
whole	O	O
breast	O	O
beginning	O	O
october	O	O
27	O	O
,	O	O
2008	O	O
.	O	O
margin	O	O
submitted	O	O
.	O	O
discussed	O	O
recommendations	O	O
for	O	O
ongoing	O	O
breast	O	O
cancer	O	O
surveillance	O	O
following	O	O
cancer	O	O
diagnosis	O	O
and	O	O
treatment	O	O
.	O	O
the	O	O
bone	O	O
scan	O	O
was	O	O
reported	O	O
to	O	O
be	O	O
normal	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
excision	O	O
biopsy	O	O
:	O	O
radial	O	O
scar	O	O
with	O	O
fl	O	O
ductal	O	O
hyperplasia	O	O
.	O	O
she	O	O
was	O	O
19	O	O
when	O	O
she	O	O
had	O	O
her	O	O
first	O	O
child	O	O
.	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
;	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
nos	O	O
.	O	O
1	O	O
,	O	O
2a	O	O
,	O	O
2	O	O
,	O	O
3a	O	O
,	O	O
3	O	O
,	O	O
and	O	O
4	O	O
;	O	O
sentinel	O	O
biopsies	O	O
:	O	O
multiple	O	O
(	O	O
6	O	O
)	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
hold	O	O
over	O	O
to	O	O
confirm	O	O
by	O	O
immunostains	O	O
.	O	O
ad	O	O
,	O	O
m	O	O
.	O	O
patient	O	O
education	O	O
ready	O	O
to	O	O
learn	O	O
,	O	O
no	O	O
apparent	O	O
learning	O	O
barriers	O	O
were	O	O
identified	O	O
;	O	O
learning	O	O
preferences	O	O
include	O	O
listening	O	O
.	O	O
cl	O	O
of	O	O
the	O	O
pathology	O	O
of	O	O
this	O	O
specimen	O	O
as	O	O
reported	O	O
by	O	O
her	O	O
outside	O	O
institution	O	O
.	O	O
c	O	O
.	O	O
the	O	O
nipple	O	O
and	O	O
skin	O	O
show	O	O
no	O	O
diagnostic	O	O
abnormality	O	O
.	O	O
page	O	O
:	O	O
127	O	O
-	O	O
1863	O	O
and	O	O
dr	O	O
.	O	O
:	O	O
h	O	O
"	O	O
hi	O	O
reports	O	O
that	O	O
she	O	O
overall	O	O
is	O	O
doing	O	O
well	O	O
.	O	O
blue	O	O
dye	O	O
is	O	O
identified	O	O
in	O	O
the	O	O
lymph	O	O
node	O	O
.	O	O
total	O	O
bi	O	O
0	O	O
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
no	O	O
.	O	O
3	O	O
\	O	O
"	O	O
is	O	O
a	O	O
single	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
1	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
lymph	O	O
node	O	O
.	O	O
the	O	O
patient	O	O
risk	O	O
profile	O	O
for	O	O
breast	O	O
cancer	O	O
:	O	O
men	O	O
at	O	O
age	O	O
13	O	O
.	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
,	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
nos	O	O
.	O	O
1	O	O
and	O	O
2	O	O
,	O	O
sentinel	O	O
biopsy	O	O
:	O	O
multiple	O	O
(	O	O
2	O	O
)	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
nodes	O	O
are	O	O
negative	O	O
for	O	O
metastatic	B-htype-value	B-htype-value
carcinoma	I-htype-value	I-htype-value
[	O	O
aj	O	O
pn0	B-stage-value	B-stage-value
(	O	O
i	O	O
-	O	O
)	O	O
(	O	O
s	O	O
)	O	O
]	O	O
.	O	O
e	O	O
.	O	O
b	O	O
.	O	O
long	O	O
.	O	O
she	O	O
is	O	O
concerned	O	O
about	O	O
diet	O	O
and	O	O
exercise	O	O
at	O	O
this	O	O
time	O	O
.	O	O
this	O	O
has	O	O
been	O	O
moved	O	O
up	O	O
to	O	O
october	O	O
3	O	O
,	O	O
2017	O	O
,	O	O
so	O	O
that	O	O
they	O	O
can	O	O
discuss	O	O
alternatives	O	O
to	O	O
tamoxifen	O	O
in	O	O
case	O	O
this	O	O
is	O	O
the	O	O
source	O	O
of	O	O
the	O	O
di	O	O
.	O	O
2011	O	O
:	O	O
skin	O	O
:	O	O
grade	O	B-grade
1	O	B-grade-value
der	O	O
within	O	O
the	O	O
radiation	O	O
treatment	O	O
fields	O	O
.	O	O
there	O	O
are	O	O
no	O	O
abnormalities	O	O
to	O	O
the	O	O
con	O	O
of	O	O
either	O	O
breast	O	O
.	O	O
multiple	O	O
(	O	O
2	O	O
)	O	O
needle	O	O
local	O	O
wires	O	O
are	O	O
identified	O	O
.	O	O
as	O	O
indicated	O	O
above	O	O
,	O	O
during	O	O
the	O	O
course	O	O
of	O	O
the	O	O
patient	O	O
evaluation	O	O
,	O	O
she	O	O
also	O	O
had	O	O
a	O	O
pet	O	O
scan	O	O
,	O	O
which	O	O
revealed	O	O
a	O	O
second	O	O
lesion	O	O
in	O	O
the	O	O
upper	B-site-value	B-site-value
medial	I-site-value	I-site-value
right	B-laterality-value	B-laterality-value
breast	O	O
.	O	O
block	O	O
summary	O	O
:	O	O
part	O	O
a	O	O
:	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
(	O	O
simple	O	O
mastectomy	O	O
)	O	O
1	O	O
lt	B-laterality-value	B-laterality-value
sentinel	O	O
#	O	O
l	O	O
1	O	O
2	O	O
lt	B-laterality-value	B-laterality-value
sentinel	O	O
#	O	O
l	O	O
2	O	O
3	O	O
lt	B-laterality-value	B-laterality-value
sentinel	O	O
#	O	O
l	O	O
1	O	O
4	O	O
lt	B-laterality-value	B-laterality-value
sentinel	O	O
#	O	O
l	O	O
2	O	O
5	O	O
lt	B-laterality-value	B-laterality-value
ax	O	O
non	O	O
l	O	O
1	O	O
6	O	O
lt	B-laterality-value	B-laterality-value
ax	O	O
non	O	O
l	O	O
2	O	O
7	O	O
*	O	O
lt	B-laterality-value	B-laterality-value
u	O	O
biopsy	O	O
site	O	O
-	O	O
1	O	O
8	O	O
*	O	O
lt	B-laterality-value	B-laterality-value
u	O	O
biopsy	O	O
site	O	O
-	O	O
2	O	O
9	O	O
*	O	O
lt	B-laterality-value	B-laterality-value
u	O	O
biopsy	O	O
site	O	O
-	O	O
3	O	O
10	O	O
*	O	O
lt	B-laterality-value	B-laterality-value
u	O	O
biopsy	O	O
site	O	O
-	O	O
4	O	O
11	O	O
left	B-laterality-value	B-laterality-value
nipple	O	O
12	O	O
lt	O	B-laterality-value
upper	O	O
outer	O	O
quadrant	O	O
13	O	O
lt	O	B-laterality-value
upper	O	O
inner	O	O
quadrant	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
simple	O	O
mastectomy	O	O
:	O	O
invasive	B-htype-value	B-htype-value
lobular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
nottingham	O	O
grade	B-grade	B-grade
i	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
,	O	O
forming	O	O
two	O	O
masses	O	O
1	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
and	O	O
0	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
.	O	[CLS]
she	O	O
went	O	O
through	O	O
men	O	O
at	O	O
age	O	O
49	O	O
with	O	O
a	O	O
hysterectomy	O	O
for	O	O
ut	O	O
fi	O	O
and	O	O
o	O	O
at	O	O
that	O	O
time	O	O
.	O	O
mr	O	O
.	O	O
she	O	O
will	O	O
continue	O	O
with	O	O
surveillance	O	O
imaging	O	O
of	O	O
both	O	O
breasts	O	O
,	O	O
and	O	O
i	O	O
will	O	O
be	O	O
available	O	O
as	O	O
needed	O	O
.	O	O
2011	O	O
:	O	O
breasts	O	O
:	O	O
breast	O	O
exam	O	O
reveals	O	O
symmetric	O	O
breasts	O	O
.	O	O
she	O	O
also	O	O
had	O	O
an	O	O
f	O	O
of	O	O
a	O	O
lesion	O	O
in	O	O
the	O	O
upper	B-site-value	B-site-value
inner	I-site-value	I-site-value
quadrant	I-site-value	I-site-value
of	O	O
the	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
after	O	O
a	O	O
suspicious	O	O
area	O	O
was	O	O
identified	O	O
on	O	O
a	O	O
pet	O	O
scan	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
new	O	O
anterior	O	O
margin	O	O
,	O	O
re	O	O
:	O	O
negative	O	O
for	O	O
tumor	O	O
.	O	O
all	O	O
imaging	O	O
abnormalities	O	O
were	O	O
completely	O	O
worked	O	O
up	O	O
as	O	O
noted	O	O
.	O	O
d	O	O
.	O	O
b	O	O
.	O	O
syn	O	O
report	O	O
:	O	O
laterality	B-laterality	B-laterality
:	O	O
left	B-laterality-value	B-laterality-value
.	O	O
the	O	O
syn	O	O
report	O	O
incorporates	O	O
information	O	O
from	O	O
all	O	O
relevant	O	O
surgical	O	O
material	O	O
and	O	O
includes	O	O
all	O	O
required	O	O
data	O	O
elements	O	O
of	O	O
the	O	O
current	O	O
cap	O	O
cancer	O	O
protocol	O	O
.	O	O
all	O	O
surgical	O	O
resection	O	O
margins	O	O
are	O	O
negative	O	O
for	O	O
tumor	O	O
(	O	O
minimum	O	O
tumor	O	O
free	O	O
margin	O	O
,	O	O
1	O	O
cm	O	O
,	O	O
inferior	O	O
margin	O	O
)	O	O
.	O	O
document	O	O
header	O	O
999	O	O
:	O	O
09	O	O
/	O	O
28	O	O
/	O	O
2010	O	O
surgical	O	O
pathology	O	O
(	O	O
mr	O	O
-	O	O
77	O	O
)	O	O
requested	O	O
by	O	O
:	O	O
david	O	O
r	O	O
.	O	O
there	O	O
was	O	O
no	O	O
angiolymphatic	O	O
invasion	O	O
.	O	O
the	O	O
next	O	O
nearest	O	O
margin	O	O
is	O	O
the	O	O
medial	O	O
margin	O	O
by	O	O
0	O	O
cm	O	O
.	O	O
she	O	O
is	O	O
to	O	O
radiation	O	O
therapy	O	O
well	O	O
,	O	O
and	O	O
we	O	O
will	O	O
continue	O	O
as	O	O
planned	O	O
.	O	O
the	O	O
reason	O	O
for	O	O
her	O	O
visit	O	O
today	O	O
is	O	O
associated	O	O
with	O	O
her	O	O
persistent	O	O
close	O	O
margins	O	O
and	O	O
whether	O	O
any	O	O
additional	O	O
surgery	O	O
is	O	O
recommended	O	O
for	O	O
her	O	O
.	O	O
the	O	O
non	O	O
breast	O	O
par	O	O
shows	O	O
ductal	O	O
hyperplasia	O	O
without	O	O
atypia	O	O
.	O	O
microscopic	O	O
extent	O	O
of	O	O
dcis	B-htype-value	B-htype-value
:	O	O
nipple	O	O
:	O	O
not	O	O
present	O	O
.	O	O
ki	O	O
-	O	O
67	O	O
(	O	O
mi	O	O
-	O	O
1	O	O
)	O	O
proliferation	O	O
data	O	O
must	O	O
be	O	O
interpreted	O	O
within	O	O
the	O	O
clinical	O	O
context	O	O
for	O	O
which	O	O
the	O	O
test	O	O
was	O	O
ordered	O	O
.	O	O
breast	O	O
,	O	O
right	B-laterality-value	B-laterality-value
,	O	O
lumpectomy	O	O
:	O	O
no	O	O
residual	B-htype-value	B-htype-value
invasive	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
.	O	O
received	O	O
fresh	O	O
labeled	O	O
\	O	O
"	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
new	O	O
lateral	O	O
margin	O	O
\	O	O
"	O	O
is	O	O
a	O	O
4	O	O
x	O	O
3	O	O
x	O	O
0	O	O
cm	O	O
portion	O	O
of	O	O
fi	O	O
tissue	O	O
.	O	O
frozen	O	O
section	O	O
histologic	O	O
interpretation	O	O
performed	O	O
by	O	O
:	O	O
jean	O	O
e	O	O
.	O	O
patient	O	O
was	O	O
maintained	O	O
on	O	O
aspirin	O	O
for	O	O
d	O	O
prop	O	O
during	O	O
the	O	O
hospital	O	O
stay	O	O
.	O	O
the	O	O
skin	O	O
and	O	O
nipple	O	O
are	O	O
un	O	O
.	O	O
ari	O	O
started	O	O
on	O	O
march	O	O
7	O	O
,	O	O
2016	O	O
.	O	O
block	O	O
summary	O	O
:	O	O
part	O	O
a	O	O
:	O	O
right	B-laterality-value	B-laterality-value
retroareolar	O	O
margin	O	O
1	O	O
right	B-laterality-value	B-laterality-value
retroareolar	O	O
margin	O	O
part	O	O
b	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
1	O	O
deep	O	O
margin	O	O
2	O	O
biopsy	O	O
site	O	O
1	O	O
3	O	O
biopsy	O	O
site	O	O
2	O	O
4	O	O
biopsy	O	O
site	O	O
3	O	O
5	O	O
biopsy	O	O
site	O	O
4	O	O
6	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
bio	O	O
site	O	O
-	O	O
5	O	O
7	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
site	O	O
-	O	O
6	O	O
8	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
bio	O	O
site	O	O
-	O	O
7	O	O
9	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
site	O	O
-	O	O
8	O	O
10	O	O
rt	B-laterality-value	B-laterality-value
breast	O	O
biopsy	O	O
site	O	O
-	O	O
9	O	O
rafael	O	O
e	O	O
.	O	O
block	O	O
summary	O	O
:	O	O
part	O	O
a	O	O
:	O	O
right	B-laterality-value	B-laterality-value
breast	O	O
excision	O	O
biopsy	O	O
1	O	O
right	B-laterality-value	B-laterality-value
core	O	O
biopsy	O	O
site	O	O
-	O	O
1	O	O
2	O	O
right	B-laterality-value	B-laterality-value
core	O	O
biopsy	O	O
site	O	O
-	O	O
2	O	O
3	O	O
right	B-laterality-value	B-laterality-value
core	O	O
biopsy	O	O
site	O	O
-	O	O
3	O	O
part	O	O
b	O	O
:	O	O
left	B-laterality-value	B-laterality-value
axillary	O	O
sentinel	O	O
lymph	O	O
node	O	O
#	O	O
1	O	O
left	B-laterality-value	B-laterality-value
sentinel	O	O
l	O	O
#	O	O
part	O	O
c	O	O
:	O	O
left	B-laterality-value	B-laterality-value
breast	O	O
wide	O	O
local	O	O
excision	O	O
1	O	O
lt	O	O
inferior	O	O
margin	O	O
1	O	O
2	O	O
lt	O	O
inferior	O	O
margin	O	O
2	O	O
3	O	O
lt	O	O
anterior	O	O
margin	O	O
-	O	O
1	O	O
4	O	O
lt	O	O
anterior	O	O
margin	O	O
-	O	O
2	O	O
5	O	O
lt	O	O
deep	O	O
margin	O	O
-	O	O
1	O	O
6	O	O
lt	O	O
deep	O	O
margin	O	O
-	O	O
2	O	O
7	O	O
lt	O	O
superior	O	O
margin	O	O
-	O	O
1	O	O
8	O	O
lt	O	O
superior	O	O
margin	O	O
-	O	O
2	O	O
9	O	O
lt	O	O
superior	O	O
margin	O	O
-	O	O
3	O	O
10	O	O
lt	O	O
superior	O	O
margin	O	O
-	O	O
4	O	O
11	O	O
lt	O	O
superior	O	O
margin	O	O
-	O	O
5	O	O
12	O	O
lt	O	O
lateral	O	O
margin	O	O
-	O	O
1	O	O
she	O	O
has	O	O
no	O	O
history	O	O
of	O	O
radiation	O	O
therapy	O	O
.	O	O
diagnosis	O	O
226	O	O
:	O	O
breast	O	O
,	O	O
left	B-laterality-value	B-laterality-value
,	O	O
wide	O	O
local	O	O
excision	O	O
:	O	O
invasive	B-htype-value	B-htype-value
lobular	I-htype-value	I-htype-value
carcinoma	I-htype-value	I-htype-value
,	O	O
nottingham	O	O
grade	B-grade	B-grade
ii	B-grade-value	B-grade-value
(	O	O
of	O	O
iii	O	O
)	O	O
,	O	O
forming	O	O
a	O	O
0	B-size-value	B-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
x	I-size-value	I-size-value
0	I-size-value	I-size-value
cm	I-size-value	I-size-value
mass	O	O
(	O	O
aj	O	O
pt1b	B-stage-value	B-stage-value
)	O	O
.	O	O
